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In 1997 in the Netherlands 8.6% of the gross domestic product was spent on health care 
(Statistics Netherlands, 1999) and this indicates the relevancy of the economic aspects of 
health care. As in many countries, in our country containment of health care expenditures is an 
important political topic. Thus, nowadays, efficacy can not be the only criterion on which 
basis choices to implement medical technologies can be made. Efficiency or cost-
effectiveness of medical technologies, being the relation between outcome and input 
(resources, costs), is considered when choices are being made on the macro level (e.g. the 
Ministry of Health) as well as on meso- and micro-level (e.g. management of health care 
institutions and the practising health care workers)(Luce & Brown, 1995). The decisions have 
to be made about the availability and use of both therapeutic interventions and diagnostic 
technologies. By performing economic evaluations, health economic researchers intend to 
give decision-makers information about the relative efficiency of medical technologies by 
comparing alternative courses of action for consideration (Drummond et al., 1997). In the past 
decades an increasing trend in the number of reported economic evaluations in the medical 
literature has been identified (Elixhauser, 1993a; Elixhauser et al, 1993b). 
The methodology of economic evaluation is still evolving. This evolution can be 
illustrated not only by the rising number of economic evaluations, but also by the increasing 
number of health economic journals which (partly) concentrate on methodological issues of 
performing economic evaluations. Discussion about these methodological issues is still going 
on and will probably continue for years to come. However, methodological principles of the 
economic evaluations that are currently executed influence the study results. This is one 
reason why several countries have implemented guidelines for performing economic 
evaluations either for specific subjects or economic evaluations in general (Access and 
Financing Division, 1998; Canadian Coordinating Office for Health Technology Assessment, 
1996; Canadian Coordinating Office for Health Technology Assessment, 1997; Langley, 
1996; National Health Insurance Board, 1999; Rutten et al, 1993). The existing guidelines 
can be of help when performing economic evaluations of medical technologies. However, 
despite the guidelines, comparability of the results of economic evaluation can be difficult. 
When faced with the difficult task of assessing study results a critical appraisal checklist can 
be used which was published by Drummond et al. in 1987 (Drummond et al, 1987) and 
revised in 1997 (Drummond et al, 1997). This 10-item checklist may help to identify the key 
elements and assess the characteristics of an economic evaluation on which the study results 
are based. The items of this checklist can be divided into methodological and non-
methodological issues, the latter being issues such as the way the research question was 
formulated, the timing of the study, and how the study findings were reported. The 
methodological issues mentioned in the checklist are the issues of the competing alternative, 
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relevant costs and consequences, accurate measurement of costs and consequences, credible 
valuing of costs and consequences, differential timing, incremental analysis, and the issue of 
uncertainty. 
AIM OF THE THESIS 
In this thesis several methodological issues for the economic evaluation of health care 
technologies will be discussed. This thesis addresses research questions on the following 
issues in economic evaluation: 
- The choice of the competing alternative; 
- The relevant costs and consequences; 
- Accurate measurement of costs and consequences; 
- Credible valuing of costs and consequences; and 
- The uncertainty of the results. 
Finaly, regarding these issues, a comparison is made of the different guidelines for performing 
economic evaluations. 
OUTLINE OF THE THESIS 
In Chapter 2, the issue of the choice of the competing alternative is described. The choice of 
the alternative to which the intervention under study is compared to is essential for the 
findings of a study. For decision-makers, the comparator should be relevant in the sense that 
the study should reflect the actual decision at stake. Chapter 2.1 concentrates on the 
competing alternative in the situation where a diagnostic technology is being evaluated. In the 
case of economic evaluation of diagnostic technologies, there are various categories of 
alternatives for comparison: test vs. no-test, test A vs. test B, and so on. Diagnostic facilities 
are hardly ever used solitary and in this case the evaluation of a specific test should be 
performed in the context of alternative tests, or more specifically, in the context of the 
sequence of tests. When more than one diagnostic test is considered, decisions have to be 
made not only about which diagnostic tests to perform, but also about the sequence of testing. 
A method is described to evaluate the use of a diagnostic test in the context of the use of 
alternative tests. The aim of this method was to explore a model for optimising the sequence 
of diagnostic tests based on the principles of a cost-minimisation analysis. Thus, an emphasis 
has been put on efficient sequence of testing without losing any diagnostic information. First, 
the principles of the model are described, followed by a description of two applications of the 
model: diagnosis of Helicobacter Pylori and benign prostatic hyperplasia. Chapter 2.2 focuses 
on the issue of the competing alternative in the situation of comparing therapeutic alternatives. 
As with evaluating diagnostic technologies, the question of a therapeutic comparator is 
essential to the findings of a study. For instance, for licensing purposes most pharmaceutical 
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trials are based on a placebo comparison while for policy decisions, a comparison with normal 
care or the best alternative would be relevant. Modelling, which involves applying 
mathematical techniques to synthesis available information concerning a therapeutic 
intervention, can be used to extend comparators. Besides, modelling can be useful to extend 
trail results in the situation that effectiveness has been studied but costs were not subject to 
analyses. In this chapter a decision analytic cost-effectiveness comparison is made of different 
empirical treatment strategies of invasive fungal infection (EFT) in patients with 
haematological malignancy. In the first strategy, amphotericin В desoxycholate (DC-Amb) 
was given as first line empirical treatment of IFI and was changed to liposomal amphotericin 
В (L-Amb) in case of a treatment failure or nephrotoxicity (DC/L-Amb strategy). In the other 
strategy, L-Amb was used for empirical first line therapy of ГИ (L-Amb strategy). As far as 
we know the costs and effectiveness of these strategies have never been studied prospectively 
or retrospectively. 
The choice of the costs and consequences that are to be analysed in an economic 
evaluation depends on their relevancy. Two aspects play an important role when choosing 
costs and consequences. First, the time horizon used should extend far enough in the future to 
capture the major health and economic outcomes. Second, the viewpoint or perspective of a 
study can influence the choice of the cost calculation method. These aspects are related to the 
issue that is described in Chapter 3: the relevant costs and consequences in an economic 
evaluation. In Chapter 3.1 the importance of determining the time horizon is examined. 
Determining the time horizon of a study is especially relevant when evaluating diagnostic 
tests, because this might influence the study findings. In principle, the process of diagnosis 
focuses on reducing uncertainty about the presence of a disease of a person. Hence, the 
number of cases detected is an effectiveness parameter that is used regularly in this type of 
research. However, this parameter can be regarded as an intermediate outcome measure in the 
sense that it does not reflect the actual health outcome as a result of diagnosis and possible 
treatment of a patient. In case it is not possible to prospectively measure health outcome 
because of the limited time horizon of the prospective part of the study, modelling can be a 
solution to extend the time horizon of the analysis. A decision analytic model is used to 
compare alternative strategies for diagnosis and treatment of invasive aspergillosis. Chapter 
3.2 illustrates the relevancy of the methods used to determine costs involved in medical 
technologies. The methods to analyse costs of health care technologies are highly dependent 
on the perspective of the economic evaluation. This is demonstrated by an analysis of the 
costs related to cochlear implants for children where after an explicit comparison with results 
of cost analyses of other studies is made. 
Accurate measurement in appropriate physical units of costs and consequences is 
discussed in Chapter 4. Incorporating productivity costs in an economic evaluation can have a 
substantial influence on the study findings; however, the methods used to measure 
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productivity costs are still being developed . Retrospective measurement of absence from 
work as a basis for calculating productivity costs is often used. Different recall periods up to 
twelve months can be found in the literature. Precision and accuracy measuring absence from 
work retrospectively is studied using both questionnaire data and prospectively registered 
data. 
In Chapter 5, the issue of credible valuing of costs and consequences is dealt with. 
Chapter 5.1 concentrates on valuing productivity costs. As stated before, incorporating these 
costs can have a substantial influence on the study findings. However, valuing each day of 
absence from work merely reflects potential productivity costs instead of real productivity 
costs. The impact of considering compensating mechanisms for not being able to work when 
calculating these type of costs is shown using diagnosis and treatment of patients having 
dyspeptic complaints. 
Valuing consequences of a diagnostic technology can be done in several ways. Often 
the consequences are reflected in measures such as the number of patients diagnosed 
accurately or the impact of the physician's decision. However, the principle reason to perform 
diagnostic tests is to gain information and the questions arises if the diagnostic information as 
such can be valued. Willingness to pay analysis was used as a measure of outcome to reflect 
value of the non-decisional diagnostic information to persons at risk for histoplasma 
capsulatum. In Chapter 5.2 several hypotheses related to the value of non-decisional 
diagnostic information are presented and studied in order to investigate the construct validity 
of willingness to pay measurement. 
The issue of the uncertainty of the results of an economic evaluation is dealt with in 
Chapter 6. The summary outcome of an economic evaluation in general is an incremental 
cost-effectiveness ratio, which is calculated by dividing difference in costs between 
alternatives by difference in consequence or effect. This ratio reflects the investment that is 
necessary to gain one unit of effect. However, this ratio is a point estimate that does not give 
insight into the uncertainty of the study findings. In this chapter a comparison is made 
between different statistical methods to study the uncertainty of this ratio using data from a 
prospective randomised trial. 
In Chapter 7 the findings of the previous chapters are briefly summarised and 
discussed in the light of the aims of this thesis. A comparison is made of the different 
guidelines for the economic evaluation of health care technologies that exist in several 
countries. 
1. The term 'productivity costs' is recommended by the Panel on Cost Effectiveness in Health and 
Medicine, appointed by the US Public Health Service, as an alternative term for indirect non-medical 








THE ISSUE OF THE CHOICE OF THE COMPETING 
ALTERNATIVE: DIAGNOSTIC TEST SEQUENCE 
Based on Severens JL, Vries Robbé PF de & Verbeek ALM (1999). Optimising diagnostic 
test sequences: the probability modifying plot. Methods of Information in Medicine 38: 
50-55, 
and Severens JL, Sonke GS, Laheij RJF, Verbeek ALM & Vries Robbé PF de. Efficient 





An important issue when performing an economic evaluation is the choice of the competing 
alternative to which the intervention under study is compared, because this can influence 
study findings (Berger, 1995). For decision-makers, the comparator should be relevant in a 
sense that the study should reflect the actual practical decision at stake. In the case of 
evaluating diagnostic facilities, there are various categories of alternatives for comparison: for 
instance test versus no test, one test versus another test, and test versus direct treatment. In a 
literature review it was shown that the test versus test comparison is performed most 
(Severens & van der Wilt, 1999b). However, diagnostic facilities are hardly ever used solitary 
and therefore the evaluation of a specific test should not only be performed in contrast to other 
tests but also, when relevant, in the context of the other tests. On the assumption that time 
delay is of no importance, sequential use of diagnostic tests is potentially more efficient than 
performing multiple tests simultaneously (Doubilet & Cain, 1985). Therefore, decisions have 
not only to be made about which diagnostic tests to perform, but also about the sequence of 
testing. In the former case, the marginal gain of each test in a sequence can be determined and 
knowledge from previously performed tests can be used to decide which, if any, test should be 
performed next. In case many factors such as test characteristics and costs of numerous 
diagnostics tests are to be included in diagnostic strategy considerations, the physician's 
ability to intuitively integrate the results seem to be reaching a limit (Henschke et al., 1997). 
There is a need for a methodology for evaluation of different testing strategies. 
Several methods can be used to evaluate the optimal sequence of diagnostic tests. 
Most methods which are designed to evaluate test sequences, however, are based on the 
principle of including tests with respect to their gain in certainty of disease status. The quest 
for diagnostic certainty about a specific disease can cause excessive testing, but complete 
certainty about the presence of disease is rarely achieved (Kassirer, 1989; Putterman & Ben-
Chetrit, 1995). The choice of effective diagnostic tests is crucial, but should not only be based 
on test characteristics such as sensitivity and specificity; probability of disease and utilities of 
correct and incorrect disease classification should also be considered (Boyko, 1994). The 
decision problem of which diagnostic test to use and besides this, comparison of diagnostic 
strategies can be structured in decision trees (Kent et al, 1995; Erkel et al, 1996; Goldberg 
Kahn et al., 1997; Severens et al., 1997). However, unmanageable bushy decision trees result 
when all theoretically possible strategies of two or more tests are investigated instead of a 
predetermined strategy. Besides, incomplete and inconsistent decision trees might result from 
this exercise. Decision tables, which are a simplification of bushy decision trees, can be used 
to overcome these problems (Glasziou & Hilden, 1986). Despite this advantage, decision 
tables are under-utilised, for which the reason is not clear (Glasziou, 1994). 
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In this chapter a method is described to evaluate the use of a diagnostic test in the context of 
the use of alternative tests. The aim of this method was to explore a model for optimising the 
sequence of diagnostic tests based on efficiency criteria, thus using the principles of cost-
minimisation analysis. This means thai an emphasis has been put on efficient sequence of 
testing without losing diagnostic information relevant for the treatment decision. 
METHODS 
Data from a study on urinary tract infection were used to develop the model. The data 
concerned the results of eleven diagnostic tests which examined the urine from a group of 550 
patients who were suspected of having urinary tract infection. For reasons of simplicity, all 
test results were transformed into dichotomous outcomes. Besides these tests, a urine culture 
was performed which was used as a gold standard on the basis of which the pre-test 
probability of disease in this population was determined to be 0.145 (80/550). Disadvantages 
of the urinary culture are that it is expensive and that it takes several days before the test 
results are available (Lachs et al., 1992). Therefore, other, faster tests can be used to 
determine whether treatment is indicated. Analysis of the data showed that only three of out of 
the eleven tests made a significant contribution to predicting the presence of urinary tract 
infection, defined as having a positive urinary culture. These tests will be called Ti, T2 and T3. 
In summary, the data of Ть T2 and T3 and the urinary culture were selected to develop the test 
sequence model2. 
Defining the treatment threshold 
The concept of a treatment threshold reflects the fact that decisions about treating a patient are 
usually made under uncertainty. If the probability of a person having the disease is low, 
treatment is not indicated; if the probability of disease is high, treatment is indicated. The 
estimation of the probability of disease at which one is indifferent as to giving treatment and 
withholding treatment is called the treatment threshold probability. This treatment threshold 
probability can be estimated intuitively or calculated from the net benefits and cost of 
treatment (Sox et al, 1988). This threshold is a result of weighing the following situations 
(Pauker & Kassirer, 1980; Kassirer, 1989): 
- a healthy person, not being treated, 
- a person having the disease, not being treated, 
- the deterioration in health status by treating a healthy person, and 
2. Unpublished; the data on urinary tract infection are solely used as an illustration for our model. 
The three test included in the model are Gram preparation, which is a microscopic test to determine 
the presence of bacteria; Kova microscopic test to determine the number of bacteria; Miditron urine 
dipstick to determine the presence of nitrite. 
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Probability of disease 
Figure 2.1 The graph visualises the relationship between the probability of disease and the utility 
of possible treatment or withholding treatment decisions. The intersecting lines indicate the expected 
utility of withholding treatment and the expected utility of treatment. The treatment threshold probability 
of having the disease is determined to be 0.67. 
- the gains in health status by treating a person having the disease. 
Consequently, determining the treatment threshold is possible when the four possible 
situations are valued, which may occur after having made a decision about treatment or no 
treatment. 
In our example, the treatment threshold is estimated for the decision about treating or 
not treating a person suspected of having urinary tract infection. A specific health state can be 
given a utility, which can be defined as a value between 0 and 1 which reflects the relative 
value of one health state to another. Suppose a healthy person (a person without urinary tract 
infection) is given the highest possible utility 1. A person who has urinary tract infection and 
who is not treated will have a lower utility because of the burden of the disease, for instance 
0.75. In Figure 2.1 these two levels of utility are indicated on the left and right ordinate y. The 
probability of disease is indicated on the x-axis. The line which is drawn between the points is 
called the expected utility line of withholding treatment and indicates which utility can be 
expected when treatment is being withheld, given a certain probability of disease. 
In this example, this line is defined by y = 1 - 0.25*, where y is the expected utility 
and χ is the probability of disease. An expected utility line of treatment can be drawn 
between the next two points. If a healthy person is treated for urinary tract infection, the 
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burden of treatment (and suspicion of having the disease) will decrease the utility, for 
instance, the utility will become 0 9 A sick person who is treated will gain utility from being 
treated, but will not have a perfect utility of 1 because of the burden of treatment, for instance 
0 8 In this example, the expected utility line of treatment is indicated by y = 09-Ol* The 
intersection between the two lines represents the treatment threshold probability At this point 
there is indifference between expected utility of treatment and withholding treatment, hence at 
1-0 25л: = 09 - 0 lx This equation results in a treatment threshold probability of 0 67 As can 
be seen from the graph, at a lower probability of disease the expected utility of withholding 
treatment is higher than the expected utility of treatment and, therefore, withholding treatment 
is the best thing to do A probability of disease which is higher than the treatment threshold 
probability indicates treatment as the choice with the highest utility For our example, the 
utilities on which the treatment threshold is based are estimations Depending on the defined 
utility lines, the treatment threshold can be sensitive to changes in utilities In summary, the 
treatment threshold probability approach reflects the utilities which are given to both 
situations of misclassification healthy persons misclassified as being sick, and sick persons 
misclassified as being healthy 
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When more than one test is considered to determine the presence of a disease, a decision table 
is made which contains an overview of the possible combinations of test results (Table 2.1). 
Given three dichotomous tests in our illustration, eight combinations of test results are 
possible. For each of these combinations the post-tests probability of having urinary tract 
infection is determined on the basis of the gold standard. Furthermore, for each test result 
combination, the post-tests probability is compared to the treatment threshold. The final 
column of this table indicates whether the test result combination leads to a probability higher 
or lower than the treatment threshold. In the former case treatment is indicated; in the latter no 
treatment is indicated. As Table 2.1 shows, the combinations of test results (Ті+,Т2+,Тз+), 
(Т|+,Т2+,Тз") and (Ті+,Т2,Тз+) indicate treatment. The other combinations of test results 
indicate no treatment because the post-tests probability is lower than the treatment threshold 
probability. A decision table gives a clear overview of the possible combinations of test 
results, but it does not indicate whether applying a diagnostic test is useful at all. 
Test thresholds 
Applying a diagnostic test or a combination of diagnostic tests is only considered to be useful 
if it can change the probability of disease from being lower to being higher than the threshold 
probability (or the other way around). Only if this is the case, a test result will influence the 
therapeutic decision. Successively, the range of pre-test probabilities can be determined for 
which testing is useful. In this way, the pre-test probability of having the disease is part of the 
model. Two threshold probabilities have to be calculated, the no-treat/test threshold 
probability and the test/treatment threshold probability (Sox et al., 1988). Between these 
threshold probabilities testing is indicated. These threshold probabilities are calculated on the 
basis of the defined treatment threshold probability and the likelihood ratios of positive 
combinations of test results and negative combinations of test results3. In our example, three 
combinations of test results, (Ті+,Т2
+,Тз+) or (Ті+,Тг+,Тз") or (Ті+,Т2",Тз
+), indicate presence of 
disease. As can be summarised from Table 2.1, 44 out of the 80 diseased people had one of 
the above mentioned positive combinations of test results, which leads to a sensitivity of 0.55. 
The specificity is calculated to be 0.99 (466/470). The sensitivity and specificity lead to a 
likelihood ratio of negative combinations of test results of 0.45 (thus, a negative result is 0.45 
more likely in patients than in non-patients). This likelihood ratio and the treatment threshold 
probability of 0.67 are used to calculate the test/treatment threshold probability, which is 0.82. 
Similarly, the likelihood ratio of the positive combinations of test results is calculated to be 55 
(thus, a positive result is 55 more likely in patients than in non-patients). Again, when the 
treatment threshold probability and this likelihood ratio are considered, the no-treat/test 
3. For reasons of simplicity, a combination of test results which indicates the presence of disease is 
called positive. A combination of test results which indicates the absence of disease is called negative. 
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threshold probability is found to be 0.04. In conclusion, two threshold probabilities have to be 
calculated between which applying diagnostic tests is useful, regarding the treatment/no-
treatment decision. Given the pre-test probability of 0.145 in our population, testing is useful. 
The probability modifying plot 
Once testing is determined to be useful, the probability modifying plot can be used as an 
instrument to visualise and examine the efficiency question about the sequence of tests. With 
our example on urinary tract infection, arbitrarily starting with Ti as a first test, the probability 
of disease given a positive Ti is 0.82 and the probability of disease after a negative Ti is 0.11. 
The change from the pre-test probability to the probabilities after using Ti as the first test can 
be seen in a probability modifying plot (Figure 2.2). The y-axis indicates the probability of 
having the disease, and the x-axis indicates the different steps in the diagnostic process: the 
stage after a first test, the stage after a first and second test, and the stage after all three tests. 
The horizontal line indicates the treatment threshold probability at 0.67. The points above 
each test mark on the x-axis indicate the probability after a certain test result or combination 
of test results. At each point in the plot, the specific test being used at a certain stage is 
mentioned. Because of the dichotomous tests, from each point in the plot two lines continue to 
the next test mark, one line ascending and one line descending. An ascending line indicates 
that a positive test will result in a higher probability of disease; a descending line indicates a 
lower probability after a negative test result. After a specific result from Ti, again an 
ascending and a descending line continue as a result of performing Тг. This diversion from 
each point in the plot continues until the eight possible post-test probabilities as mentioned in 
Table 2.1 are reached. These post-test probabilities are indicated on the right y-axis. 
Efficiency of testing 
To incorporate efficiency criteria in the probability modifying model, the principle of 
determining the usefulness of a test or a series of tests can be used. As can be seen from the 
probability modifying plot, after Tf the results of Тг and T3 being either Ί2
+ and Тз+, Тг" and 
Тз+, T2
+ and Тз", or T2" and T3', do not lead to a probability that lies above the treatment 
threshold probability. Therefore, once Ti has a negative test result, further testing is not useful 
considering the treatment versus withholding treatment decision (Fendrick et al., 1995). The 
situation after a positive result of Τ1 is completely different. A negative result from Тг (after 
Ti+) can still lead to a probability which is higher or lower than the threshold. Therefore, all 
persons with Ti+ should be subjected to Тг. After Ti+ and Тг+, the result of T3 (either positive 
or negative) no longer influences the decision about treatment and is therefore considered to 
be redundant for this subgroup of patients. Although the persons with Ti+ and T2~ have a 
probability which is lower than the threshold, this situation is not yet certain given the fact 
that the result of a third test critically influences the probability of having the disease (0.46 
23 
Chapter 2.1 
Probability of disease 
Figure 2.2 The probability modifying plot of the test sequence T b T2, T3 shows the treatment 
threshold probability and the changes in the probability of having the disease after specific test results. 
The plot indicates in which case further testing is redundant. For instance, when T Í is negative, the 
results of the use of T2 and T3 no longer influence the treatment/no-treatment decision. 
versus 0.83). With regard to the test sequence ТіЛгЛз, the result of the third test Тз will be of 
importance considering the treatment decision for only those persons who already had test 
results Ti+ and T2~. In conclusion, from the probability modifying plot it is clear when further 
testing is redundant. 
With the help of the plot, the total number of tests needed or the total cost of testing 
can be determined for a specific test strategy. For each subgroup of patients it is possible to 
determine for a given sequence whether one, two, or three tests are necessary to decide 
between treatment or withholding treatment. Once the number of tests needed is determined, 
the cost of diagnostic tests involved can easily be included in the probability modifying 
model. With regard to our example of urinary tract infection, the prices of the tests are as 
follows: TV (Gram preparation) Dfl. 25.50; T2: (Kova bacteria) Dfl. 1.70; T3: (Miditron 
nitrite) Dfl. 6.804. To decide which test sequence is most efficient, regarding either the 
criterion number of tests needed or the total cost of testing, all possible sequences must be 
evaluated. 
4. One US dollar is approximately 1.72 Dutch guilder (Dfl.) 
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RESULTS 
The probability modifying model is used to explore the efficiency of alternative sequences of 
tests. In the first probability modifying plot, the test sequence Ti, T2, T3 is given; however, 
there are six possible sequences of the three tests which all lead to the same final post-test 
probabilities. These six sequence strategies are shown in Figure 2.3. As can be seen from the 
different probability modifying plots in this figure, the incremental increase or decrease of the 
probability differs for each sequence and is dependent on the next test in a row. The question 
remains which sequence is the most efficient. Consider the original sequence T b T2, T3 in plot 
A. On the basis of this plot, the total number of tests needed to answer the treatment/no-
treatment question is presented in Table 2.2. 
To decide which test sequence is most efficient, all possible sequences must be 
evaluated as has been done with the sequence Ti, T2, T3. The results of the calculations for all 
six test sequences are presented in Table 2.3. As can be seen from this table, the test sequence 
Ti, T3, T2 gives the lowest number of tests needed to determine whether a person of this 
specific population has a disease probability that indicates treatment or withholding treatment. 
This is the most efficient sequence, considering the number of tests as a criterion. 
Incorporating the cost of testing gives the results as shown in the last column of Table 2.3. 
Despite the lowest number of tests, strategy 2 does not have the lowest total cost for testing. 
Sequences 3 and 5 have the least cost and are therefore the most efficient test sequences if 
cost is to be the criterion. The combination of both T2 and T3 selects a number of persons for 
whom the expensive Ti is no longer necessary. It is not possible to make a distinction between 
strategies 3 and 5 on the basis of the cost criterion alone. 









no further testing 
+ (12) 
-(13) 
no further testing 
number of tests 
(36) * 2 
(12) *3 
(13) *3 
(489) * 1 
total number of tests 636 
( ): number of patients between parentheses 
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Probability of disease 
0 4 0 
0 20 






Probability of disease 




0 6 0 
0 40 
0 20 






Probability of disease 
P(D+) P(D*U1) P(D+U1.T3) P(D+IT1 .T3.T2) 
Plot В 





P(D+) P(D+IT2) P(D+IT2,T3) P(D+IT2.T3,T1) Р(Оч-) P(DtlT2) P<D+rT2,T1) P(DtlT2.T1 ,T3) 
Plot С Plot D 
Probability of disease 
000 
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Plot E 
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Plot F 
Figure 2.3 In the situation of three dichotomous tests, six different sequences of test strategies 
exist. The incremental value of information of each test can be noted by the slope of the lines in the 
plots. These plots are the basis for calculating the number of tests needed and the total costs of 
testing. 
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Table 2.3 Number of tests needed and cost of testing, given all possible test sequences. 
sequence 
Τ,Τ 2 Τ 3 






550 * Τ, 
550 * Τ, 
550 * Τ2 
550 * Τ2 
550 * Τ3 




550 * Τ3 
550 * Τ, 
550 * Τ2 
550 * Τ, 
third test 
2 5 * Τ 3 
17*Τ 2 
193* Τ, 
2 5 * Τ 3 
193* T Í 
17*Τ 2 















We described a model to optimise the sequence of diagnostic tests on the basis of efficiency, 
illustrated with data on urinary tract infection. Extensive validation of the test results 
according to this specific disease was beyond the scope of this description; no definite 
conclusions can be drawn about the specific test sequence for urinary tract infection. 
However, we applied the model using two databases on diagnostic tests: diagnosis of 
Helicobacter Pylori and Benign Prostatic Hyperplasia. 
Diagnosis of Helicobacter Pylori 
Description of disease and diagnosis 
Helicobacter Pylori is one of the most common chronic infections in humans. The infection 
may lead to substantial morbidity, and, in the long run, it may cause peptic ulcer or gastric 
cancer, thus mortality can be attributed to this phenomenon. However, widespread non­
invasive testing, such as a breath test and serology, followed by treatment of non-symptomatic 
infected persons is beyond issues of feasibility and financial consideration. Besides this, 
information on possible unwanted side effects of this approach is lacking (Rabeneck & 
Graham, 1997). Therefore, whether a person is infected with Helicobacter Pylori only 
becomes relevant in persons with dyspepsia, which can be described as episodic or persistent 
upper abdominal pain or discomfort that is thought by the physician to arise in the upper 
gastrointestinal tract. Only the invasive upper endoscopy will reveal the cause of these 
complaints and is therefore the most widely used diagnostic tool (de Boer, 1997). Endoscopy 
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results in diagnosis of erosive esophagitis, peptic ulcer disease and gastric cancer only in one 
third of the times (Rabeneck & Graham, 1997). The question arises what to do with dyspeptic 
patients with no detectable organic disease. During endoscopy, multiple mucosal biopsy 
specimens can be taken from the stomach. To determine the presence of Helicobacter Pylori in 
the biopsies several tests can be used. Histologic examination is performed by a pathologist on 
several cuts of the biopsies and is based on the identification of micro-organisms with 
appropriate morphology, location and staining characteristics. Bacterial culture of the biopsies 
is based on the principle that Helicobacter Pylori bacteria can grow on media in the laboratory 
(Barthel & Dale Everett, 1990). Rapid urease tests are based on demonstrating urease activity 
in the biopsy specimen and these test can easily be performed in the endoscopy suite. Besides 
these, polymerase chain reaction and phase contrast microscopy can be used but are left out of 
our analyses because they presently have no significant clinical application (de Boer, 1997). 
Patient data 
The patient data which were used for our probability modifying model concerned a study 
population of consecutive patients undergoing routine endoscopy at a general hospital in the 
Netherlands. The patients included in the study all had dyspeptic complaints and had been 
sent to the outpatient clinic by a specialist or a general practitioner for open-access endoscopy. 
Endoscopy was performed and biopsies were taken. Two biopsies were used for bacterial 
culture, histologic examination was performed on another two biopsies, and one biopsy was 
used for a CLO-test, a specific make of a rapid urease test, which was analysed after 24 hours. 
The materials of 869 endoscopic procedures regarding 627 patients were used in our analyses. 
An extensive description of the data can be found elsewhere (Laheij et ai, submitted). 
Application of the model 
As mentioned earlier, the treatment threshold probability can be estimated intuitively. In the 
case of Helicobacter Pylori this can be done by weighing the situations of treating a 
Helicobacter Pylori positive person, not treating a Helicobacter Pylori positive person, and 
treating a Helicobacter Pylori negative person. In case of Helicobacter Pylori it can be argued 
that the health status of a healthy person without Helicobacter Pylori and a person who is 
successfully treated for Helicobacter Pylori is equal. In case the relatively low level in health 
state of a Helicobacter Pylori positive person not being treated and the burden of treatment of 
a Helicobacter Pylori negative person would estimated to be equal, this would result, for 
instance, in y = 1 - O.lx for withholding treatment and y = 0.9 + O.lx for treatment. The 
treatment threshold would therefore be 0.50 (Figure 2.4). For the situation that a Helicobacter 
Pylori positive person is not being treated and a Helicobacter Pylori negative person is being 
treated it can be motivated that the first situation is worse because dyspeptic symptoms have a 
negative impact on health status whereas falsely being treated only have a slight impact. 
Presume a proportion of 1 to 2 for both situations of misclassification; this can be expressed 
as y = 1 - 0.2* for withholding treatment and, given y - 0.9 + 0.1* for treatment, the threshold 
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would become 0.33 (Figure 2.4). Thus, in this situation, the absolute utilities of the health 
states are not relevant; the relation or proportion between both situations of misclassification 
is decisive when determining the threshold (Phelps, 1997). 
Table 2.4 reflects the decision table based on our data. Again, given three dichotomous 
tests, eight combinations of test results are possible. The post-test probability for each of these 
combinations in the Helicobacter Pylori diagnosis case is determined on the basis of a gold 
standard which was ascertained by a least square method (Laheij et al, submitted). Four of the 
eight possible test result combinations indicate presence of Helicobacter Pylori, in fact all 
combinations in which at least two tests are positive. As can be summarised from this table, 
sensitivity of these test result combinations is 0.997 (342/343), and specificity 0.988 
(520/526). The likelihood ratio of positive test combinations and negative test combinations 
are therefore 83.1 and 0.003 respectively. Given the defined treatment threshold and these 
likelihood ratios, calculation of the test-thresholds results in a no-treat/test threshold 
probability of 0.012 and a test/treatment threshold probability of 0.997. Regarding the pre test 
probability of disease in our study population of 0.40 it can be concluded that testing is 
indicated. 
Probability of disease 
Figure 2.4 Plot showing the treatment threshold probabilities for different proportions between two 
situations of misclassification: the decline of utility because of withholding treatment to a diseased 
person on the one hand and the decline of utility because of treating a healthy person on the other 
hand. 
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Table 2 4 Post-test probabilities of test combinations of Helicobacter Pylon tests in relation to the 








































P(D1 C+, H+, U+) = 1 00 
P(D+I C+, H+, U ) = 1 00 
P(D+I C+, Η , U+) = 0 97 
P(D+IC+, H,U) = 0 10 
P(D+I С , H+, U+) = 1 00 
P(D*I С , H+, U ) = 0 08 
P(D + IC,H,LT) = 0 16 










С bactenal culture, Η histologic examination, U rapid urease test 
> post-test probability higher than treatment threshold probability 
< post-test probability lower than treatment threshold probability 
( ) number of patients between parentheses 
Again, once testing is determined to be useful, the probability modifying plots can be drawn 
(Figure 2 5) Because culture, histology and urease test all have a rather high sensitivity and 
specificity the six plots look more or less the same This is confirmed when the calculations 
for the number of tests needed for the various test sequences are compared (Table 2 5) Only 
in a relatively small number of cases a third test is necessary to finally determine the 
Helicobacter Pylon infection status of a patient, related to the treatment threshold Using the 
total number of tests needed as an efficiency criterion, a straightforward preference can hardly 
be made However, when the costs for the different test are incorporated in the calculations, it 
seems to be clear that the sequence in which histologic examination is performed last and only 
in patients for which culture and the urease test do contradict, is the sequence which is most 
efficient Regarding the costs of testing which can be expected for each patient these 
sequences result in Dfl 48 The sequences in which either culture or urease is performed last 
result in Dfl 96 and Dfl 115 per patient, respectively 
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Figure 2.5 Overview of 6 plots showing the different test sequences regarding bacterial culture 




Table 2.5 Number of tests needed and cost of testing, given all possible test sequences for 
diagnosis of Helicobacter Pylori. 
sequence 
C H U 
C U H 
H U C 
H C U 
U H C 




































C: bacterial culture; H: histologic examination; U: rapid urease test. 
Diagnosis of Benign Prostatic Hyperplasia 
Description of disease 
Benign Prostatic Hyperplasia (BPH) is a common disease in elderly men. BPH is a histologic 
condition which may give rise to a benign enlargement of the prostate. The enlargement of the 
prostate gland can cause progressive blockage of urinary flow. Thus, four properties are 
related to the disease process of BPH: 1) histologic BPH 2) macroscopic benign enlargement 
of the prostate gland (ΒΡΕ), 3) obstruction of the bladder outlet (BOO) and 4) lower urinary 
tract symptoms (LUTS), such as diminution in the calibre and force of the urinary stream, 
hesitancy initiating voiding, inability the terminate micturition abruptly, a sensation of 
incomplete bladder emptying and nocturia (Abrams, 1995). More than 30% of the men older 
than 40 years of age do have symptoms which might indicate BPH. This percentage gets 
higher regarding age: at the age of 85 about 90% of men have to deal with urinary symptoms 
which may indicate BPH (Jolleys et al, 1994). Mean age at diagnosis is approximately 60 
years. However, the high prevalence of symptoms does not indicate a high prevalence of BPH, 
because the symptoms associated with BPH can result from other urinary conditions such as 
prostate cancer, urethral stricture and neurogenic bladder (Norman et ai, 1994). On the other 
hand, only about 50% of all microscopically identifiable BPH lesions ever give rise to a 
macroscopically enlarged prostate. An enlarged prostate may obstruct the urethra leading to 
5. Prices of the tests are based on estimates of real costs: Dfl. 31 for culture; Dfl. 83 for histology; 
and Dfl. 10 for the urease test (price level 1998). 
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LUTS, although many of the more bothersome symptoms are caused by resulting bladder 
hypertrophy. Moreover, an enlarged prostate not always causes LUTS. 
Patient data 
Although in general people tend to use the word BPH, in this application of the probability 
modifying model we evaluate the test sequence to diagnose of BOO. We used patient data 
from a population of consecutive patients form the outpatient urology department of the 
St.Radboud University Hospital Nijmegen. All patients who were included in the study were 
referred to the hospital by their general practitioner or by urologists from community hospitals 
because of LUTS. Patients underwent a diagnostic protocol which besides physical 
examination included several diagnostic tests: transrectal ultrasound evaluation of the size of 
the prostate (P, Prosvol); free uroflowmetry to determine the maximum flow rate (Q, Qmax), 
and post void residual urine volume measured by a abdominal ultrasound (R, Resvol). For the 
sake of the model we determined the cut-off values at 50 ml, 15 ml/sec, and 50 ml, 
respectively. As the gold standard for presence or absence of BOO, pressure flow study (PFS) 
was used (Abrams, 1995). The urethral resistance factor was based on the point of maximum 
Table 2.6 Post-test probabilities of test combinations of diagnostic tests for Bladder Outlet 








































Ρ(ϋΊ P+, Q\ FT) = 0.80 
P(D+I P\ Q+, R") = 0.79 
P(D+I P+, Q, R+) = 0.78 
P(D+I P*, Q", R) = 0.30 
P(D+I P", Q+, R+) = 0.75 
P(D*I P", Q+, R") = 0.54 
P(D+I P", Q", R+) = 0.23 










P: prostate volume; Q: maximum flow rate; R: post void residual volume 
>: post-test probability higher than treatment threshold probability 
<: post-test probability lower than treatment threshold probability 
( ): number of patients between parentheses 
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flow rate and corresponding detrusor pressure For this standard, a cut-off value of 28 cmHiO 
was used The data of a total of 1,040 patients were used in our analyses Rosier et al (1996) 
give an extensive description of the patient population and the diagnostic tests performed 
Application of the model 
Regarding a treatment decision, it should be noted that for BOO a wide range of treatment 
options are available ranging from watchful waiting and pharmacotherapy to open 
prostatectomy Each treatment option with its specific possible benefits and potential risks 
does influence the final treatment decision Besides this, it is advised that the patient should 
play a central role in determining the need for a specific treatment (McConnel et al, 1994) 
Therefore the treatment threshold could not be determined empirically, nor estimated, and we 
analysed the model using several treatment thresholds An overview of the possible 
combinations of test results and the number of patients related to each combination is 
presented in Table 2 6 As can be seen from this table the post-tests probabilities of having 
BOO range from 0 24 to 0 80 This range indicates for which pre-test probabilities of BOO 
testing is useful regarding the treatment/no-treatment decision Using the lowest and the 
highest value of this range, the no-treat/test threshold and test/treat threshold are calculated to 
be, respectively, 0 10 and 0 89 Given the pre-test probability of 0 62 in our population 
(643/1,040), testing is useful Regarding the final column in this table we used a treatment 
threshold of 0 50 
Table 2 7 Number of tests needed and cost of testing, given all possible test sequences for 
diagnosis of Bladder Outlet Obstruction using a threshold of 0 50 
sequence 
P Q R 
P R Q 
Q R P 
Q P R 
R Q P 




































Ρ prostate volume, Q maximum flow, R post void residual volume 
6 Pnces (level 1998) are based on estimates of real costs Dfl 128 50 for transrectal ultrasound 
evaluation of the size of the prostate, Dfl 254 50 for free uroflowmetry to determine the maximum 
flow rate, and Dfl 60 for measuring the post void residual volume by a abdominal ultrasound (pnce) 
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Figure 2.6 Overview of 6-plots showing the different test sequences regarding prostate volume 
(P), maximum urinary flow rate (Q), and post void residual urine volume (R) for determining the 
presence of Bladder Outlet Obstruction. 
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The six sequence strategies regarding diagnostic tests of BOO are shown in Figure 2.6. Again, 
to decide which test sequence is most efficient, using a predetermined treatment threshold, the 
number of tests needed and cost of testing is calculated for each sequence. The results when 
using a threshold of 0.50 are given in Table 2.7. From this table it can be seen that regarding 
the number of tests needed to finally decide if a patient is indicated to be treated (post-test 
probability above the treatment threshold) or not to be treated (post-test probability below the 
treatment threshold) the test sequence Qmax-Prosvol-Resvol is most efficient. Regarding the 
cost of testing this is the sequence Qmax-Resvol-Prosvol. However, we decided to evaluate 
the most efficient sequence of testing using a range of treatment thresholds. These results are 
shown in Table 2.8. 
Table 2.θ Most efficient test sequences (number of tests needed and cost of testing) of 
diagnostic tests for Bladder Outlet Obstruction, regarding different treatment thresholds. 
treatment threshold most efficient test sequence 






















In this chapter we described a model to optimise the sequence of diagnostic tests on the basis 
of efficiency, first, illustrated with data on urinary tract infection. Extensive validation of the 
test results according to urinary tract infection was beyond the scope of this illustration; no 
definite conclusions can be drawn about the specific test sequence for this disease. Although 
the applications of the model regarding diagnosis of Helicobacter Pylori and Benign Prostatic 
Hyperplasia are based on more appropriate patient data, remarks for discussion have to be 
made. 
Efficiency of the sequence of diagnostic tests was either defined as the least number of 
tests or the lowest total cost for testing. In fact, the model shows that the different sequences 
have identical effectiveness defined as the number of persons being misclassified, but the 
alternative sequences differ regarding the efficiency of the use of diagnostic tests. The 
probability modifying model is an extension of the existing, but hardly used approach of 
decision tables (Glasziou & Hilden, 1986). The fact that tests are redundant for subgroups of 
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patients is clearly shown and of influence on the preferred sequence when efficiency criteria 
are considered to be important. Other methods to optimise diagnostic test sequences such as 
the CART method are based on the principle to determine the optimal sequence on the basis 
of gain in certainty of disease status instead of efficiency (Breiman et al, 1984). Besides this 
method, a literature review revealed several studies in which sequence of diagnostic tests was 
studied. Decision analytic models were used regularly to compare alternative sequences of 
diagnostic tests (Severens & van der Wilt, 1999b), however, it was found that these studies 
evaluated predetermined sequences without studying all theoretical possible sequences (Kent 
et al, 1995; Goldberg Kahn et al, 1997; Henschke et al, 1997; Raab & Hornberger, 1997). 
The latter might have lead to unmanageable bushy decision trees. Examples of evaluation of 
diagnostic test sequences based on either prospective or retrospective patient data were also 
found, but again, the test sequence was predetermined without being exhaustively regarding 
all possible sequences (Chouaid et al, 1993; Einstein et al, 1995). Michel et al. (1996) 
studied the cost-effectiveness of diagnostic strategies in patients with suspected pulmonary 
embolism using a moddeling approach in which they evaluated all possible combinations of 
diagnostic tests. However, they assumed independence of the various diagnostic test, which is 
according to our model, a shortcoming of this approach. 
Limitations 
The model itself has certain limitations. First, test results are dichotomised and in reality 
information which is gained by performing a test is often not restricted to a dichotomous 
answer, thus consequently, information about the status of a patient can be lost. In the case of 
diagnosis of Helicobacter Pylori, especially the bacterial culture provides more information 
than only the presence or absence of Helicobacter Pylori. Culture not only answers whether 
Helicobacter Pylori is present, but also provides information on antimicrobial susceptibility of 
a patient and this information will allow to treat patients optimally on a individual basis (de 
Boer, 1997). Considering the other tests involved in this application, histologic examination 
can not be replaces by a rapid urease test in cases where malignancies must be excluded 
(Kolts et al, 1993). Besides this, as with most dichotomised tests, the post-test probabilities of 
disease are dependent on an arbitrary cut-off point (Diamond, 1992). For the BPH application 
the current evidence regarding uroflowmetry is insufficient to recommend a given cut-off 
value (McConnel et al, 1994). Besides this, the disease status of a patient has to be 
dichotomised using a gold standard and the results of the model are highly dependant of the 
accuracy of this standard. For instance, for the diagnosis of BOO, PFS is considered to be the 
gold standard. Despite the fact that PFS is an invasive technique (with possible 
complications), currently it is being considered as a standard diagnostic tool, making it 
necessary to define a different gold standard for BOO when incorporating PFS in the sequence 
of tests (Abrams, 1995). A second aspect which can not be incorporated in the model unless a 
financial translation of waiting time is made, is the turnaround time. In the Helicobacter Pylori 
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application, a drawback of the bacterial culture is that the turnaround time of diagnosis is 
rather long (4 to 7 working days) compared to both histology (2 to 3 working days) and rapid 
urease test (1 to 24 hours) (Kolts et ai, 1993). However, regarding Helicobacter Pylori 
diagnosis, the findings of the probability modifying model are in line with the idea that 
concordance of two tests leads to the conclusion that, related to any treatment no-treatment 
threshold, further testing is redundant. The suggestion by Cutler et al. (1995) that it may be 
reasonable to obtain histologic specimens at the time of endoscopy, but not submit them 
unless the rapid urease test results are negative, is not confirmed by our data and calculations. 
In contrast to their findings, from our model we have to conclude that there is a diagnostic 
benefit in performing additional tests after the rapid urease test is positive. Third, as with 
evaluating medical technologies in general, the selection of the research population is crucial 
for the result of the probability modifying model. Test characteristics, such as the likelihood 
ratios, are highly dependent on the patients selected and/or referred for testing and on the 
overall frequency of abnormal test results in the selected population (Knottnerus & Leffers, 
1992b; Schouw et ai, 1995; Phelps, 1997). Using data of consecutive patients in several 
academic and non-academic hospitals might overcome this problem. Fourth, the calculations 
for optimising the sequence of tests are done for the group of patients as a whole, which leads 
in principle to the same sequence for all patients, despite the results of a previous test. It might 
be preferable, once a first test has been performed, to have different sequences for the 
different subgroups of patients, depending on the first test result. The probability modifying 
model should be adjusted to overcome this limitation. Fifth, uncertainty about the point 
estimates of the different post-test probabilities is not incorporated in our model. The 
uncertainty of the point estimates may not be equal for the points in the plot because these are 
based on different numbers of patients. In addition, for three tests a sample of 1000 patients is 
considered to be suitable to use the probability modifying model (Knottnerus, 1992a). 
However, in our applications it is shown that patients are not equally divided regarding the 
points in the plot, which, despite the satisfactory number, uncertainty of point estimates is a 
topic of concern. Sixth, the treatment threshold probability plays an important role in the 
model. As far as we know, the concept of this threshold has not yet been empirically 
established. In both the urinary tract example and the applications, the threshold was therefore 
estimated on the basis of intuitively determined utilities or a wide range of thresholds was 
used. However, from the different probability modifying plots it can be seen that the post-tests 
probabilities after three tests are the same, regardless of the sequence of tests. The range 
between the two post-tests probabilities between which the treatment threshold is defined, can 
be regarded as the range in which the treatment threshold can be varied without influencing 
the models' findings analogously to the principles of sensitivity analysis (Glasziou & Hilden, 
1986). For the example of the urinary tract infection data, the treatment threshold of 0.67 lies 
between two post-test probabilities of test result combinations (Ti+,T2+,TO and П ДУЛУ), 
0.75 and 0.46, respectively. Regarding the Helicobacter Pylori example, the estimated 
treatment threshold may vary between 0,16 and 0,97 before the conclusions of our model 
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might change. For the BPH example we used a range of treatment thresholds to show the 
impact of this threshold on the choice for the most efficient test sequence. Seventh, although it 
does not seem to be relevant in the application of Helicobacter pylori because all tests need a 
biopsy specimen, a possible weakness of the model is that the probable (non financial) burden 
of testing is not taken into account. Risks such as morbidity and mortality related to testing 
might exist and are not incorporated in the model. Models which incorporate these aspects do 
exist, but do have their specific difficulties. One method is to translate test morbidity and 
mortality in monetary terms (Henschke et al., 1997). The other method determines a utility 
value of the risks of morbidity and mortality, which is reflected in a higher no-treat/test 
threshold and a lower test/treatment threshold (Sox et ai, 1988; Phelps, 1997). The latter 
method can be incorporated in our model, however, this implicates that for all tests considered 
a cumulative burden of testing has to be determined. 
Despite these limitations, the probability modifying model can be useful for discussing 
guidelines or protocols concerning diagnostic test strategies and test sequence when efficiency 
questions are at stake. Further research on the model is needed to handle the current 
limitations. 
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THE ISSUE OF THE CHOICE OF THE COMPETING 
ALTERNATIVE: MODELLING OF THERAPEUTIC ALTERNATIVES 
Based on Severens JL, Verweij PE, Bos JJ, Donnelly JP & Meis JFGM. Cost-effectiveness of 
liposomal amphotericin В for the treatment of invasive fungal infections in 




As with the economic evaluation of diagnostic technologies, the question which comparator 
should be used in the economic evaluation of a therapeutic technology is essential for the 
study findings. Efficacy trials normally concentrate on a comparator to isolate the actual 
outcome in a highly controlled context. Placebo controlled trials are therefore widely used. 
However, in the situation of performing an economic evaluation, effectiveness is to be studied 
and a placebo is not a relevant decision alternative. Thus, a different comparator should be 
used in an economic evaluation, such as the technology most effective, cheapest, most 
frequently used, or any other possible alternative. In case empirical trials are reported in the 
literature that use comparators that are not highly relevant in a specific decision making 
context, modelling can be used to investigate alternative comparisons. The main difference 
between empirical studies and modelling studies is that empirical studies gather information, 
whereas the modelling studies synthesise information (often-empirical data) without the aim 
of gathering new empirical data (Brennan & Akehurst, 1999). In this chapter a modelling 
study is reported that aimed to compare different treatment strategies for patients suspected of 
having an invasive fungal infection (IFI). The strategy of interest was to our knowledge not 
reported in the literature. 
Invasive fungal infection remains a major cause of morbidity and mortality in the 
immunocompromised patient (Nemunaitis et al, 1993; Patel et al., 1996; George et al, 1997). 
Patients who receive cytotoxic treatment for haematological malignancy including those who 
receive a haemopoietic blood stem cell transplant are especially vulnerable for developing IFI. 
Candida and Aspergillus species are responsible for the majority of the opportunistic 
infections and up to 50 % of these patients may develop invasive disease (Denning et al, 
1997). The management of IFI is difficult because diagnostic tests are often negative at an 
early stage of the disease and the choice of antifungal agents is limited. Therefore, it has 
become standard clinical practice to start antifungal treatment empirical for neutropenic 
patients with fever who fail to respond despite treatment with broad spectrum antibacterial 
agents. 
In some centres up to 68% of neutropenic patients receive antifungal drugs empirical 
for persistent fever alone (Goodman et al, 1992; Winston et al, 1993). Usually the treatment 
of choice is amphotericin В desoxycholate (DC-Amb), while this drug is a fungicidal against a 
broad spectrum of fungi including Candida and Aspergillus species but is often poorly 
tolerated. Lipid formulations of amphotericin В including liposomal amphotericin В 
(AmBisome, Nexstar, St. Odilicnberg, The Netherlands), amphotericin В lipid-complex 
(ABELCET, The Liposome Company, Reeuwijk, The Netherlands) and amphotericin В 
colloidal dispersion (Amphocil, Zeneca Farma, Ridderkerk, The Netherlands) have been 
shown to be considerably less toxic than DC-Amb and appear to be equally effective. Yet, 
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despite their lower toxicity the use of lipid formulations of amphotericin В (L-Amb) is 
restrained by their high costs. Consequently, L-Amb is only considered for treating those who 
fail to respond to DC-Amb or those who are intolerant and for patients who develop dose-
limiting nephrotoxicity during treatment with DC-Amb (Hiemenz et al, 1998). The results of 
a recent randomised, double blind trial indicated that empirical treatment of ΓΡΙ with L-Amb 
may result in fewer breakthrough fungal infections than occurs with DC-Amb and it was 
proposed that L-Amb should be considered for first line empirical treatment (Walsh et al., 
1999). 
Since the costs of L-Amb play such an important role deciding the place of these drugs 
in treating fungal infections, we undertook a cost-effectiveness analysis. As far as we know 
the costs and effectiveness of DC-Amb and L-Amb have never been studied prospectively or 
retrospectively. A method to compare costs and effects of L-Amb and DC-Amb in the face of 
uncertainty is a decision analytic model. The benefit of a decision analytic model compared to 
a controlled clinical trial is that for a controlled clinical trial a large, time-consuming and 
costly study would be required (Drummond et al, 1997). A decision analytic model can be 
based on data from clinical trials already performed. We compared the cost-effectiveness of 
using L-Amb for first line empirical treatment of IFI in patients with haematological 
malignancy with that of DC-Amb by means of decision analytic modelling. 
METHODS 
Model and Assumptions 
Data used in our analysis was limited to studies involving adult patients with haematological 
malignancies and with a suspicion of IFI. A decision tree was constructed which compared 
two different treatment strategies. In the first strategy, DC-Amb at a dose of 1 mg/kg/day was 
given as first line empirical treatment of IFI and was changed to L-Amb for a subset of 
patients (Figure 2.7, DC/L-Amb strategy). In the other strategy, L-Amb was used for empirical 
first line therapy of EFI at a dose of 3 mg/kg/day (Figure 2.7, L-Amb strategy). Treatment was 
considered to be successful when fever subsided (body temperature < 38 °C) and resolution 
of symptoms resolved whether or not side-effects occurred. 
For each strategy a limited number of possible side effects of treatment with DC-Amb 
or L-Amb was included in the decision tree. Only side effects which are common or which 
have a probability of mortality were used in the model. Furthermore, the need for co-
medication or extra hospitalisation for the side effects was incorporated in the decision tree. 
The side-effects which met these criteria included fever (body temperature of 38°C or more) 
and/or chills related to the infusion of the drug (Walsh et ai, 1997; Prentice et al., 1997; 
Walsh et α/.,1999; Ellis et al., 1998), nephrotoxicity (as a rise in the serum creatinine level of 
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Figure 2.7 Decision tree for two strategies for the treatment of suspicious invasive fungal infection 
(IFI). In the first strategy, amphotericin В desoxycholate (DC-Amb) was given as first line empirical 
treatment of IFI and was changed to liposomal amphotericin В (L-Amb) in case of a treatment failure or 
nephrotoxicity (DC/L-Amb strategy). In the other strategy, L-Amb was used for empirical first line 
therapy of IFI (L-Amb strategy). 
44 
Modelling of therapeutic alternatives 
at least twice the upper limit (Walsh et al, 1997; Prentice et al, 1997; Walsh et al, 1999) of 
normality), and electrolyte deficiency. In the DC/L-Amb strategy, first line treatment of 
suspected IFI was DC-Amb. DC-Amb was discontinued and changed to L-Amb, when 
treatment failed whereas L-Amb was continued in the L-Amb strategy. This was included in 
the model. When nephrotoxicity was assumed to lead to extra hospitalisation in both strategies 
and change to L-Amb was modelled in the decision tree. The occurrence of either fever or 
chills or electrolyte deficiency could result in either continuation of the drug in both strategies 
and the administration of co-medication, or stopping the drug altogether. 
The probability of death due to the underlying disease was considered to be equal for 
both strategies. An additional cause of mortality was death due to a proven IFI in case of a 
treatment failure. Treatment failure was defined as progression of IFI during treatment with 
either DC-Amb or L-Amb, and the probability of treatment failure was presumed to differ 
between both strategies. Another additional cause of mortality included in the model was 
related to side effects due to treatment with DC-Amb or L-Amb. 
Data and probabilities 
MEDLINE was searched to retrieve relevant publications, using the search criteria 
amphotericin В desoxycholate, liposomal amphotericin B, invasive fungal infection, and 
haematologic. In addition, articles were located from the bibliographies of the papers retrieved 
and published abstracts of randomised clinical trials were included. Articles and abstracts 
were then selected that reported the following criteria: 1) treatment with DC-Amb or L-Amb 
of adult patients with haematological malignancies; 2) the number of cases in which IFI was 
suspected before giving treatment; 3) and the number of patients who died. All articles that 
reported the results of studies performed in mixed patients groups without making a 
distinction between those infected with НГ + or solid organ transplant recipients and those 
with haematological malignancies were excluded. 
Data were extracted by first calculating the number of successfully treated cases (total 
number of cases minus the treatment failures) then the number of cases without side effects 
was determined. If the number of patients without side effects was not explicitly mentioned in 
the article, the number was calculated by subtracting the number of cases of nephrotoxicity, 
electrolyte deficiency and fever or chills from the total number successfully treated patients. 
Although most papers provided data on the occurrence of individual side effects, the number 
of cases that experienced more than one side effect was generally not reported. In order to 
prevent overestimating of the total number of patients affected by side effects, we made the 
assumption that patients who experienced nephrotoxicity or electrolyte deficiency also 
experienced fever or chills. Cases of fever or chills that could not be accounted for as 
nephrotoxicity or electrolyte deficiency were allocated to fever or chills alone. We considered 
fever or chills to have no impact on effectiveness and hardly any impact on costs. The data 
were pooled once the number of patients was determined for the different categories for each 
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study, by calculating the probabilities of successful treatment, treatment failure, and 
occurrence of side-effects, based on the total number of cases of the joint studies. Since the 
probability of mortality due to underlying disease was considered to be similar for both 
treatment strategies, these probabilities were pooled over all data. The probability of treatment 
failure and the probability of mortality due to failure of treatment for proven IFI differed 
between both strategies and was calculated exclusively with the results of data from 
randomised trials (Prentice et al, 1997; Walsh et al, 1999). Finally, it was assumed that 
events not reported in the article or abstract did not actually occur. 
Costs 
The costs were assumed to have been incurred from the time of starting treatment until 
discharge from the hospital and included the costs of antifungal treatment and those associated 
with the occurrence of side-effects. Costs were calculated in Dutch guilders and exchanged to 
US dollars (USD) using the mean exchange rate of 1997. The total costs of treatment with 
DC-Amb and L-Amb were based on the cost per day and the duration of treatment. The 
duration of treatment with both DC-Amb and L-Amb was set at 28 days on the basis of expert 
opinion and chart review of patients treated for IFI at the Department of Haematology of the 
University Hospital Nijmegen. The dose of DC-Amb was set at 1 mg/kg/day for a patient 
weighing 70 kg and the cost of the drug was estimated to be USD 23.2 per day based on retail 
prices in the Netherlands which averaged USD 33.1 per 100 mg. The cost of L-Amb per day 
was based on two drugs available in the Netherlands; Ambisome and Amphocil. Both are sold 
for the same price of USD 231 per 50 mg which, for a 70-kg patient given a dose of 3 
mg/kg/day amounted to a daily cost of USD 969. 
Nephrotoxicity due to treatment with DC-Amb or L-Amb was assumed to increase the 
length of stay (LOS) by seven extra days (Hiemenz et al., 1998), which amounted to USD 
4,648. A single day of hospitalisation in an academic hospital was estimated at USD 664 
(Rutten et al., 1993). In addition, it was assumed that due to electrolyte deficiency the LOS 
increased by seven days. Infusion related reactions such as fever or chills were assumed to 
take place throughout treatment and pethidine at a dose of 25 mg was assumed to be given as 
treatment costing USD 0.6/day. 
Analysis 
The expected costs and expected effectiveness expressed as lives saved were calculated for 
each treatment strategy using a differential approach, thus concentrating on th costs that were 
expected to differ between the strategies. The sum of either the cost or the effect for each of 
the branches was multiplied by their probability of occurrence. 
A cost-effectiveness analysis was performed to compare the two strategies. Given the 
nature of the clinical problem, the time frame considered in this analysis was limited to the 
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LOS. The cost-effectiveness analysis was performed from the perspective of the health-care 
system, which implied that only direct medical costs were incurred. The strategy yielding the 
greater effectiveness at a lower cost was considered to be dominant. If this was not the case 
and one strategy was both more effective and more costly, the relationship between costs and 
effectiveness was expressed in an incremental cost-effectiveness ratio. Incremental cost-
effectiveness ratios were calculated by dividing the additional costs of the L-Amb strategy 
compared to DC/L-Amb by the effectiveness gained, and was expressed in terms of additional 
US dollars per life gained. 
First, the cost-effectiveness analysis was performed using baseline values for 
probability and cost estimates. Next we varied these estimates in the decision tree by using a 
sensitivity analysis. This enabled us to explore for which probabilities or costs the results of 
the analyses were robust and for which they were sensitive regarding the range used in the 
sensitivity analysis. The ranges of probabilities were determined by calculating 95% 
Table 2.9 Summary of clinical studies of amphotericin В desoxycholate (DC-Amb) for the 
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confidence intervals. The ranges of the costs used in the sensitivity analysis were calculated 
according the following principles. The baseline value of cost of DC-Amb was estimated at 
USD 649.9. The range of these costs was estimated on the difference in duration of use 1-35 
days (USD 23.2-811.9). Similarly, the baseline value of cost of L-Amb was estimated at USD 
21,137. The sensitivity analysis was done in two ways. The first sensitivity analysis was based 
on a difference in prices of L-Amb (USD 10 to 1,000), for a fixed duration of 28 days 
amounting to (USD 280 to 28,000). The second sensitivity analysis was based on the 
difference in duration of use 1-35 days based on a fixed cost of USD 969 resulting in (USD 
969 to 33,915). The baseline value of costs of treatment for both nephrotoxicity and 
electrolyte deficiency were estimated at USD 4,649 for the increased LOS and sensitivity 
analysis was based on 0-14 days extra hospitalisation yielding an extra cost of USD 0 to 
9,298. 
The model was generated using DATA version 2.6 software (TreeAge Software Inc., 
Boston USA) for Windows (Microsoft Corporation). 
RESULTS 
Literature review 
Fourteen articles met our criteria of which four reports provided data from treatment with DC-
Amb in open noncomparative trials (Blade et al, 1992; Richard et al, 1993; Ellis et al, 1995; 
Anaissie et al, 1996;), six dealt with treatment with L-Amb (Tollemar et al, 1990; Chopra et 
al, 1991 ; Chopra et al, 1992; Krüger et al, 1995; Oravcová et al, 1995; Ellis et ai, 1998) of 
which only one was a randomised study comparing 1 mg/kg/day with 4 mg/kg/day L-Amb 
(Ellis et al, 1998). The remaining four publications reported a comparison of treatment with 
DC-Amb with L-Amb of which two were randomised clinical trials (Prentice et al, 1997; 
Walsh et al, 1999), the other two being non-randomised comparative studies (Tollemar et al, 
1992; Pascual et al, 1995). Two studies included patients with haematological malignancies 
and reported solid tumours (Oravcová et al, 1995; Ellis et al, 1998) and two studies reported 
on patients with lymphomas (Ellis et al, 1995; Prentice et al, 1997). The fourteen studies 
reported the results of treating 512 patients with haematological malignancies receiving 
treatment with DC-Amb (Table 2.9) and 579 similar patients receiving treatment with L-Amb 
(Table 2.10). An overview of the reported side effects and the treatment of these side effects 
of DC-Amb and L-Amb are shown in Tables 2.11 and 2.12 respectively. Based on these 
figures, pooled data were calculated and are shown in Table 2.13. These were used for 
baseline estimates of the probabilities used in the decision tree. 
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Table 2 10 Summary of clinical studies of lipid formulations of amphotericin В (L-Amb) for the 
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Table 211 Summary of reported side-effects and treatment of these side-effects of 
amphotericin В desoxycholate (DC-Amb) 
successfully treated 
no side-effects 
nephrotoxicity / possibly 
fever 
electrolyte deficiency / 
possibly fever 
withdrawn due to 
electrolyte deficiency 
treatment for electrolyte 
deficiency 
fever and/or chills 
withdrawn due to fever 
and/or chills 























































































































# data is based on adult patients 
§ organ transplant patients excluded 
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Table 2.12 Summary of reported side-effects and treatment of these side-effects of lipid 
formulations of amphotericin В (L-Amb). 
ю CJ о 
Ж Î - SS Sí en o> σ> 
Oì fO (O ^ O) ,__ W T _ w 
w ΐ* > υ Si °- ω 9 - ш 
S L U C L O C L ^ O I - O I - S 
successfully treated 300 46 30* 20 10 50 31 8§ 20 4 519 
no side-effects 180 41 27 15 3 48 27 8 20 4 373 
nephrotoxicity / possibly 
fever 65 5 3 0 73 
electrolyte deficiency / 
possibly fever 0 5 7 4 16 
withdrawn due to 
electrolyte deficiency 0 0 0 0 
treatment for electrolyte 
deficiency 7 4 11 
fever and/or chills 55 0 0 2 0 57 
withdrawn due to fever 
and/or chills 0 0 1 1 
treatment for fever 
and/or chills 0 0 1 1 
# data is based on adult patients 
§ organ transplant patients excluded 
Cost-effectiveness 
The cost estimates used in our model are listed in Table 2.14. Analysing the decision tree 
using the baseline values, first-line treatment with L-Amb proved to be the most effective 
resulting in an expected probability for survival of 0.853 compared with 0.771 for the DC/L-
Amb strategy. However the L-Amb strategy was more effective, it was also more expensive 
than the DC/L-Amb strategy, thus no strategy was dominant to the other. The expected cost 
per patient of L-Amb was USD 27,810 while the expected cost per patient of DC/L-Amb was 
USD 12,776. Note that the last cost estimate includes not only the costs of DC-Amb but also 
the costs of L-Amb used in case of a treatment failure or when there was nephrotoxicity. To 
calculate the incremental cost-effectiveness ratio of the L-Amb strategy compared to the 
DC/L-Amb strategy, the additional cost (USD 27,810 - USD 12,776 = USD 15,034) of the 
L-Amb strategy was divided by the probability of saving a life (0.853-0.771 = 0.082). This 
calculation yielded a ratio of nearly USD 183,000 per life saved. 
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Table 2.13 Probabilities of side-effects of the treatment, the treatment of these side-effects, and 
mortality used in the model. 
DC-Amb L-Amb 
pooled calculated pooled calculated 




nephrotoxicity / fever 
electrolyte deficiency / fever 
treatment withdrawn due to 
electrolyte deficiency 
treatment for electrolyte deficiency 
fever and/or chills 
treatment withdrawn due to fever 
and/or chills 
treatment for fever and/or chills 
mortality 
mortality due to underlying disease* 
additional mortality due to proven invasive 
fungal infection in case of treatment failure 
additional mortality due to nephrotoxicity* 
additional mortality due to electrolyte def.* 
# C/ -> 95% = ρ ± 1.96 j S t ^ 
§ fever is the node in the model with a probability estimate dependent on the other probabilities 
and therefore it can not be used in a sensitivity analysis 
& pooled over all data 
t set by expert opinion 
Sensitivity analysis 
Sensitivity analyses performed over all calculated ranges of the variables in the model showed 
that two variables had an important impact on the findings of our decision model namely, the 
cost of L-Amb per day and the duration of treatment with the drug. Changing the cost of L-
Amb per day showed that if L-Amb cost less than USD 121.6 a day the L-Amb strategy was 
more effective than the DC/L-Amb strategy in terms of lives saved at a lower cost. If L-Amb 
cost more than USD 121.6, L-Amb was more effective at a higher cost. Varying the duration 
of treatment with L-Amb showed that when treatment exceeded 4 days it was more effective 
but at a higher cost. L-Amb always yielded a higher effectiveness at a higher cost than DC/L-
Amb for all the other cost variables explored in the sensitivity analyses, with a maximum 
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Table 2 14 Baseline cost estimates in US dollars (USD) and ranges for the sensitivity analyses 
used in the model 
baseline value (USD)" range (USD) 
amphotericin В desoxycholate 
(1 mg/kg/day) 649 (28 days) 23-812 (1 -35 days) 
liposomal amphotericin В 
(3 mg/kg/day)ê 27137 (28 days) 969-33,921 (1-35 days) 
extra hospitalisation due to nephrotoxicity 
or electrolyte deficiency 4,649 (7 days) 0-9,298 (0-14 days) 
fever and/or chills treatment 
(pethidine 25 mg/day) 17 (28 days) 13-22 (21-35 days) 
# the mean exchange rate for 1997 from US dollars to Dutch guilders was 1 95 
§ based on the average prices of Amphocil and AmBisome 
2 15) Sensitivity analyses over the probabilities of side effects had no significant impact on 
the incremental cost-effectiveness ratios Assuming a probability of failure of treatment with 
DC-Amb of 0 15 demonstrated an incremental cost-effectiveness ratio of USD 204,000 per 
life saved and USD 166,000 per life saved if the probability was set at 0 21 Mortality due to 
underlying disease demonstrated an incremental cost-effectiveness ratio of USD 196,000 per 
life saved if the probability was calculated at 0 12 and USD 174,000 per life saved when it 
was calculated at 0 16 Additional mortality due to a proven ΓΡΙ in case of treatment failure of 
DC-Amb demonstrated an incremental cost-effectiveness ratio of USD 210,000 per life saved 
when the probability was 0 1 and USD 164,000 per life saved when the calculated probability 
was 0 26 By contrast, the additional mortality due to a proven ΓΠ that failed treatment with L-
Amb had barely any impact with an incremental cost-effectiveness ratio of USD 181,000 and 
USD 186,000 per life saved when the calculated probability was 0 05 and 0 09 respectively 
DISCUSSION 
The costs of liposomal formulations of amphotericin В play a decisive role in determining 
their place in the treatment of IFI in neutropenic patients Indeed the high costs of treatment 
with these drugs for empirical antifungal therapy has led in many institutes to reserve them for 
those patients who either fail to respond to the conventional formulation of the drug or to who 
develop dose-limiting nephrotoxicity In order to explore the feasibility of using L-Amb for 
first line empirical treatment of IFI we compared the effectiveness and expected costs of such 
strategy with empirical therapy with DC-Amb using decision analysis Within all the ranges 
explored, L-Amb remained the most effective strategy increasing the probability of survival 
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Table 2 15 Results of the one way sensitivity analyses incremental cost-effectiveness ratios 
(ICER) of using lipid formulations of amphotericin В (L-Amb) versus amphotericin В desoxycholate 
(DC-Amb) as first line empirical treatment of for patients suspected of invasive fungal infections (IFI), in 
1,000 US dollar (USD) per life saved 
baseline values' 
probability of treatment failure 
DC-Amb 
L-Amb 
probability of nephrotoxicity 
DC-Amb 
L-Amb 
probability of electrolyte deficiency 
DC-Amb 
L-Amb 
probability of treatment withdrawn due to electrolyte 
deficiency 
DC-Amb 
probability of treatment for electrolyte deficiency 
DC-Amb 
L-Amb 
probability of treatment withdrawn due to fever 
and/or chills 
L-Amb 
probability of treatment for fever and/or chills 
DC-Amb 
L-Amb 
probability of no side-effects 
DC-Amb 
L-Amb 
probability of mortality due to underlying disease 
probability of additional mortality due to proven IFI 
in case of treatment failure 
DC-Amb 
L-Amb 




range of values 
0 1 5 - 0 2 1 
0 0 8 - 0 1 2 
0 32 - 0 42 
0 1 2 - 0 1 8 
0 02 - 0 06 
0 02 - 0 05 
0 - 0 1 7 
0 21 - 0 67 
0 51 - 0 87 
0 - 0 0 6 
0 22 - 0 48 
0 - 0 0 6 
0 4 1 - 0 5 1 
0 68 - 0 76 
0 1 2 - 0 1 6 
0 1 - 0 26 
0 05 - 0 09 
0 - 0 0 1 
0 - 0 0 1 
ICER 






















Modelling of therapeutic alternatives 
Table 2 15 continued 






L-Amb in time use (days) 
L-Amb in costs 
add hospitalisation due to 
add hospitalisation due to 
nephrotoxicity 
electrolyte deficiency 
treatment for fever or chills/chills 
0 - 0 0 1 
0 - 0 0 1 
USD 23-USD 812 
1 - 35 (days) 
USD 10-USD 1000 
USD 0 - USD 9,298 
USD 0 - USD 9,298 









# see Table 2 13 for more details on the values used in the baseline analysis 
§ the L-Amb strategy is dominant compared to the DC/L-Amb strategy, thus, the L-Amb strategy 
yielded a higher effectiveness at lower costs 
& see also Table 2 14 for more details on the values used in the baseline analysis and the 
sensitivity analyses 
by 8% but it was also a more expensive strategy than DC/L-Amb costing at least USD 15,000 
more per treated patient However, the additional cost per life saved exceeded USD 235,000 
over all calculated ranges of the variable values explored which corresponds to USD 23,500 
per life-year saved for a patient with a remaining life expectancy of 10 years The costs and 
the duration of treatment with L-Amb was dominant provided L-Amb cost less than USD 
121 6 per day in which case the strategy was more effective at a lower price Thus, reducing 
the pnce of L-Amb can only have positive impact on implementing a strategy, which involves 
giving L-Amb as first line treatment rather than initially starting with DC-Amb The 
sensitivity analyses also showed that varying probabilities of side effects had only a negligible 
impact on the cost-effectiveness ratios 
Furthermore, in a two-way sensitivity analysis the complementary impact of varying both cost 
per day and the duration of treatment of L-Amb was studied We conclude that the costs per 
day or the duration of use of L-Amb has to decrease considerably before L-Amb becomes the 
dominant strategy If L-Amb cost USD 200 (baseline was USD 969) and the duration of use 
was 18 days (baseline was 28 days) L-Amb was the preferred strategy (Figure 2 8) 
Ellis et al (1998) performed a randomised controlled trial comparing treatment with 1 
mg/kg/day L-Amb and 4 mg/kg/day L-Amb and found no significant difference between the 
two groups in the number of side effects We therefore undertook another analysis assuming 
that L-Amb was given at a 1-mg/kg/day dose instead of 3 mg/kg/day thereby reducing the 
daily costs of the product This yielded an incremental cost-effectiveness ratio of nearly USD 
68,000 per life saved Which corresponds to USD 6,800 per life year saved for a patient with a 




200 400 600 800 1000 
Cost of L-Amb per day (USD) 
Figure 2.8 Two-way sensitivity analysis of the decision tree to determine the effect simultaneously 
varying of costs per day and duration of use of L-Amb In this figure it is clear that L-Amb became the 
preferred strategy if the product became cheaper and the duration of use became shorter. The 
baseline values are represented with a *. Every point under the curve indicates a higher effectiveness 
in lives saved and lower costs (dominance), every point above the curve indicates a higher 
effectiveness in lives saved and higher costs for the L-Amb strategy compared to the DC/L-Amb 
strategy. 
(Goldman et al, 1992). Although the L-Amb strategy did not reach dominance it induced a 
considerable reduction in incremental costs per life saved compared to the analysis done over 
3 mg/kg/day, which was USD 183,000 per life saved. 
Theoretically, the probability of mortality due to the underlying disease should be the 
same for both strategies and therefore we pooled the estimated probability over all data for our 
analysis resulting in a probability of 0.14. However, after pooling the data of DC-Amb and L-
Amb separately we found a probability of mortality due to the underlying disease of 0.11 for 
the DC-Amb group and of 0.17 for the L-Amb group (Tables 2.9 and 2.10). In the studies 
which evaluated the efficacy of L-Amb a number of patients were treated first with DC-Amb 
before switching to L-Amb but, it was not possible to separate these patients from those who 
received first line therapy with L-Amb. It is therefore possible that the patients who were first 
treated with DC-Amb differed from those who received first line treatment with L-Amb with 
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probability of mortality due to the underlying disease had been pooled in the same manner as 
the other probability estimates, this might have introduced selection bias. 
The probability of treatment failure and of mortality due to a proven ПЧ in case of a 
treatment failure also suffers from possible selection bias. It is still possible that these 
probabilities are higher for the patients who initially received DC-Amb than for those who 
received first line treatment with L-Amb. Therefore these probabilities were calculated on the 
basis of data derived exclusively from randomised clinical trials (Prentice et al, 1997; Walsh 
et al, 1997). 
None of the studies we retrieved made a distinction between patients who had only one side 
effect and those who had more than one side-effect which was apparent from the fact that 
summation of all probabilities of side-effects of L-Amb or DC-Amb reported, resulted in a 
probability greater than 1. 
The study by Prentice et al (1997) enumerated the drug-related adverse events which 
allowed us to estimate accurately the number of patients who had no side-effects. In addition, 
it was also possible to estimate accurately those who developed nephrotoxicity and electrolyte 
deficiency. However, simple addition of the number of patients exceeded those successfully 
treated minus the number of those without side effects so there was double counting of 
nephrotoxicity and electrolyte deficiency. It is possible that a side effect occurred at the same 
time as treatment was deemed to have failed since failure was defined as no response to the 
drug. Therefore, since it was not clear in any of the selected studies, this information was not 
included in our decision tree. In the article by Prentice et ai. (1997) at least one side effect 
could have occurred while treatment failed. This is possibly also the case in the other retrieved 
studies. However, this omission is likely to have limited consequences for our analyses 
because all side effects with a significant impact were included as treatment success. 
Possible dose-response relationships were not taken into consideration in our decision 
analytic model; the results might well have been different if these had been taken into account. 
A mean of 3.3 mg/kg/day for L-Amb was estimated from the selected studies. Which is a 
slightly higher than the assumed 3 mg/kg/day and the dose of DC-Amb was 0.6 mg/kg/day 
which is less than the 1 mg/kg/day we employed. However, neither the efficacy nor the 
toxicity of treatment with amphotericin В appears dose dependent (Ellis et al, 1998), so these 
deviations may not have had any consequences. 
The probability of mortality due to a proven ГИ in case of a treatment failure is rather 
low in the retrieved studies. Presumably, patients who were considered to have a fungal 
infection while treated with L-Amb or DC-Amb were not always infected because the 
probability of mortality due to a proven ПЧ in case of a treatment failure would be much 
higher than the probability found; 0.18 for DC-Amb and 0.15 for L-Amb. 
In conclusion, our decision analytic model yielded a higher effectiveness in lives saved 
if L-Amb is used as first line treatment compared to initial treatment with DC-Amb but that, 
as expected, the L-Amb strategy was also more expensive. Since this is highly dependent 
upon the cost and the duration of treatment with liposomal amphotericin B, L-Amb could only 
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become the drug of first choice for the empirical treatment of neutropenic patients if the cost 
of this product is decreased dramatically. 
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THE ISSUE OF THE RELEVANT COSTS AND CONSEQUENCES: 
DETERMINING THE TIME HORIZON OF THE ANALYSIS 
Based on Severens JL, Donnelly JP, Meis JFGM, Vries Robbé PF de, Pauw BE de & Verweij 
PE (1997). Two strategies for managing invasive aspergillosis: a decision analysis. 




The process of diagnosis focuses on the reduction of uncertainty about the presence of a 
disease of a person (Elstein et ai, 1993). Hence, the number of cases detected is an 
effectiveness parameter which can be used in economic evaluations. Because, normally, the 
results of an economic evaluation are expressed in a cost-effectiveness ratio, this leads to the 
costs per case detected. However, this parameter can be regarded as an intermediate outcome 
measure in the sense that it does not reflect the actual health outcome as a result of diagnosis 
and eventual treatment of a patient. In the literature review it was shown that this intermediate 
outcome is used regularly (18.3% of the studies in which a ratio was defined) (Severens & van 
der Wilt, 1999b). Besides this, cost per 'specific measure' was found in 31.4% of the studies 
mentioning a ratio. The latter category was often used in studies which evaluated screening 
programmes. Ratios like 'costs per case of infection prevented', 'costs per born baby with 
abnormalities prevented', but also 'cost per treated patient' were used. Thus, this category can 
also be regarded as studies using intermediate outcomes. In fact, 49.7% of the studies 
mentioning a ratio used intermediate effectiveness measures which does not reflect, as 
mentioned above, the actual health outcome as the main objective of medical interventions. 
Determining the effectiveness measure used in an economic evaluation is related to the 
relative time span in which effectiveness is measured, in other words, the time horizon of 
analysis. The time horizon used when evaluating efficiency of an intervention in general 
should extend far enough in the future to capture the major health and economic outcomes 
(Torrance et al, 1996). This chapter aims to stress the importance of determining the time 
horizon of a study when evaluating diagnostic tests. 
A second topic of this chapter concerns modelling. Modelling techniques can be 
useful, in case it is not possible to prospectively measure health outcome when evaluating a 
diagnostic technology because of the duration of the study and an intermediate outcome 
measure has to be used (Canadian Coordinating Office for Health Technology Assessment, 
1997). The mentioned aspects are illustrated with diagnosis and treatment of invasive 
aspergillosis. 
Invasive aspergillosis 
Invasive pulmonary aspergillosis is a life-threatening complication of intensive chemotherapy 
for malignancies, chronic treatment with high dose corticosteroids, transplantation, and AIDS. 
Treating this infection as early as possible is one of the prerequisites for a favourable outcome 
(Aisner et al, 1977), but since no reliable means of early diagnosis exists, it has become 
commonplace to treat patients at high risk empirically with amphotericin В when there is the 
slightest clinical suspicion of invasive aspergillosis (Denning, 1994). As many as 68% of 
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neutropenic patients will receive amphotericin В empirically, often for persistent fever alone 
(Goodman et ai, 1992; Winston et al., 1993), even though the desoxycholate formulation of 
amphotericin В (DC-Amb; Fungizone, Bristol Myers Squibb, Woerden, the Netherlands) is 
associated with adverse drug reactions such as fever, rigors, and impaired renal function. In 
addition, the incidence of disease for most groups at risk is -10%. Therefore, alternative 
strategies are needed for the early recognition of invasive aspergillosis to allow better 
selection of patients who need treatment, while reducing the number of patients who are 
exposed unnecessarily to these drugs and their side effects. 
In addition, better selection of patients who require treatment for invasive aspergillosis 
will also help to contain the cost of treatment when novel and expensive drugs are used. For 
instance, lipid-formulations of amphotericin B, such as liposomal amphotericin В (L-Amb; 
Ambisome, Nexstar, St. Odilienberg, the Netherlands), amphotericin В lipid-complex 
(Abelcet, The Liposome Company, Reeuwijk, the Netherlands), and amphotericin В colloid 
dispersion (Amphocil, Zeneca Farma, Ridderkerk, the Netherlands), are available and are 
being used increasingly for treating invasive aspergillosis because they induce fewer side 
effects than occur with the same dose of DC-Amb. Although equal or improved efficacy of 
lipid formulations of amphotericin В in treating invasive aspergillosis has not been proven, all 
the studies to date have shown that lipid-formulations of amphotericin В are at least as 
effective as DC-Amb, even in those patients who did not respond (Hiemenz & Walsh, 1996; 
Ng TTC & Denning, 1995; Hiemenz et ai, 1995). Moreover, clinical trials are ongoing to 
establish the efficacy of lipid-formulations of amphotericin В as empirical therapy for fever 
and neutropenia and as first-line therapy for documented aspergillosis (Hiemenz & Walsh, 
1996). 
However, the cost of treatment with these formulations is high. L-Amb is as much as 
40 times more expensive than DC-Amb and is only considered for managing invasive 
aspergillosis in patients with impaired renal function or in those who are intolerant of DC-
Amb or for managing progressive disease despite treatment with the desoxycholate 
formulation of the polyene (Hiemenz & Walsh, 1996). Even if desirable, empirical treatment 
with L-Amb is simply not feasible since resources for health care are finite and there is 
increasing pressure to contain costs despite a indisputable rise in demand. 
To address this issue we devised a diagnostic approach (alternative strategy) that 
incorporates Aspergillus antigen detection, high resolution CT scanning, and radionuclide 
imaging with-indium-lll-labelled human IgG (ulIn-IgG). Each of these procedures have 
been shown to contribute to establishing the diagnosis of invasive aspergillosis, but the 
diagnostic value of an approach in which the tests and procedures are combined is unknown. 
The Aspergillus antigen galactomannan can be detected in plasma or serum samples from 
patients with invasive aspergillosis by using a commercially available sandwich ELISA 
(Platelia Aspergillus, Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France) (Stynen et al, 
1995). This assay has been found to possess a sensitivity of 67%-100% and a specificity of 
81%-98.7% when performed with sera from patients receiving treatment for haematological 
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malignancies (Verweij et al, 1995; Rohrlich et al, 1996; Sulahian et al, 1996; Poirot et al., 
1996; Tabones ai, 1996). 
The sandwich ELISA becomes positive at an early stage of infection, and 
galactomannan has been detected in the sera of some patients even before signs and symptoms 
consistent with invasive aspergillosis became apparent (Rohrlich et al, 1996). Furthermore, 
ELISA results are available within 4 hours of collecting the sample (Stynen et al, 1995). 
Thoracic CT scanning is a major tool for the diagnosis of invasive aspergillosis in 
neurotropenic patients, and the presence of halo sign or air-crescent sign is highly indicative 
of disease (Kuhlman et al, 1985). Recently, it was confirmed that the detection of halo-signs 
in neutropenic patients is an early indicator of the presence of invasive aspergillosis (Caillot et 
al, 1997). However, the diagnostic sensitivity of a CT scan depends largely on tissue 
attenuation and an inflammatory response following fungal invasion, so the impaired 
inflammatory responses of immunocompromised patients may render the interpretation of the 
results of this technique more difficult than it is when patients are immunocompetent (Rubin 
& Fischman, 1996). 
Radionuclide imaging with u'in-labeled human IgG is both sensitive and specific for 
detecting microbial invasion, even in the presence of a blunted inflammatory response, since 
accumulation of '"in-labeled IgG is a result of capillary leakage (Rubin & Fischman, 1996). 
This technique has been successfully used to detect Aspergillus fumigatus infection in 
granulocytopenic patients (Oyen et al, 1992) and may also be helpful in detecting non 
respiratory fungal lesions such as those in the sinuses or gut (Rubin & Fischman, 1996). 
It is expected that by combining these diagnostic tests and procedures, candidates for 
treatment will be better selected than they are when the more permissive conventional 
strategy, which relies solely on the presence of persistent fever that is refractory to 
antibacterial agents and on the presence of pulmonary infiltrates on the chest roentgenogram, 
is used. However, since the costs incurred by the alternative diagnostic work-up will be 
higher, we decided to see whether these costs might be offset by savings made in the overall 
cost of treatment. 
We used decision analysis, a modelling instrument for specifying complex choices in 
the face of uncertainty, to construct a model for comparing the number of patients expected to 
receive a diagnosis of invasive aspergillosis and to receive treatment according to each 
strategy. The expected costs of diagnosis and treatment with DC-Amb were calculated, and 
the impact of using L-Amb as first-line treatment in at least some cases of probable invasive 
aspergillosis was assessed. Finally, sensitivity analyses were performed to assess the impact of 
the necessary assumptions and impact of the estimates of certain variables on the robustness 
of the conclusions by varying one of the variables in the model while holding the other 
variables at their baseline value (McNeil & Pauker, 1984). 
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Figure 3.1 Decision tree for two strategies for the management of invasive aspergillosis. The 
squares in the decision tree indicate a decision node. If one branch continues from a decision node, 
only one decision is possible. The nodes represented by circles are used if subsequent outcomes 
occur by chance. Theoretical outcomes of chance nodes with a zero probability, such as no symptoms 
of aspergillosis after a false-negative ELISA, are not shown in the tree. The path probabilities (P) of 
each branch of the tree are shown. Under baseline assumptions, the probability of receiving antifungal 
treatment in the conventional strategy (A) which is based on persistent fever, bronchoalveolar lavage 
(BAL), and chest roentgenogram findings, is 0.24 (0.06 + 0.18). The probability of receiving antifungal 
treatment in the alternative strategy (6), based on screening plasma for an Aspergillus antigen by using 
a sandwich ELISA, thoracic CT scanning, and radionuclide imaging ('"in-labeled IgG) is 0.073 (0.054 
+ 0.005 + 0.003 + 0.003 + 0.008 + 0.000). 
MATERIALS AND METHODS 
Diagnostic work-up 
Presently in the Haematology Department at the University Hospital Nijmegen, invasive 
pulmonary aspergillosis is considered possible diagnosis in neutropenic patients when fever 
persists for at least 5 days despite treatment with broad-spectrum antibacterial agents and 
when pulmonary infiltrates are apparent on the chest roentgenogram. Bronchoalveolar lavage 
is then performed, and treatment is started empirically. Additional chest roentgenograms and 
culture results are used to determine the level of suspicion of invasive aspergillosis 
(conventional strategy, Figure 3.1). The alternative diagnostic work-up involves prospective 
twice-weekly screening of serum or plasma for galactomannan in neutropenic patients 
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receiving treatment for a haematological malignancy during their stay in the hospital. When 
galactomannan is detected for the first time, a second sample is obtained for confirmation and, 
if the antigen is detected again, a high-resolution CT scan of the thorax and sinuses is 
obtained. If nothing is seen, ' ' 'in-IgG scintigraphy is performed. 
A diagnosis of invasive aspergillosis will be presumed if antigen is detected and either 
imaging technique confirms the presence of a pulmonary infiltrate, sinusitis, or another sign of 
inflammation consistent with invasive aspergillosis. Antifungal treatment will then be started 
pre-emptively (alternative strategy, Figure 3.1) (Verweij et ai, 1996). Since patients may still 
develop invasive disease despite a negative ELISA result, a high-resolution CT scan will be 
obtained whenever there are grounds for suspecting invasive aspergillosis. 
Table 3.1 Baseline values and ranges of variables and test characteristics used to construct the 
decision tree for comparing two strategies for managing invasive aspergillosis. 
reference variable baseline value (%) 
hospital data prevalence of invasive aspergillosis 6 
(Rohrlich et al., 1996) ELISA sensitivity 100 
(Rohrlich era/., 1996) ELISA specificity 94 
(Kuhlman étal., 1985) CT scan sensitivity 89 
set CT scan specificity 95 
(Oyen et al., 1992) 111ln-labeled IgG scintigraphy sensitivity 90 
set 111ln-labeled IgG scintigraphy specificity 90 
hospital data patients receiving empirical treatment with 
desoxycholate formulation of amphotericin В 
24 
hospital data: data are used from the haematology department of the University Hospital Nijmegen 
set: estimates of performance characteristics. 
Empirical and pre-emptive treatment. 
Currently, 24% of the neutropenic patients in the Haematology Department receive DC-Amb 
empirically; 18% of these patients receive the drug for an average of 21 days for treatment of 
possible invasive aspergillosis, whereas the actual prevalence rate of this disease among 
patients admitted to this department is estimated to be 6%. Since the average course of 
treatment is 35 days for these patients, we chose this figure to set the duration of pre-emptive 
treatment for patients whose infections were diagnosed by using the alternative strategy. 
However, we assumed that patients would receive only a 21-day course of treatment if the 
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diagnosis of invasive aspergillosis was shown to be unlikely later during the course of 
treatment. 
The probabilities used in the decision analysis were based on our own data and those 
from the literature (Table 3.1). We relied on estimates of the performance characteristics of 
the CT scanning and the l 'in-IgG scintigraphy published for unselected neutropenic patients, 
since neither estimate is known for those in whom galactomannan is detected. The costs of 
diagnosis and treatment with use of both strategies were derived from hospital tariffs, for 
which diagnostic materials, depreciation costs of medical equipment, administration services, 
and consultation fees are taken into account (Table 3.2). Treatment costs of both the 
desoxycholate and lipid formulations of amphotericin В were based on their retail prices, 
assuming a 70-kg man was given 1 mg/(kg d) of DC-Amb or 3 mg/(kg d) of L-Amb, and were 
estimated to total US dollar (USD) 27 per day and USD 1,115 per day, respectively. No 
additional costs accruing to toxicity were taken into account because there were no accurate 
estimates available. 
Table 3.2 Costs of diagnostic tests (US dollar, USD) and number of procedures used (N) in the 
two strategies for the management of invasive aspergillosis. 
costs per test 
diagnostic procedure specification N 
(USD) 
conventional strategy 
chest roentgenogram 44 3 
includes cytology and bacteriologie, 
virological and mycological cultures 562 1 
bronchoalveolar lavage 
alternative strategy 
aspergillus antigen detection sandwich ELISA 
high-resolution CT-scanning lungs and sinuses 







# all patients are screened by sandwich ELISA during each neutropenic episode 
Decision analysis 
The conventional and alternative strategies were denned, and baseline values of the 
probabilities of each test result, together with the costs of the diagnostic tests and treatments, 
were estimated and incorporated into the decision tree by using the software program DATA 
version 2.6 (TreeAge Software, Williamstown, MA). After the path probabilities of each 
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branch of the tree and the expected costs of diagnosis and treatment per patient were 
calculated for each strategy, sensitivity analysis was performed. 
Primary calculations on the costs of both strategies were based on treatment with DC-
Amb to determine whether the additional costs of diagnostic tests included in the alternative 
strategy were outweighed by any savings resulting from the avoidance of unnecessary 
treatment. Since different values for both sensitivity and specificity of the sandwich ELISA 
have been reported (Verweij et al, 1995; Rohrlich et al, 1996; Sulahian et al, 1996; Poirot et 
al, 1996; Tabone et al, 1996), the impact of varying the performance characteristics of the 
sandwich ELISA on the positive and negative predictive values and the expected costs of the 
alternative strategy was determined by varying the sensitivity and specificity with use of 
values from the literature and the hypothetical values of 50% and 99%, given a 6% prevalence 
rate of infection. Besides this, we used the variables prevalence of infection (baseline value, 
6%), the probability that a patient would receive empirical treatment with DC-Amb (baseline 
value, 24%), and the costs of the sandwich ELISA (baseline value, USD 10) in the sensitivity 
analysis. 
Treatment with L-Amb 
The impact of the availability of L-Amb was evaluated by incorporating three different 
possibilities of using this expensive drug in the model. First, we assumed that all patients with 
invasive aspergillosis diagnosed by the alternative strategy would be treated with L-Amb and 
that all patients whose cases were diagnosed by the conventional strategy would be treated 
with DC-Amb. Second, we analysed the situation in which all patients with invasive 
aspergillosis diagnosed by the alternative strategy would be treated with L-Amb and that a 
varying proportion of those cases diagnosed by the conventional strategy would also be treated 
with L-Amb. Last, we assumed that the same proportion of patients whose cases were 
diagnosed according to both strategies would receive L-Amb. In addition, for the second and 
third scenarios, we calculated the threshold at which the expected costs were equal for both 
strategies. We also performed a two-way sensitivity analysis to examine the relationship 
between the proportion of patients treated with L-Amb and the prevalence of invasive 
aspergillosis. 
RESULTS 
Probability of receiving treatment 
The probability of receiving antifungal treatment as a result of the conventional strategy was 
0.24 (Figure 3.1; path probabilities 0.06 + 0.18), while the probability of receiving antifungal 
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treatment unnecessarily was 0 18 The probability of receiving antifungal treatment as a result 
of the alternative strategy was 0 073 (Figure 3 1, path probabilities 0 054 + 0 005 + 0 003 + 
0 003 + 0 008 + 0 000) with 74% of these cases identified by antigen detection and confirmed 
by CT scanning The probability of a patient incorrectly receiving treatment was 0 013, 
whereas only one of every 1,000 patients would incorrectly not receive treatment as a result of 
a positive ELISA result unconfirmed by imaging The expected costs of diagnosis by the 
conventional and alternative strategies were estimated respectively to be USD 167 per patient 
and USD 463 per patient, respectively, and those of treatment were USD 156 per patient and 
USD 63 per patient, respectively Thus, the calculated savings on therapy of USD 93 per 
patient, accrued by using the alternative strategy, did not compensate for the extra investment 
in the diagnostic tests and procedures (USD 296 per patient) Under baseline assumptions, an 
overall investment of USD 203 per patient would be required to implement the alternative 
strategy 
Table 3 3 Positive predictive value (PPV) and negative predictive values (NPV) and expected 
costs (US dollar, USD) per patient of an alternative strategy for the management of invasive 
aspergillosis, calculated for varying values of the sensitivity and specificity of the sandwich ELISA 
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As expected, the positive predictive value for the conventional strategy was low (25%), and 
the negative predictive value was high (100%) Irrespective of the level of sensitivity, the 
positive predictive value of the alternative strategy declined from 88% to 54% as the 
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specificity of the ELISA decreased, but the negative predictive value remained high (Table 
3.3). Decreasing the specificity of the test from 99% to 50% nearly doubled the expected costs 
per patient because the number of false-positive results increased, leading to the more frequent 
performance of CT scanning. By contrast, lowering the sensitivity of the ELISA from 99% to 
50% had only a marginal effect on the expected costs per patient, reducing them from USD 
480 per patient to USD 476 per patient when the specificity was 99%, and from USD 922 per 
patient to USD 919 per patient when the specificity was 50%. This effect is due to the fact that 
patients with a false diagnosis of freedom from disease will ultimately develop clinical signs 
and symptoms consistent with invasive aspergillosis and will still undergo CT scanning. 
Sensitivity analyses 
When the baseline values for the sensitivity and specificity of the sandwich ELISA were used, 
the alternative strategy became less expensive than the conventional strategy once the 
prevalence of invasive aspergillosis exceeded 13% (Figure 3.2), and even when the worst test 
performance values were used, this threshold increases only slightly to 15.1%. Similarly, the 
threshold dropped only marginally to a prevalence of 11.5% when the best test performance 
values of sensitivity and specificity of the sandwich ELISA were used. At a prevalence rate of 
13%, the probability of patients having invasive aspergillosis but wrongly not receiving 
treatment remained approximately one in 1,000. Given baseline values for the performance of 
the alternative strategy, the conventional strategy became more expensive than the alternative 
strategy when the likelihood that a patient would be treated with DC-Amb exceeded 48.8%. 
The expected costs per patient of the two strategies were equal when the cost of the sandwich 
ELISA was USD 3.30. 
Treatment with L-Amb 
The expected costs of the alternative strategy were estimated to be USD 3,096 per patient, 
assuming that each patient with probable invasive aspergillosis was treated with L-Amb. This 
approach was always be more expensive than the conventional strategy and treatment with 
DC-Amb, since thresholds could not be identified for the prevalence of infection, for the 
probability that a patient would receive empirical treatment, or for the costs of the sandwich 
ELISA. However, if L-Amb was available to all patients, 43.3% of the 24% of patients given 
empirical antifungal therapy as a result of the conventional strategy could be treated with this 
formulation before the alternative strategy became less expensive. Assuming that only a 
proportion of patients were treated with L-Amb, irrespective of the diagnostic strategy used, 
the one-way sensitivity analysis showed that the expected costs of the alternative strategy were 
only lower than those of the conventional strategy when >5.3% of all patients given antifungal 
therapy were treated with L-Amb. The two-way sensitivity analysis (Figure 3.3) showed an 
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Figure 3.2 One-way sensitivity analysis of the decision tree to determine the effect of the 
prevalence of invasive aspergillosis on the expected costs per patient. The prevalence of aspergillosis 
is varied in the sensitivity analysis which results in lines indicating the expected costs of each strategy 
Where the lines of the strategies intersect (prevalence of 13%, given baseline test performance), this 
intersection defines a threshold point If the prevalence of invasive aspergillosis is below the threshold, 
the conventional strategy is optimal, if this prevalence is above the threshold, then the alternative 
strategy is optimal Baseline values for the sensitivity and specificity of ELISA in the alternative strategy 
are 100% and 94%, respectively The worst case values, 67% for sensitivity and 84% for specificity, 
result in a threshold of 11 5%; in the best case these values are both 100%, which results in a 
threshold of 15.1%. ( - - = conventional strategy; — = alternative strategy, baseline test 
performance, = alternative strategy, worst test performance; - . - = alternative strategy, best 
test performance). 
inverse relationship between the proportion of patients treated with L-Amb for invasive 
aspergillosis and the prevalence of invasive aspergillosis. 
DISCUSSION 
The increasing incidence of invasive aspergillosis (Groll et al, 1996), the high morbidity and 
mortality associated with the infection, and the costs of treatment with novel antifungal agents 
underscore the need for alternative approaches to managing this disease. The decision tree we 
constructed can be used as a model to predict the outcome and expected costs of 
implementing strategies for diagnosing or treating invasive aspergillosis in patients with 
haematological malignancies We chose the proportion of patients who would receive 
antifungal treatment, rather than survival, as the measure of outcome since the former variable 
71 
Chapter 3 1 
is more commonplace and useful, whereas the mortality associated with invasive aspergillosis 
depends not only on antifungal treatment but also on whether remission from the underlying 
disease is achieved (Aisner et al., 1977). However, we acknowledge that the baseline values 
necessary for decision analysis are likely to differ between different institutions and depend on 
the nature and type of tests and procedures used to diagnose invasive aspergillosis, the 
prevalence of the disease, and, more important, the guidelines governing the institution of 
empirical antifungal therapy. 
Under the assumed baseline values obtained at our hospital, the probability of 
receiving treatment unnecessarily could be reduced -14-fold from 0.18 to 0.013 by using the 
alternative strategy we propose. We were also encouraged by the finding that the probability 
of withholding treatment incorrectly was likely to be very low (0.001), although not zero. 
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Figure 3.3 Two-way sensitivity analysis of the decision tree to determine the effect of the 
prevalence of invasive aspergillosis and the percentage of treated patients who received liposomal 
amphotericin В (L-Amb) in both strategies according to the expected costs per patient As in Figure 
3.2, the results for the worst-case and best-case values of sensitivity and specificity, as well as 
baseline values for sensitivity and specificity of ELISA, are given. The curves indicate the combinations 
of values for the prevalence of aspergillosis and percentage of patients treated with L-Amb for which 
the expected costs of the two strategies are equal. Any co-ordinate to the left of the curves favours the 
conventional strategy, whereas any co-ordinate to the right of the curves favours the alternative 
strategy. There is an inverse relationship between prevalence of aspergillosis and percentage of 
patients treated with L-Amb. Thus, with our current prevalence, we would only need to treat one of 20 
treated patients with L-Amb, and the alternative strategy would begin to pay for itself. 
( — : baseline test performance; : worst test performance; - - - : best test performance). 
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which is unlikely to be the case, since invasive aspergillosis only becomes apparent at autopsy 
for the majority of patients (Groll et al, 1996). 
The strategy we propose requires physicians to withhold treatment from patients who 
would otherwise have received therapy empirically. Typically, these patients would be febrile 
and neutropenic, but galactomannan would not be detected in blood samples, and CT scans 
would show not show lesions consistent with invasive aspergillosis. Of course, other fungal 
pathogens may cause clinical signs and symptoms that are difficult to differentiate from 
invasive aspergillosis; nevertheless, the fear that patients may die of invasive aspergillosis 
compels many physicians to begin treatment empirically, after 3-5 days of persistent fever that 
is refractory to antibacterial therapy, even in the absence of any pulmonary or sinus 
abnormalities. Thus, as many as two-thirds of all neutropenic patients are given empirical 
antifungal therapy (Goodman et al, 1992; Winston et al, 1993). 
Clearly, the withholding of treatment will be difficult to achieve in such circumstances 
because the morbidity associated with DC-Amb therapy is regarded as less harmful than is the 
withholding of treatment from a patient with disease. Furthermore, when other less toxic 
antifungal agents are made available, the threshold for treating patients empirically will be 
lower still, with only the high cost of novel antifungal agents and the constraint of resources 
providing disincentives to using these drugs empirically. The evaluation of alternative 
strategies for managing invasive aspergillosis is therefore imperative if we are to define the 
place of new antifungal agents and control their use. 
The baseline values for the performance of the sandwich ELISA were based on the 
results of a prospective study of children during treatment for a haematological malignancy 
(Rohrlich et al, 1996). However, false-positive ELISA results have been reported to occur 
within 30 days after bone marrow transplantation (Sulahian et al, 1996). and within 10 days 
after cytotoxic therapy (Swanink et al, 1997). In the latter study, antigen was detected 
intermittently in a series of serum samples from some patients who had no evidence of 
invasive aspergillosis, which necessarily lowers the specificity of the sandwich ELISA 
(Swanink et al, 1997). However, since sequential tests and procedures are used in the 
alternative strategy to diagnose invasive aspergillosis, the impact of a less sensitive and 
specific ELISA on the positive and negative predictive values of the strategy as a whole is 
likely to be negligible. Nevertheless, the total costs per patient will increase considerably, 
especially if the specificity proves low. In addition to better selection of patients for antifungal 
treatment, the use of the sandwich ELISA as a screening test for galactomannan may also 
allow for the diagnosis to be made at an early stage of infection, at least for some patients 
(Hiemenz et al, 1995; Stynen et al, 1995; Verweij et al, 1995). 
Under baseline assumptions, we found that the current conventional strategy was less 
expensive per patient than was the alternative strategy when patients were treated exclusively 
with DC-Amb. However, we omitted the costs related to toxicity of treatment with this 
formulation even though they were expected to be high because a larger number of cases 
diagnosed by the conventional strategy will receive treatment. As a consequence, all 
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calculated expected costs were a conservative estimate of the actual costs. Nevertheless, the 
alternative strategy we propose will become less expensive than the conventional strategy if 
>5.3% of the treated patients are treated with L-Amb and it will become even less expensive if 
it proves tenable in circumstances where the majority of patients with haematological 
malignancies currently receive empirical antifungal treatment. 
Moreover, the probability of invasive aspergillosis is also high among these patients, 
so those cases of invasive aspergillosis that are diagnosed by using the alternative strategy 
may benefit the most from being given first-line treatment with L-Amb. However, the costs of 
treating all such patients with L-Amb will be high; thus a comparative study of L-Amb and 
DC-Amb is still required to determine the feasibility of this approach by taking into account 
other important aspects such as outcome, adverse drug reactions, and costs. 
In conclusion, wc constructed a decision model to explore the feasibility of 
implementing an alternative strategy for diagnosing invasive aspergillosis in patients receiving 
treatment for haematological malignancies. This model indicated that screening for 
galactomannan and using imaging techniques, as compared with the conventional strategy, 
will reduce the number of patients who require treatment and therefore may help to control the 
use of toxic or expensive antifungal agents. The model showed the relevance of defining a 
time horizon when evaluating diagnostic technologies. Limiting the time horizon to the 
diagnostic process itself showed that the financial implications of using ELISA for screening 
of serum for detecting galactomannan and possibly obtaining a CT scan and a "'in-IgG 
scintigraphy is more costly and equal effective in terms of detecting cases compared to the 
conventional diagnostic strategy. However, expanding the time horizon in this model, thus 
including the treatment process leads to the conclusion that the financial investment needed 
for the alternative diagnostic work up can be compensated by less costs of treatment in the 
case of using the newly developed lipid formulations of amphotericin B. 
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THE ISSUE OF THE RELEVANT COSTS AND CONSEQUENCES: 
DETERMINING THE PERSPECTIVE OF THE ANALYSIS 
Based on Severens JL, Brokx JPL & Broek Ρ van den (1997). Cost analysis of cochlear 





The issue of relevant costs and consequences, in particular the role of determining the 
perspective of analysis, is important when performing economic evaluation alongside clinical 
trials (Drummond & Davies, 1991). The definition of the perspective influences the relevancy 
of the different costs that have to be analysed. Of course, the choice for the units in which 
costs are analysed is of influence of the final results of a cost analysis. Besides this, the choice 
of the perspective determines the way cost prices should be calculated. Therefore, when 
comparing results of cost analyses of different studies, comparison of the results solely is 
hardly useful. The methods used for measurement of costs should be examined before 
conclusion about discrepancies can be made. This issue is illustrated by a study on costs of 
cochlear implants, which included comparison with the results of several studies found in the 
literature. 
On the basis of a series of studies demonstrating safety and efficacy, multichannel 
cochlear implants were approved by the Food and Drug Administration for use in adults in 
1984 and in children in 1990 (Balkany, 1993). Up till 1995, approximately 6000 cochlear 
implant procedures had been undertaken world-wide (Lea & Hailey, 1995). There is no 
comparable alternative medical treatment for total deafness. In many countries policy makers 
are faced with the decision whether or not to include cochlear implants to the basic benefit 
package. In the face of scarce resources, policy makers and health care purchasers are not only 
interested in the effects of certain health care interventions, but also in the costs, which are 
involved. Several studies have been published which report about costs of cochlear implants, 
which cover only a few countries: Australia (Lea, 1991; Lea & Hailey, 1995), the United 
Kingdom (Summerfield & Marshall, 1995a; Davis et ai, 1995; Hutton et ai, 1995) and the 
United States (Wyalt et ai, 1995; Harris et ai, 1995). Some of these include analysis on 
implantation programs for children. However, differences in health care settings in the 
different countries influence the results of a cost analysis (Summerfield et ai, 1995b). This 
makes application of the results in a specific policy making context difficult. This article 
describes the results of a cost analysis, which was performed alongside a clinical study of 
cochlear implants in children in The Netherlands. The results regarding the effectiveness of 
cochlear implants in children analysed in this study are reported elsewhere (Vermeulen et ai, 
1995; Snik et ai, 1997a; Snik et ai, 1997b; Coerts et ai, 1996). 
METHODS 
Between 1993 and 1996 106 prelingually deaf children were screened as candidates for a 
cochlear implant. Of these, 20 children were implanted. An extensive description of selection, 
inclusion and exclusion criteria is reported elsewhere (Vermeulen et ai, 1995). The children 
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received a multichannel cochlear implant, the Nucleus Mini System 22 with a MSP Processor. 
Their mean age was 7 years, 1 month (range 3 ; 11 to 11 ; 11 ). 
A societal perspective was used for the analysis. This perspective implies that real 
costs of medical care were calculated, instead of using tariffs. In addition, non-medical costs, 
like patients or parents travelling costs were included in the analysis. The time horizon was 
five years. The cost analysis of selection, implantation and rehabilitation during the first year 
were based on empirical data. Costs that are incurred during the remaining years, were based 
on the planned after care. Costs of maintenance of the external cochlear implant hardware 
during this period were estimated. 
The data used for the costs analysis were obtained from two institutes involved in the 
project. For the selection and implantation data from the University Hospital Nijmegen were 
used, based on respectively 106 and 20 children. In one of the 20 children use of the cochlear 
implant was abandoned after one year because inadequate hearing sensation levels. This child 
had a partial insertion because of total obliteration of the cochlea after meningitis. The data of 
the remaining 19 children were used for the cost analysis of rehabilitation and after care. 
These data were obtained from the Institute for the Deaf in Sint Michielsgestel. 
The measurement of volumes 
Volumes of utilisation of human resources and materials were prospectively registered. Time 
spent by different types of personnel was recorded during the phases of selection, implantation 
and rehabilitation. Utilisation of facilities such as operation theatre, recovery room, 
audiological centre and the special rehabilitation centre was recorded in production entities 
like number of hours operating time, number of audiology contacts and days in the 
rehabilitation centre. Besides this, hospitals days, out patient visits and return visits for 
rehabilitation were registered. Registration covered one year follow up after the implantation 
of each child. For the subsequent period volumes were modelled on the basis of planned after 
care activities. 
The measurement of prices 
Basis for the calculations were 1994 prices7. If prices were not available for this year, a price 
index was used to make the necessary inflation corrections. Overhead costs of general 
departments like hospital administration and personnel department were not included. Prices 
of the different personnel categories involved (ENT specialist, audiologists, psychologist, 
speech therapist etc.) were based on the midpoint on the scale for each grade of professional 




involved, including scale specific social taxes. Expenses for other salary overheads like 
holiday premiums and fringe benefits were added (8% and 3% respectively). 
Costs of materials used were based on retail prices. Capital costs for this equipment were 
based on costs of depreciation, interest and a surcharge for annual maintenance costs (8%) 
(Rutten et al, 1993). Depreciation and interest were based on annuities of the initial capital 
outlay and the economic lifetime of the equipment involved. The annual annuity and 
maintenance costs were divided by the annual production number. For instance, annual costs 
for general equipment in the operating theatre were divided by the annual number of operating 
hours. The annual costs of operating equipment specific for cochlear implants were divided by 
the number of implants performed annually. Costs for using accommodation were added in 
proportion to the time that the accommodation was used. Energy costs and cleaning costs per 
square meter were calculated on the basis of actual space used. The price of a hospital day was 
obtained by dividing the annual costs for nursing staff, materials used, feeding and other hotel 
costs by the number of hospitals days realised in the ENT department. The calculations 
resulted in Dfl. 679 per hospital day. The price per hour of the ENT out patient department 
was determined on the same basis, which resulted in Dfl. 102 per hour out patient department 
time (ENT specialist excluded). Diagnostic tests like CT scan, MRI and ECoG/EBER were 
valued according to the appropriate tariffs. Reason for not performing extensive cost analyses 
was that these tariffs were an approximation of the integral price (Rutten et al, 1993). For 
rehabilitation, a special cochlear implantation centre was available which was not used for any 
other purpose. The annual costs of this facility were calculated on an integral basis, including 
annual costs of the building, equipment, power etc. These annual costs were divided by the 
number of patients that entered the rehabilitation phase annually. Costs of after care which 
were planned to take place after the year of implantation were discounted on the basis of a 5% 
discount rate (Drummond et ai, 1987). 
Non medical costs consisted of travelling costs of the children and parents. On the 
basis of the postal codes travelling distances for the children and parents to the institutions 
were estimated by means of a route-planning program. In accordance with Dutch guidelines 
for cost analysis in health care a price of Dfl. 0.39 per kilometre was used (Rutten et ai, 
1993). 
Sensitivity analysis 
To assess the impact of certain variables on the robustness of the conclusions, a sensitivity 
analysis was performed. During the clinical study 20 out of 106 children (19%) were selected 
for having a cochlear implant. This rate of implanted children as part of the number of 
screened children was varied between 9 and 29% as being possibly important on the estimated 
total costs of cochlear implant per child. 
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RESULTS 
Costs of selection 
106 deaf children entered the selection phase for a cochlear implant. The application and 
intake of each of these children consumed relatively little time of the members of the cochlear 
implant team. Surcharges for accommodation and costs of used administrative materials were 
added. This resulted in Dfl. 1,228 per child, and Dfl. 130,154 in total. 
The screening resulted in 20 candidates who were considered suitable for a cochlear 
implant. These children were subjected to audiological, psychological and medical tests. All 
of them underwent a CT scan to see if the cochlea was suited to insert the electrode arrays. For 
seven of the children general anaesthesia was needed to perform the CT scan, which required 
a one-day stay in the hospital. More costly were tests like MRI (sometimes with general 
anaesthesia and thus one day hospital stay) and ECoG/EBER. The latter was done operatively 
under general anaesthesia and required a three day hospital stay. However, these tests were 
only applied to five of the children. The costs for audiological, psychological and medical 
testing were Dfl. 94,349 total. 
Besides these child-specific activities, costs of the team involved in this selection 
phase were analysed. These activities consisted mainly of team meetings to discuss candidacy 
of the children for a cochlear implant. Besides travelling costs, main part of this was the actual 
time spent by the team members, which resulted in Dfl. 60,608 in total. 
Thus, the total costs involved of the selection procedures, amounted Dfl. 285,111. 
These costs were ascribed to the 20 implanted children. This resulted in Dfl. 14,256 selection 
costs per implanted child. 
Costs of implantation 
Main costs of the implantation phase were the costs of the cochlear implant hardware. 
Although the internal hardware is meant to last a lifetime and the external hardware for at 
least eight years, no depreciation calculations were performed. Reason for the strategy to 
consider the price of the hardware as costs in the year of implantation, was that the cochlear 
implant is solely used for the benefit of one patient. At the time of the study the price for the 
hardware was Dfl. 46,397. Small materials used, including costs of sterilisation were Dfl. 
2,098 per operation. Capital costs for medical equipment was calculated as a surcharge for an 
implant operation. Implant specific equipment resulted in Dfl. 58, ENT specific equipment in 
Dfl. 107 and general equipment in Dfl. 298 per operation. Including overhead costs of the 
operating theatre (cleaning, housing) this resulted in Dfl. 592 overhead costs per operation. 
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The time spent in the operating theatre formed the basis for calculating the costs of personnel, 
which resulted in Dfl. 2,281 per operation. In total the implantation costs were Dfl. 51,368 per 
child. 
The costs for a one-day stay in hospital were determined to be Dfl. 679. Mean stay in 
hospital was 6.6 days. After a patient had been discharged an out patient visit was planned to 
check the recovery of the operation wound and overall condition of the patient. This visit 
lasted 45 minutes, costing ENT specialist time and a surcharge for accommodation (total Dfl. 
162). The costs for hospital stay and out patient clinic visit resulted in Dfl. 4,646 per patient. 
Together with the cost of the operation itself, the costs of the implantation were Dfl. 56,014 
per child. 
Costs of rehabilitation 
All activities in the rehabilitation phase took place in the cochlear implant rehabilitation 
centre of the Institute of the Deaf in Sint Michielsgestel. Per rehabilitated person Dfl. 4,947 
for infrastructure costs was calculated. The remaining costs were calculated on a variable 
basis. Not only the institute's audiologist, audiology assistant, speech pathologist and speech 
therapist were involved in this phase, but also the child's teacher and the school speech 
therapist. The rehabilitation phase can be divided in several stages. Several weeks after 
implantation, the external cochlear implant hardware had to be fitted. The time spent by the 
different persons involved was 28 hours by the audiologist, 4 hours by the audiological 
assistant and 20 hours by the speech therapist. This time spent incurred Dfl. 3,110 per child. 
After the regulation, the actual rehabilitation started. A child would stay with one or two 
parents in the centre for two times a midweek. Each day several sessions were performed with 
a child. For efficiency reasons, two implanted children stayed in the centre at the same time. 
Analyses of time spent by the team members resulted in 6 hours audiologist time, 201 hours 
speech therapist time and 16 hours speech pathologist and school speech therapist time. For 
each rehabilitated child this resulted in estimated costs of Dfl. 13,611. After this period of 
intensive rehabilitation, the child's progress is assessed regularly. This was done either at the 
cochlear implant rehabilitation centre or at the regular school. These assessments were done 
monthly during the first three months, once every six weeks during the remaining months of 
the first year. This assessment period resulted in Dfl. 3,039 per child and existed only out of 
costs for personnel. In total the costs of the rehabilitation phase were Dfl. 24,707 per child. 
Costs of long term care 
During the second year after transplantation, assessment and tuning days are planned four 
times, during the third year two and during each subsequent year 1 contact day is planned. 
Each visit consists of several hours of contact between the patient and the different team 
members involved. The total costs for a day were calculated to be Dfl. 1,556. Besides this. 
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each child receives a fixed number of hours speech and hearing therapy annually, which 
results in Dfl 1,093 per child per year Adding up the different discounted costs per year, this 
results in Dfl 15,249 per child for this four-year post-operative period 
Besides the costs of the after care days, maintenance of the cochlear implant hardware 
was estimated The external hardware needs periodic maintenance and has more breakdowns 
in children than in adults For this reason one spare processor is needed per eight children 
Besides this the infrastructure for maintenance and small replacement materials were needed, 
Table 3 4 Costs (in US Dollars) of cochlear implants in children 
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which leads to the estimation of Dfl. 2,085 per child per year. The discounted maintenance 
costs for the five years is Dfl. 7,393 per child 
Adding all after care costs per year and using a discount rate of 5% the total costs for 
the after care for the second until the fifth year is Dfl. 22,641 per child. 
Non medical costs 
Non medical costs related to the cochlear implant procedure consisted of travelling costs of 
the parents accompanying the child. The children came from all over The Netherlands, with a 
mean distance of 133 kilometre to the University Hospital and 139 kilometre to the Institute 
for the Deaf. The number of visits times the costs for travelling resulted in mean travelling 
costs for the whole period of five years. Like the selection costs, the travelling costs of all the 
children who entered the selection phase were ascribed to the finally implanted children. 
Using a 5% discount rate for the costs after the first year, the travelling costs were Dfl. 3,838 
per implanted child. 
Overall result 
The overall results of the cost analysis of cochlear implants in children are presented in Table 
3.4. The total medical costs per implanted child are Dfl. 117,617, given the baseline rate 19% 
of implanted children as part of the number of screened children. Varying this rate in a 
sensitivity analysis between 9 and 29% results in total costs per child of Dfl. 129,274 and Dfl. 
114,232 respectively, which means that the rate does not have a large impact. 
DISCUSSION 
The result of our cost analysis of cochlear implants in children is primarily useful for 
reimbursement issues of policy makers. No comparison has been made with another facility 
since the clinical study was a non-comparative observational study. For this reason, the 
concept of opportunity costs, e.g. financial comparison with alternative facilities for the deaf, 
has not been applied. 
The costs related to the educational situation of the children were not part of the cost analysis, 
due to the limited period of follow up. However, Hutton et al. (1995) suggested that the 
impact of cochlear implant on education is a key factor on the evaluation of cochlear implants 
in children. They presented very different estimates. Considerable lifetime savings on costs of 
education have been estimated (£51,265, approximately Dfl. 133,389) but as the authors state 
these results must be treated with caution. Other longer-term financial benefits might occur 
when persons involved are prevented from being dependent on social services and could 
contribute to taxation instead of draining from the social security system (Roberts, 
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1993). Concerning cochlear implants in adults an increase in income after implantation was 
measured (Harris et al, 1995). However, as long as the impact of cochlear implant on the 
educational setting of the children is not properly investigated it will remain difficult to 
predict any changes in costs for education and eventually their employment status (Moog & 
Geers, 1995). 
The societal viewpoint of the analysis would require the incorporation of more 
relevant cost categories in our analysis. Parents spend considerable time accompanying their 
deaf child during the selection and implantation phase. Besides this, especially the 
rehabilitation and after care phase require parents' time. The indirect costs involved (lost 
labour time) were not part of our analysis due to the fact that the relevant data were not 
available. 
During our study no major complications with the 19 children were faced. Major 
complications could cause our calculations to be a serious underestimation. In the literature 
only few complications have been reported (National Agency for Medical Development and 
Evaluation, 1994). Removal of the implant was only necessary in 0.6 to 1% of the cases. 
Besides this, complications like anaesthetic complications, flap related problems, and 
electrode placement problems might occur. Of course such an event would increase costs for 
treatment for the specific patient. However, regarding the very small chance, the mean costs of 
cochlear implants in children do not increase significantly. The results of sensitivity analyses 
performed in published studies showed that the influence of these probabilities was negligible 
on the ratio between costs and quality adjusted life years gained (QALY) (Summerfield & 
Marshall, 1995a; Wyatt et al, 1995). 
The price of the implant hardware is a large part of the total costs of cochlear implant 
procedure as is confirmed by our study. Other studies show that the ratio between costs and 
effects is highly sensitive to this price. The price might fall in future (Summerfield et al, 
1995a), however, no considerable change in price of the cochlear implant hardware can be 
expected for the time being (Roberts, 1993). 
Comparison of results 
Compared to the results from cost analyses in other countries, the costs of the paediatric 
cochlear implants program in the Netherlands are relatively high. Most differences however, 
can be explained by methodological differences. 
In a decision modelling approach, costs of cochlear implantation in the UK were 
described (Hutton et al, 1995). The costs of selection were £ 790 (approximately Dfl. 2,000), 
costs of implantation were estimated to be £ 15,522 (Dfl. 40,237) and the rehabilitation phase 
is estimated to cost only £ 900 for the first year and £ 3,750 for the other years (Dfl. 12,090 in 
total) until 16 years of age. Although the costs were categorised in the same phases as in our 
study, straightforward comparison of the results is difficult since no information was provided 
concerning the sources for the cost data, overhead and accommodation costs and the year of 
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the prices. Besides this, the costs of the selection phase were not ascribed to the children who 
were implanted. As the authors state, the results of their exploratory work must be treated with 
caution because the analyses incorporate a very large number of assumptions. 
The studies by Lea (1991) and Lea & Hailey (1995) mention costs for selection, 
operation, the implant hardware ($17,030, equals approximately Dfl. 30,995) and 
rehabilitation for cochlear implants for prelingually children, which in total would be $36,630. 
However, these costs were based on Australian 1991 fees instead of real costs, which 
invalidates comparison with the results of this study. Besides this, relatively low prices for the 
hardware were used in the calculations. 
The estimated costs mentioned by Wyatt et al. (1995) were based on a decision 
analytic model which concerns postlingually adults. Because of the essential differences in the 
selection and rehabilitation phase, only the costs of the implantation phase can be compared 
with our results. Total costs of implantation consist of the implant hardware costs ($19,383, 
approximately Dfl. 35,277) and the operating costs ($12,227, approximately Dfl. 22,253). It is 
not clear whether these costs were based on fees or on real costs. However, concerning the 
operating costs these results were considerable higher than our results. 
In the studies by Davis et al. (1995) and Harris et al. (1995) only costs of the implant 
hardware and in the latter study, costs of operation were considered. The basis for these 
estimations is not clear. Considering our results these studies seem to underestimate the costs 
that were really involved in cochlear implants. 
Because costs of cochlear implants involved in adults can not be translated to children, 
the study by Summerfield & Marshal (1995a) is relevant. In this study the costs of a children's 
implant program in the United Kingdom is analysed. The authors find total costs at the end of 
the first year to be £ 24,250 (approximately Dfl. 63,050). Taking into account the much lower 
price for the implant hardware used in their estimates and the general differences in the 
paediatric programs, their result is in line with our calculations. 
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THE ISSUE OF THE ACCURATE MEASUREMENT OF COSTS AND 
CONSEQUENCES: INCORPORATING PRODUCTIVITY COSTS 
Based on Severens JL, Mulder J, Laheij, RJF & Verbeek ALM. Precision and accuracy in 
measuring absence from work as a basis for calculating productivity costs. Social 




Regarding the accurate measurement of costs and consequences, one of the topics about which 
debate is going on among health economic reseachers, is the measurement and valuing of 
productivity loss. Productivity loss is related to the consequences of persons' inability to work 
due to illness. The main point of the discussion concentrates on whether to include the 
consequences of the inability to work in monetary terms in de numerator of the ratio of costs 
and effectiveness or whether these consequences are to be measured in utility terms as an 
outcome measure and therefore must be included in the denominator of the ratio (Brouwer et 
al, 1997a; Weinstein et al, 1997; Brouwer et al, 1997b). However, in cost-effectiveness 
analyses that do not use utility measures for effectiveness it seems obvious to reflect the 
consequences of inability to work in monetary terms in the numerator of the cost-effectiveness 
ratio, thus valuing productivity loss as being costs (Luce et al, 1996). 
When analysing productivity costs, a distinction can be made between lost 
productivity related to absence from paid work, reduced productivity at paid work, and lost 
home productivity (van Roijen et al, 1996). Although the latter two can be of importance, in 
our study we concentrate on productivity costs related to absence from paid work. When 
analysing productivity costs due to absence from work, days absent from work are to be 
measured, after which the number of days is valued (Koopmanschap & Rutten, 1996b). 
To determine absence from work due to illness several instruments can be used. Sick 
leave registers would be a reliable source of information to obtain the number of days sick 
leave for participants in a study. However, when analysing the productivity cost of study 
participants related to a specific disease who, of course, are employed in different localities or 
companies this approach is not practical. To overcome this problem questionnaires are used to 
measure absence due to illness to be able to calculate productivity costs. Such questionnaires 
can be applied in a more or less prospective manner, but more often data are gathered in a 
retrospective way. Different recall periods to measure absence from work can be found in the 
literature and to our information the longest period used was 12 months (Bertera, 1991; Agius 
et al, 1994; Jones et al, 1995). The question arises whether using such questionnaires leads 
to valid results because a potential for recall bias exists in every study in which historical self-
reported information from respondents is used. The imperfect memory of respondents can 
harm the precision (difference by chance between memory and fact) and accuracy (systematic 
difference between memory and fact) of the sick leave data, which, theoretically, can cause 
recall bias. This can influence the absolute level of costs induced by absence from work. 
However, recall bias is only relevant when accuracy of recall regarding the measure of interest 
is different between the different groups, which can be distinguished in the study (Raphael, 
1987). 
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The purpose of this study was to study precision and accuracy of a retrospective self-
administered questionnaire on sick leave by comparing the self-reported absence with 
company-registered absence data. Different recall periods were used to analyse the 
relationship between memory and length of the recall period. 
METHODS 
A local branch of a pharmaceutical company involved in research, marketing, and sales 
participated in the study. All employees, existing largely of office workers, were asked to fill-
in a questionnaire to indicate the number of days absent from work due to illness concerning 
five different recall periods: the past 2 weeks, 4 weeks, 2 months, 6 months, and 12 months. 
The actual date the questionnaire was filled-in was written on the questionnaire by the 
respondent. The dates of the five different recall periods were defined separately for each 
respondent. The company kept a prospective sick leave register. Using this register for each 
respondent true absence from work was determined for the five recall periods. These register-
based data were considered to be the gold standard regarding absence due to illness. Data on 
sick leave for non-respondents were not made available. 
Mean and standard deviations of company-registered and reported sick leave were 
calculated for the subsequent recall periods for both all respondents and cases only. The latter 
were defined as respondents with reported or registered absence. The mean difference was 
calculated based on each respondent's difference in registered and reported number of days 
absent from work due to illness for the various recall periods. Accuracy was studied as a 
possible systematic difference between the data and was tested by the sign rank test, which 
tests if the differences calculated between registered and reported have a symmetric 
distribution with a zero mean. These analyses were performed for both all respondents and 
cases only. 
Analysing the precision of retrospective measurement of sick leave, the percentage of 
respondents without any difference between registered and reported sick leave was 
determined. Besides this perfect precision several other levels of precision were introduced. 
These levels were defined as the maximum absolute discrepancy between registered and 
reported sick leave using the categories 1, 2, 3, 4, 5, 6, 7, 8, and 9 or more days discrepancy. 
For each level of precision, the cumulative percentage of the respondents with perfect 
agreement or a discrepancy was determined and plotted for the different recall periods. The 
same calculations were performed only using the data of the cases. 
For the respondents with registered absence from work, the question was addressed 
how the relative difference between registered absence form work and reported absence from 
work changed regarding the length of the recall period. Thus, bias was reformulated as a 
proportion between registered and reported absence from work: ((registry-reporting)/registry). 




At the time of this project 210 people worked at the company; all were asked to participate in 
the study. Of these, 155 returned the questionnaire (response rate 74%). One questionnaire 
was incomplete, and the reported results could not be matched to the data from the company 
registry, resulting in a study sample of 154. It was possible to make company-registered 
absence due to illness available for all respondents except one. Reported sick leave for the 
different recall periods was limited slightly due to missing data. The agreement between 
reported data and registered data was based on the respondents for whom both company-
registered and reported data were available. 
Table 4.1 Registered absence from work due to illness in days (number (N) of respondents, 
mean, and standard deviation (s.d.)), reported absence from work in days (number (N), mean, and 
standard deviation (s.d)), and difference between registered and reported absence from work in days 
(number (N), mean, min to max, and p-value (p) of the sign rank test) regarding the different recall 
periods for all respondents, and cases (respondents with reported or registered absence). 
2 week recall 
all respondents 
cases 
4 week recall 
all respondents 
cases 
2 month recall 
all respondents 
cases 
6 month recall 
all respondents 
cases 
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In Table 4.1 the results of days absent due to illness are reported regarding both all 
respondents and cases. As expected, the number of cases increases with the length of the 
recall period. The longer the recall period, the higher the number of days sick leave, both for 
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3 4 5 
Absolute difference in days 
-2 weeks -4 weeks -2 months - 6 months •12 months 
Figure 4.1 Cumulative percentage of all respondents with zero to a maximum of 8 days absolute 
difference between reported number of days of sick leave, and registered number of days of sick leave 
for five different recall periods. 
all respondents and cases. The comparison of company registered sick leave and respondent 
reported sick leave is reflected in an absolute difference for each respondent for the various 
recall periods of which the mean is mentioned. The results of the sign rank test for both all 
respondents and cases showed no systematic positive (underestimation of number of days 
absence) or negative (overestimation of number of days absence) deviation between registered 
and reported sick leave. 
The cumulative percentages of respondents who did not reveal any difference between 
registered and reported sick leave, and an absolute difference of a maximum of respectively 1, 
2, 3,4, 5, 6, 7, 8, and 9 or more days for the different recall periods are shown in Figure 4.1. 
As can be seen from this figure more than 95% of the reported data matched the registered 
data perfectly when the recall period was limited to 2 weeks, and 4 weeks. This percentage 
decreased to 87%, 57%, and 51% for respectively the recall periods 2 months, 6 months, and 
12 months, respectively. Accepting, for example, a margin of a maximum of 3 days difference 
between registered and reported data, the percentages of no difference for the five recall 
periods were 100%, 100%, 96%, 85%, and 78%, respectively. 
When selecting the cases, the results are different (Figure 4.2). As mentioned in Table 4.1 the 
number of respondents included in this analysis was limited, respectively 10, 15, 31, 81, and 
97 for the subsequent recall periods. For these subgroups a discrepancy between registered 
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Figure 4.2 Cumulative percentage of respondents with registered or reported absence from work 
with zero to a maximum of 8 days absolute difference between reported number of days sick leave, 
and registered number of days of sick leave for five different recall periods. 
period (2 weeks). For the longer recall periods this figure gets worse (up to 80% for 6 months, 
and 12 months). Where a 3-days discrepancy is regarded acceptable, this results in 100%, 
100%, 74%, 70%, and 64% agreement between registered and reported data. 
The mean and median proportion for the different recall periods were respectively 
34% and 10%, 30% and 0%, 46% and 50%, 7% and 30%, and -16% and 0%. 
DISCUSSION 
The issue of the accurate measurement of costs and consequences was illustrated by the 
concept of productivity costs. To determine these costs, when performing economic 
evaluations alongside clinical trials, measurement of absence from work is inevitable. For 
reasons of reliability, prospective registration of absence from work is to be preferred above 
retrospective analysis. However, this indicates a substantial workload for participants, which 
can be one of the causes of missing data (Goossens et al, 1998). Using only a short period of 
prospective registration, and multiplying the results afterwards to estimate absence from work 
for a longer term leads to valid results only when large numbers of respondents are included in 
a study (van Roijen et al, 1996). Also, in this manner an increase or decrease in absence from 
work during a longer period can not be measured. Up until now recall periods to measure 
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absence due to illness have been established rather arbitrarily. Burdorf et al. (1996) state that a 
6-month recall period was chosen to avoid strong recall bias. Other studies chose, again 
arbitrarily, a recall period of 12 months (Bertera, 1991; Agius et al, 1994; Jones et al, 1995). 
The purpose of our study was to study precision and accuracy of a retrospective self-
administered questionnaire on sick leave by comparing the reported results with company-
registered absence data for different recall periods. Although in our study the number of cases 
was limited, the results suggest that accuracy seems to be acceptable when measuring sick 
leave retrospectively as a systematic over- or underestimation could not be detected. When 
analysing the precision to measure absence due to illness in a retrospective manner, 
researchers should be aware of a certain imprecision which increases when a longer recall 
period is used. To choose a recall period and therefore introducing a certain level of 
imprecision to our opinion should be based on the purpose of the study. Suppose a situation in 
which a health care intervention is evaluated of which medical costs are expected to be more 
or less the same compared to productivity cost; when the latter are calculated on the basis of 
reported sick leave, the precision level acquired would be rather high. In this case, imprecision 
of measuring sick leave might influence the conclusions of the evaluation. 
The mean and median proportion ((registry-reporting)/registry) for the different recall 
periods varied across a wide range. Because a clear function between recall period and 
proportion was not found, for instance increasing proportional errors, a systematic bias seems 
not to be the case. Besides this, in the context of the analysis of productivity costs, which 
should report absolute cost numbers, the meaning of the proportions is limited. A mean 
proportion of 34% when using a 2 week recall period (normally about 10 working days) can 
only be an absolute number of 3.5 days maximum, while a mean proportion of -16% (which 
seems to be more accurate) when using a recall period of 12 months (normally about 210 
working days) can be as high as -33.6 days. 
The overlapping recall periods or time frames defined in the questionnaire were also 
used in the analysis. The possibility existed that the responses to the questions regarding the 
different recall periods correlated and therefore the data of the adjacent periods in stead of 
overlapping periods could be used. However, we were mainly interested in finding out which 
recall period, starting from zero days recall, can be recommended to be used in the future 
when measuring productivity costs, given the idea that only one question should be used to 
measure absence from work retrospectively. Therefore, analysis of adjacent periods is not 
meaningful. 
In our study we did not find a systematic difference between registered and reported 
sick leave. This, however, should not lead to the conclusion that systematic over- or 
underestimation does not exist in self-reported days absent due to illness. As mentioned 
before, the number of cases in our study might be too small to find a significant difference. 
Given the mean difference above zero, the reported sick leave seems to be less than the 
company registered absence. In case a systematic difference in fact might exist, this does not 
necessarily lead to the conclusion that recall bias exists when measuring sick leave 
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retrospectively. As long as imperfect memory (both by chance or systematic) is equal in the 
different groups under comparison in a clinical trial, recall bias is not an issue. However, 
respondents are less likely to recall the absence of interest when the disease under 
investigation is no longer present or treatment is successful. If this is the case, significant 
research findings based on retrospective data might be interpreted as a methodological artefact 
(Raphael, 1987). Measuring sick leave retrospectively as part of an economic evaluation 
comparing different treatment options might introduce recall bias when a difference in 
treatment success is found. Therefore, one should be aware using rather long recall periods. 
To our knowledge the study by Burdorf et al. (1996) explicitly concerned reliability of 
a questionnaire on sickness absence. Concordance between company-registered and reported 
data were analysed by calculating Cohen's к. Cohen's к is based on the distinction between 
agreement between observations on the basis of chance, and the actual agreement between 
observations beyond chance (Landis & Koch, 1977). The number of days absent due to illness 
was categorised into four categories and, based on these figures, four by four tables were 
determined comparing registered and reported sick leave. However, we did not use this 
method because this approach has its' limitations. For instance, a perfect к can be calculated 
where respondents for whom registered data indicate 50 days and the reported number of days 
is only 5 days as long as both numbers of days belong to the same category used in the 
analysis. Thus, when using к it should be clear that after classifying the data in a limited 
number of categories, the absolute difference between registered and reported data is not taken 
into account as is done in our method. 
Several limitations must be considered when interpreting the results of our study. First, 
it was not possible to investigate the non-response. In the study by Burdorf et al. (1996) it was 
found that the prevalence and duration of sick leave was higher among non-respondents than 
respondents. They conclude that the biased response might be due to the fact that, as in our 
study, all workers were informed of the purpose of the study. Although confidentiality was 
guaranteed, this may have caused workers with high levels of absence due to illness to refrain 
from participating. Our findings were not different between analyses regarding all respondents 
and cases. This seems to indicate that the non-response probably does not influence our 
conclusion. Second, the recall periods that were used in our study were limited to five periods. 
From our analyses it seems clear that a recall period of 6 months or more might lead to recall 
bias, and a recall period of 2 months or less might not lead to recall bias. However, based on 
our data it is not possible to judge recall periods in-between 2 and 6 months. Third, compared 
to Dutch sick leave figures our study group seems to have a low rate of absence due to illness 
(Statistics Netherlands, 1997b). One of the reasons for this deviation might be the fact that the 
company that participated in our study existed largely of office workers. In the study by 
Burdorf et al. (1996), however, no significant difference was found between office workers 
and blue-collar workers regarding the reliability of retrospective measurement of sick leave. 
In conclusion, in the view of accurate measurement of costs and consequences, a 
retrospective questionnaire used for measuring absence from work due to illness can be a 
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reliable source of data. However, researchers should be aware of imprecision related to the 
recall period used. Because precision of 6 and 12-month recall is very poor when measuring 
productivity costs retrospectively, we recommend using a recall period of no more than two 
months. 
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THE ISSUE OF CREDIBLE VALUING OF COSTS AND 
CONSEQUENCES: TAKING SELF-REPORTED COMPENSATING 
MECHANISMS INTO ACCOUNT WHEN CALCULATING 
PRODUCTIVITY COSTS 
Based on Severens JL, Laheij RJF, Jansen JBMJ, Lisdonk EH van de, & Verbeek ALM 
(1998). Estimating the cost of lost productivity in dyspepsia. Alimentary 




Credible valuing is a topic which is discussed regularly when including productivity costs in 
economic evaluations of medical technologies (Luce et al, 1996; Brouwer et al, 1997a; 
Weinstein et al, 1997; Brouwer et al, 1997b). This disagreement is illustrated clearly by the 
fact that the Canadian guidelines for economic evaluation (Canadian Coordinating Office for 
Health Technology Assessment, 1997) suggest inclusion of these costs, in contrast to the 
revision of the Australian guidelines (Langley, 1996) which suggest to exclude these costs. 
One of the major concerns for not including productivity costs is the way these costs are 
predominantly valued. The currently used approach for calculating productivity costs due to 
absence from work is to take days absent valued by gross earnings, using the argument that 
this reflects the lost value of production when individuals are absent from work 
(Koopmanschap & Rutten, 1996b). This in fact reflects the potential production costs, while 
the actual costs for society may be lower because the absence is compensated for 
(Koopmanschap & Rutten, 1996a). For the long term absence, work can be taken over by an 
unemployed person or by reallocating employees over jobs. In contrast to the traditional 
human capital approach8, the so-called friction cost method takes these kind of compensating 
mechanisms into account (Koopmanschap et al, 1995). For short-term absence, a person's 
work may be covered by others, postponed, or made up by the sick person on their return to 
work. These compensating mechanisms influence the estimation of the productivity costs. 
From previous studies concerning various topics in gastroenterology it can be 
concluded that a societal perspective is obviously a relevant choice when performing an 
economic evaluation (Jönsson & Karlsson, 1996). This perspective implies incorporating all 
relevant costs for patient management into the study and thus, in gastrointestinal disease the 
productivity costs appear to be highly relevant. This is confirmed by the fact that work loss is 
substantial (up to a mean of 24 days in 1 year) among employed dyspeptic patients (Jensen, 
1988; Johannessen et al, 1990; Jönsson & Carlsson, 1991; Crean et al, 1994). Using days 
absent from work to calculate productivity costs, it was found that in the case of dyspepsia 
these costs were by far the most dominant (up to 79% of the total costs) compared to other 
types of costs (Pym et al, 1990; Nyrén et al, 1985; Sonnenberg & Everhart, 1997). In one 
study, a net economie gain was calculated for treating dyspeptic patients because of the 
reduction in productivity costs. In this case extra costs of medical treatment were outweighed 
by savings in productivity costs (Bytzer et al, 1994). However, the question arises as to 
whether these costs may be overestimated because compensating mechanisms for absence 
from work were not taken into account. 
8. The human capital approach values lost productivity by estimating the discounted future earnings 
of an individual in the years that they would have worked would they not have become ill. 
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In this study we analysed the productivity costs as a result of short-term absence from work 
due to dyspepsia, taking self-reported compensating mechanisms for absence into account. A 
comparison is made between the current method for calculating productivity costs and our 
approach, which limits overestimating productivity costs. 
MATERIALS AND METHODS 
Data 
Two studies on the relative efficacy of different combined diagnostic and treatment strategies 
in patients with dyspepsia were carried out, using a questionnaire about absence from work 
due to dyspeptic complaints. Patients who visited their general practitioner for the first time 
because of dyspeptic complaints were enrolled in the first study (Study 1). Patients who 
visited their general practitioner and were known to have persistent dyspeptic complaints 
serious enough to warrant further diagnosis by gastrointestinal endoscopy were enrolled in a 
second study (Study 2). A detailed description of the inclusion criteria of Study 2 is reported 
elsewhere (Laheij et al., 1998). In both studies, before treatment was started, patients filled in 
a questionnaire. Besides general information such as age and gender, respondents were asked 
to indicate the severity of their dyspeptic complaints. Level of education, profession, 
employment status, number of hours worked per week, and type of work (e.g. shiftwork, 
executive responsibilities) were also indicated by the respondents. Respondents were asked to 
report the number of days of missed work during the past 4 weeks due to either illness in 
general or to specific dyspeptic complaints. They were asked to indicate any compensating 
mechanisms in working activities for short-term absence. A choice could be made from six 
categories of compensating mechanisms: 1) compensation by colleagues during normal 
working hours; 2) compensation by colleagues during extra working hours; 3) compensation 
by extra temporary workers; 4) self-compensation during normal working hours; 5) self-
compensation during extra working hours; 6) no compensation for lost work and 
compensating mechanisms not known. 
Valuation of absence from work 
The analysis of productivity costs concentrated on people who had a paid job during the last 4 
weeks prior to the study. When calculating the productivity costs of a disease or a medical 
intervention due to absence from work, the number of days registered as being 'lost' must be 
multiplied by the productivity costs per day. The productivity costs are estimated by using the 
average gross wage per day, including employers' social benefit premiums for the Netherlands 
(i.e. gross earnings before deductions, plus employer-paid social benefits) (Statistics 
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Netherlands, 1997b). The logic here is that this reflects the value of production (Drummond et 
al., 1997). The number of days absent from work due to illness in general and dyspeptic 
complaints in particular were multiplied by the average gross wage per day to estimate the 
productivity costs without taking compensating mechanisms into account. In our analysis, we 
did take compensating mechanisms into account. Two types of calculations were used. First, 
we used a conservative approach in which productivity costs were considered to be relevant 
only in cases where respondents answered that compensating mechanisms were used which 
needed extra financial efforts, such as overtime work by colleagues or using extra workers. 
Second, we used an adjusted approach in which productivity costs were calculated in the same 
way as in the previous approach except when a respondent answered that no compensating 
mechanism existed at all (work was 'lost') or work could be made up by the sick employee on 
his return to work. For these latter cases productivity costs were considered to be zero. In all 
other cases productivity costs were reflected by the employee's productive value, i.e. the 
average gross wage. In both approaches the value of the unknown financial effort was 
estimated by again using the average gross wage. 
RESULTS 
Table 5.1 Baseline characteristics of the respondents. 
malesflemales 
mean and range of age (years) 
mean and range of severity of dyspeptic symptoms 
employment status N (%) 
employed 




employment characteristics N (%) 
employed full time 


















44 (20 - 74) 










In total 136 patients were included in the studies, 54 in Study 1 and 82 in Study 2. Baseline 
characteristics of the patients for the two studies are shown in Table 5.1. The baseline 
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characteristics were no different between the studies with respect to gender, age and seventy 
of dyspeptic complaints (scale from 1 to 12) Of the 136 patients studied, 66 had a paid job at 
the time of answering the questionnaire, 34 performed housekeeping or did volunteer work, 
14 were unable to work or were unemployed, 10 were retired, and one was a student (11 
missing values) 
Of the patients from both studies who had a paid job, 25 (38%) reported absence from 
work which resulted in an average of 3 0 days in the past 4 weeks Work absence of 1 9 days 
was reported as due specifically to dyspeptic complaints All working patients answered the 
question about compensating mechanisms when absent from work The results of 
compensating mechanisms for each study are reported m Table 5 2 
Table 5 2 Compensating mechanisms reported by respondents with a paid job 
study 1 study 2 
(N=21) (N=45) 
compensation by colleagues during normal working hours 12 (57%) 21 (50%) 
compensation by colleagues during extra working hours 0 (0%) 2 (5%) 
compensation by employing temporary workers 6 (28%) 8 (19%) 
self-compensation during normal working hours 1 (5%) 3 (7%) 
self-compensation during extra working hours 1 (5%) 2 (5%) 
no compensation for lost work 1(5%) 6(14%) 
compensating mechanisms not known 0 (0%) 0 (0%) 
On the basis of the days reported absent from work the productivity costs were calculated 
using the average gross wage for the Netherlands (Table 5 3) Our new conservative approach 
gave a much lower estimate of the productivity costs both in general and for productivity costs 
related to absence from work because of dyspeptic complaints Only one-quarter of the cost 
level calculated using the current approach remained, taking into account compensating 
mechamsms for absence from paid work The calculated range remained the same for the 
productivity costs Using the adjusted approach for taking the reported compensating 
mechanisms into account, only a marginal difference was found with the current approach of 
valuing each day of absence as productivity costs 
DISCUSSION 
Based on the assumption that production falls because of absence from work, work loss has 
been reported to be substantial among employed dyspeptic patients (Johannessen et al, 1990, 
Crean et al, 1994, Sonnenberg & Everhart, 1997) A database on dyspepsia from the Southern 
General Hospital in Glasgow shows that each employed patient with functional dyspepsia 
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loses on average 18.3 weeks of work per year (Crean et al, 1994). In a Swedish study it was 
found that patients with functional dyspepsia were responsible for, on average, 26 more days 
of lost production per year than other employees (Nyrén et al, 1985). Compared to these 
findings our results show that absence from work due to dyspepsia in our population is 
relatively low, calculated on the basis of the reported days absent from work during the 
previous 4 weeks. During the measurement of absenteeism data a definite diagnosis of the 
cause of the dyspeptic complaints had not yet been made. It is expected that the actual cause 
does not influence absenteeism (Johannessen et al, 1990). A comparison with other studies 
examining costs in gastroenterology should be carried with caution, because the aim of our 
study was only to compare different methods for calculating productivity costs. 
Table 5.3 Days absent from work and productivity costs due to short-term absence during a 4 
week period; mean and (range). 
days absent from work during past 4 
weeks 
productivity costs (in Dutch guilders)9 
not taking compensating 
mechanisms into account (current 




(0 - 20) 
900 




(0 - 20) 
898 











(0 - 20) 
636 
(0 - Θ.259) 
approach) 







(0 - 5.899) 
256 
(0 - 8.259) 
865 




(0 - 2.360) 
249 
(0 - 8.259) 
603 
(0 - 8.259) 
Besides absenteeism from work, productivity costs can be caused by reduced productivity of 
employees who work while suffering from symptoms of a specific disease. Until now two 
methods have been used to estimate productivity costs while working (Osterhaus et al, 1992; 
van Roijen et al, 1996). There is considerable uncertainty about the preferred valuation 
method because results vary considerably between different methods. Because of this we did 
not consider measuring productivity costs of employees working with dyspeptic complaints. 
In addition, the present study does not consider costs of absenteeism other than productivity 
9. The 1997 mean exchange rate of one Dutch Guilder is approximately 0.31 British pounds and 0.51 
US dollar. 
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costs. Such costs, for example administrative costs, undoubtedly exist (Koopmanschap & 
Rutten, 1996a). 
Recommendations 
Because productivity costs incurred or avoided when treating dyspeptic patients are 
substantial, this type of cost should be incorporated in economic evaluations of 
gastroenterologie interventions. When absenteeism from work is measured in work days lost 
and these days are translated into productivity costs, overestimation can be avoided. A general 
approach to take compensating mechanisms into account is part of the friction cost method. 
Numerous studies have shown that a reduction of annual labour time causes a less than 
proportional decrease in labour productivity (estimates between 0.6 and 0.9). To take short 
term absence compensating mechanisms into account, Koopmanschap et al. (1995) assume 
the elasticity to be 0.8 during the friction period, which is the period needed to replace a sick 
employee. Compared to our findings this estimated elasticity seems to be high. We calculated 
productivity costs as a result of absence from work due to illness in general and due to 
dyspeptic complaints, taking reported compensating mechanisms into account. The exact 
relationship between absence from work and real production loss depends on the employee's 
profession, the type of organisation and the production process (Koopmanschap & Rutten, 
1993). This suggests that a detailed study at the company level would be necessary, but when 
analysing the costs involved with a specific disease or medical intervention this appears to be 
impossible. Therefore, patients' questionnaires must be used to estimate productivity cost. In 
our study all patients who had a paid job were able to indicate the number of days absent from 
work and to respond to the question if compensation mechanisms were used during their 
absence, and if so, of what type (no missing values). This indicates that it is possible to gather 
information about postponing work and the extent of internal labour reserves and flexible 
labour for each patient's specific situation. We can conclude that in taking reported 
compensating mechanisms into account when calculating productivity costs, estimates are 
significantly lower compared to the current method. It is not possible to judge the validity of 
the different methods because true productivity costs can only be measured within the specific 
employment situation of each respondent. Further research on this topic should be developed 
before it can be decided which method is preferable. 
In conclusion, with respect to the principle that productivity costs should reflect actual 
production loss, in our opinion merely the absence from work leads to an overestimation and 
therefore compensating mechanisms should be taken into account. Complete insight of the 
consequences of compensating mechanisms requires detailed studies on the level of the firm 
which seem to be impossible when evaluating medical technologies. An approach to handling 
uncertainty in cost analysis related to health care interventions is to use sensitivity analysis 
(Briggs et al, 1994). With sensitivity analysis it is possible to explore the implications of 
selecting a particular analytic method from several alternatives. Analogous to the principles of 
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sensitivity analysis, both the current and conservative approach should be used when 
estimating productivity costs. This gives insight into the impact of the different calculating 
methods for calculating productivity costs on the final conclusions of the study. In this way, 
overestimating productivity costs can be avoided. 
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THE ISSUE OF CREDIBLE VALUING OF COSTS AND 
CONSEQUENCES: WILLINGNESS TO PAY FOR NON-
DECISIONAL DIAGNOSTIC INFORMATION 
Based on Severens JL, Boo ThM de, Roosmalen MS van, Verweij PE & Wilt GJ van der. 





Cost benefit analysis is a type of economic evaluation in which the consequences or outcome 
of a facility is expressed in monetary units. This makes it possible to compare costs and 
benefits in a direct way and to calculate the net social benefits. Thus, the goal of cost-benefit 
analysis is to identify whether a programme's benefits exceed its costs, indicating that a 
programme is worthwhile (Drummond et al, 1997). Although several methods exist for 
estimating money values for health care programmes, the willingness-to-pay (WTP) survey 
techniques, known as contingent valuation, are popular (O'Brien & Gafni, 1996). A literature 
review regarding contingent valuation studies shows that the number of such studies is 
growing rapidly and that the majority are done as part of cost-benefit analysis (Diener et al, 
1998). Considering the economic evaluation of diagnostic facilities, however, not many 
studies were based on the principles of cost-benefit analysis (Severens & van der Wilt, 
1999b). 
Diagnostic technologies and procedures in general are typically judged effective if they 
provide information which is relevant related to a treatment/no-treatment decision and 
eventual patient outcome (Fryback & Thornbury, 1991; Severens et al., 1999a). Nevertheless, 
information which is not directed towards therapeutic decision making might have a value to 
either physician or patient. This value can be defined as the non-decisional value of diagnostic 
information (Woodward et al, 1998). In the literature several methods to measure this value 
can be found varying from open-ended questions asking how respondents felt about knowing 
their diagnostic results, to health status measurement using questionnaires such as those on 
anxiety and the SF36, to WTP (Mushlin et al, 1994; Ried, 1994; Woodward et al, 1998). 
How to measure the non-decisional value of diagnostic information remains uncertain. In this 
study we addressed the question whether WTP analysis is a method which leads to credible 
valuing of non-decisional diagnostic information. 
An approach to investigate the validity of using a questionnaire when there is no 
criterion standard is to examine construct validity. A construct is a theoretically derived notion 
of the domain the instrument should measure, leading to expectations about how an 
instrument should behave if it is valid (Spilker, 1996). To examine the construct validity of 
the WTP procedure as a method to assess the value respondents place on a non-decisional 
diagnostic information, we tested the following hypotheses: 
1. Subjective importance of testing, reflecting the risk-aversion of a person, is positively 
related to the WTP for diagnostic information (Woodward et al, 1998); 
2. The burden of testing experienced is negatively related to the WTP for diagnostic 
information (Appel et al, 1990); 
3. Subjective belief in the accuracy of a diagnostic test is positively related to the WTP for 
diagnostic information; 
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4. Prior knowledge of the presence or absence of the disease is negatively related to the WTP 
for diagnostic information (Asch et al, 1990); 
5. The severity of the disease tested (perceived risk) is positively related to the WTP for 
diagnostic information (McDaniels et al, 1992; Lindholm et al, 1997; Kobelt, 1997); and 
6. The possibility of treatment after testing is positively related to the WTP for diagnostic 
information (Donaldson et al, 1995). 
Histoplasmosis 
The hypotheses were tested among individuals who are considered to be at increased risk of 
histoplasmosis. Histoplasmosis is caused by the dimorphic fungus Histoplasma capsulatum. 
The organism grows in its mycelial phase in soil, especially in soil that has been nitrogen-
enriched by bat or bird guano. Infection is acquired when microconidia are inhaled into the 
lungs where they transform into the pathogenic yeast-phase organisms (Houston, 1994; 
Gumey & Conces, 1996). The organism is widely distributed throughout the world in both 
tropical and temperate climates. However, histoplasmosis is considered a rare disease in 
Europe (Houston, 1994) and the vast majority of European cases are attributable to 
endogenous reactivation of a latent infection acquired in overseas endemic areas (Manfredi et 
ai, 1994; van Crevel et al, 1997). Several outbreaks of histoplasmosis have been reported to 
be cave-associated and therefore speleologists may be at increased risk of acquiring cave-
associated histoplasmosis (Sacks et al., 1986; Johnson et al, 1988; Noel et al, 1995; Suzaki 
et al, 1995). 
METHODS 
Respondents 
A group of Dutch speleologists was invited to participate in the study during their annual 
membership meeting. Each participant was asked to complete a self-administered 
questionnaire and blood samples were obtained. The questionnaire focused on the history of 
spelunking activities to identify the possible risk factors of acquiring cave-associated 
histoplasmosis. Furthermore, the participants were asked about clinical symptoms suggestive 
of histoplasmosis (e.g. a non-productive cough, substernal pain and shortness of breath) after 
spelunking in a particular area and about having had a previous test for histoplasmosis. The 
blood samples were tested for the presence of antibodies to H. capsulatum. A detailed 




Because treatment for histoplasmosis is not indicated in an asymptomatic person, for the 
speleologists the blood sample would give non-decisional diagnostic information. Currently, 
testing for the seroprevalence of antibodies to H. capsulatum is not part of regular health care 
in the Netherlands. Testing among a risk population and measuring their WTP can be 
described as an ex post user based perspective (O'Brien & Gafni, 1996). This perspective 
implies asking individuals who would potentially gain from using the specific medical 
technology what maximum amount in monetary units they would pay to gain access to the 
facility. Different methods for asking somebody's WTP can be found in the literature. We 
chose to frame the WTP question using five answering categories. We did so because simply 
asking the maximum a respondent would be willing to pay poses a large cognitive task for a 
respondent (O'Brien & Gafni, 1996). Besides this, when open-ended questions are used, an 
important concern for WTP analysis is the treatment of outliers (Berwick & Weinstein, 1985; 
McDaniels et al, 1992) and open-ended questions are likely to be biased and erratic 
(Donaldson et al, 1995). Furthermore, because income is an important predictor variable in 
WTP analysis (McDaniels et al, 1992; Johannesson et al, 1997), we tried to eliminate the 
possible influence of this variable by defining the WTP question using a percentage of the 
respondents' monthly income. Regarding these considerations, we measured WTP using five 
answering categories ranging from not willing to pay anything to willing to pay an increasing 
maximum percentage of the respondents' monthly income (1%, 5%, 10%, and more than 
10%) were defined in the WTP question. 
Table 5.4 Re-coding of the original variables into dichotomous variables. 
original five category variable dichotomous variable 
willingness to pay not willing to pay anything - willing to pay some amount 
subjective importance of testing not very important - very important 
the burden of testing no high burden of testing - high burden of testing 
perceived reliability of the test not very reliable - very reliable 
possibility of being infected no strong idea about infection - strong idea about infection 
perceived severity of the disease not a severe disease- a severe disease 
perceived possibility to treat the not possible to treat - possible to treat 
disease 
In order to test the hypotheses, respondents were asked to indicate 1) the subjective 
importance of testing, 2) the burden of testing (taking a blood sample), 3) the perceived 
reliability of the test, 4) the subjective believe of being infected, 5) the perceived severity of 
the disease, and 6) the perceived possibility to treat the disease (from this point called the 
hypothesis-related variables). For each question a five category scale was used. For the 
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purpose of performing further statistical analyses (avoiding the problem of near empty cells 
and thus also introducing too many dummy variables in logistic regression analysis) both the 
WTP variable and the hypothesis-related variables were recoded into dichotomous variables 
(Table 5.4). 
Analysis of the data concerned several aspects. All participants were generally 
described for age, gender, and years active in spelunking. Frequencies of the answering 
categories to the WTP and hypothesis-related questions were calculated. Spearman correlation 
coefficients were calculated between the WTP variable and the six hypothesis-related 
variables. To examine univariate relationships we used the chi-squared test on the re-coded 
variables. Multivariate dependence of WTP with the recoded variables was investigated using 
stepwise logistic regression. The level of significance used was 5% . 
RESULTS 
Of the 90 attendees at the membership meeting, 84 agreed to participate. Of the 84 
participants, 67 were male (80%) with a mean age of 38.6 years (range 20-62), and 17 (20%) 
were female with a mean age of 33.5 years (range 23-45). The mean number of years active in 
spelunking was 13 (range 2-32). Of the 84 respondents, eight did not answer the question on 
WTP for the H. capsulatum test and therefore the number of respondents for our analysis was 
76. 
Table 5.5 Number and percentage of respondents regarding their willingness to pay for non-
decisional diagnostic information (N = 76). 
answering category number (percentage) 
not willing to pay anything 22 (29%) 
willing to pay maximum of 1 % of monthly income 39 (51 %) 
willing to pay maximum of 5% of monthly income 12 (16%) 
willing to pay maximum of 10% of monthly income 3 (4%) 
willing to pay more then 10% of monthly income 0 (0%) 
Table 5.5 gives an overview of the number of respondents for each of the answering 
categories to measure the WTP for the diagnostic test. Twenty-two respondents (29%, 95% 
confidence interval (CI): 18.7% - 39.2%) indicated not to be willing to pay anything for the 
diagnostic information, as 54 respondents (71%, 95% CI: 60.9% - 81.2%) indicated to be 
willing to pay some amount for the diagnostic information. Testing our hypotheses resulted in 
a significant relationship between respondents' WTP and the subjective importance of testing. 
No univariate relationships were found between the WTP variable and the other five 
hypothesis-related variables (Table 5.6). Using the stepwise logistic regression to investigate 
multivariate dependence of WTP with the recoded variables, this resulted in a logistic model 
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only with the hypothesis-related variable subjective importance of testing. No other 
hypothesis-related variable, or any other variable such as age and gender of the respondent 
entered the model using the 5% significance level. 
DISCUSSION 
The purpose of our study was to examine the issue of credible valuing of non-decisional 
diagnostic information by measuring WTP. This issue was studied in asymptomatic healthy 
volunteers at increased risk for histoplasmosis. We were able to find a relationship between 
the subjective importance of testing and the respondents' WTP; the remaining five 
hypotheses, however, could not be confirmed. This suggests that WTP measurement may not 
be a valid method to assess the value that respondents place on non-decisional diagnostic 
information. 
Table 5 6 Percentage of respondents indicating to be willing or not willing to pay for diagnostic 
information regarmg the hypothesis related questions and the results of the chi-squared test. 
hypothesis-related variable willing to pay p-value 
subjective importance of test, very important 
burden of testing: high burden of testing* 
Reliability of the test: very reliable 
possibility of being infected strong idea about infection 
severity of the disease, a severe disease 
possibility to treat the disease- possible to treat* 
# Because of missing values N=75 instead of N=76. 
In an early study by Thompson (1986) it is stated that a high response rate indicates overall 
feasibility of the method to measure WTP. Given a response rate of more than 90%, our study 
population seems not to have had any difficulty answering their WTP for diagnostic 
information. Golan & Shechter (1993) measured WTP for changes in the Israeli health care 
system. Because the WTP estimates were 'reasonable', they conclude that the method seems 
to adhere to the conditions for reliability and validity. Chestnut et al. (1996) measured the 
WTP for changes in symptoms in patients suffering angina. Actual expenditures and 
perceived angina episodes avoided and WTP for a hypothetical treatment led to comparable 
results and therefore the authors concluded that the WTP method was valid. Flowers et al. 
(1997) showed that test-retest reliability was high, more than 80% of the healthy volunteers 
participating in the study reported the method to be reasonable for therapeutic decision 






















WTPfor diagnostic information 
From these the authors concluded that the WTP method is valid. In a recent study by O'Brien 
et al. (1998) Health Maintenance Organisation members were asked their WTP for a new 
drug, using a user based scenario (assuming they were about the moment to use the drug) and 
an insurance based scenario (at risk for the disease in the future). Construct validity was 
concluded to be encouraging. 
Our results do not mesh with the results from other studies as described above. A 
possible explanation for our findings is the fact that these studies were performed in several 
countries (United States, Canada, Israel) which do not have a health care financing system 
comparable to the system in the Netherlands. In the Netherlands the system of a 
comprehensive health insurance is the basis for financing health care facilities. Except for 
(luxury) health care interventions which are not covered by the basic insurance package, 
patients are hardly ever confronted with paying health care facilities out of pocket. Therefore, 
asking a persons' WTP for something one is not used to paying for, might be defined as an 
unrealistic hypothetical scenario leading to invalid results (O'Brien & Gafni, 1996). In the 
literature only one study using WTP measurement was found that was performed in the 
Netherlands. Krabbe et al. (1997) asked healthy student volunteers to imagine that they were 
in a certain impaired health state and asked their WTP to return to their previously healthy 
condition. The authors conclude that the reliability of WTP measurement was low and the 
number of inconsistencies was substantial. Although their method for asking the respondents 
WTP is different from the method we used, these results agree with our findings regarding the 
construct validity of the WTP measurement. It seems that WTP measurement as a means to 
value non-decisional information of diagnostic tests is not a valid method, especially when 
used with respondents who are not used to actually paying for health care services. 
Our study has several limitations. First, the number of respondents is limited. 
Although a significant relation between the WTP and the subjective importance of testing was 
found, for the other variables to test our hypothesis, this relationship could was not found. The 
question arises if the power of our study based on these numbers is sufficient. Indeed, with 
sample sizes of 22 and 54, the difference in percentage 'success' between the two groups has 
to be at least 30% in order to be detectable with a power of 80%. A second aspect which 
might have influenced our results is the selection of respondents. Although an ex post user 
based perspective was used and therefore only individuals who were at increased risk were 
included in our study, asking the same WTP and hypothesis related questions at individuals 
not at risk for histoplasmosis might have led to more contrast in our findings. In the literature 
it is described that asking persons at risk (potential users of the facility) leads to higher WTP 
results than asking non-users (O'Brien & Gafni, 1996). However, in our case of testing for the 
seroprevalence of antibodies to H. capsulatum among a risk population it is practically 
impossible to identify a population of potential losers when this diagnostic facility in reality 
would be introduced in health care. Third, different methods to ask for somebody's WTP for 
non-decisional diagnostic information might lead to different results. Overestimating 
respondents' WTP might be the case because the question is hypothetical while actual 
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willingness to pay can be expected to lead to more moderate results (O'Brien & Gafni, 1996). 
Besides this, using answering categories instead of open-ended questions might also lead to 
higher WTP results (Donaldson et ai, 1995). However, because our study does not give any 
clear predictive factors for the WTP of the respondents, our findings give no indications for an 
overestimation of the WTP of our respondents. 
Diagnostic information might be of value, even if it does not affect treatment decisions 
(Woodward et al., 1998). In such cases however, the question remains how such non-
decisional diagnostic information should be valued. In conclusion, using the concept of 
construct validity, we examined whether WTP measurement is a suitable method. Given the 
results, we were not able to conclude that WTP leads to credible valuing of non-decisional 
diagnostic information. We suggest that this may be primary related to the fact that as Dutch 
citizens, the respondents are not familiar with paying health care facilities out of pocket. This 
would mean that WTP is not the method of choice when assessing the monetary value that 
subjects place on health care interventions in countries with comprehensive coverage 
schemes. Further development of this method is clearly warranted. 
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THE ISSUE OF UNCERTAINTY OF THE RESULTS: STATISTICAL 
ANALYSIS OF INCREMENTAL COST-EFFECTIVENESS RATIOS 
Based on Severens JL, Boo ThM de & Konst EM (1999). Uncertainty of incremental cost-
effectiveness ratios: a comparison of Fieller and bootstrap confidence intervals. 




Increasingly, cost-effectiveness analyses are conducted as part of clinical trials (Glick, 1995; 
Drummond & Davies, 1991). Gathering data on both effectiveness and cost for each patient 
makes it possible to determine the mean and standard deviation of the different variables. This 
makes the issue of uncertainty of the results of an economic evaluation relevant. 
Although some debate exists about the usefulness of average cost-effectiveness ratios 
of each alternative, the incremental cost-effectiveness ratio comparing an often new treatment 
or diagnostic facility to some alternative is considered to be the main result of cost-
effectiveness analysis (Johannesson, 1995a; Briggs & Fenn, 1997a; Laska et ai, 1997b). 
Because the true costs С and effects E of the medical interventions to be compared 
(respectively 1 and 0) are not known for the population, the true incremental cost-
effectiveness ratio R can not be determined. Information about the sample costs and effects 
are used to calculate the sample incremental cost-effectiveness ratio. This incremental cost-
effectiveness ratio is defined as: 
£, E0 
However, Л is a point estimate and reporting confidence intervals of at least the differences 
in costs and effects in addition to this estimate is advisable (O'Brien et ai, 1994; van Hout et 
al, 1994). This in itself does not give any real insight into uncertainty of R itself. Several 
methods have been explored to estimate a confidence interval for R. O'Brien et al. (1994), 
van Hout et al. (1994), and Wakker & Klaassen (1995) use parametric methods for estimating 
confidence intervals for R. Willan & O'Brien (1996) concentrate on Fieller's theorem and 
Laska et al. (1997a) compare the Fieller method with two-sided Bonferoni confidence 
intervals. Briggs et al. (1997b) describe four methods for determining confidence intervals for 
R based on nonparametric bootstraps using different numbers of bootstrap replicates. Polsky 
et al. (1997) and Chaudhary & Steams (1996) have compared both parametric and 
nonparametric methods for determining a confidence interval for R. Polsky et al. (1997) 
recommend the percentile method based on nonparametric bootstrap replicates and the 
parametric Fieller method. Robustness to distributional variation in costs and effects and the 
correlation between them are taken into account in these methods. Chaudhary & Steams 
(1996) conclude that the key consideration in choosing between methods should be the extent 
to which the data are consistent with the assumptions behind the methods. A recent 
publication by Tambour & Zethraeus (1998a) compares the percentile bootstrap method with 
the method introduced by Wakker & Klaassen (1995). The bootstrap method is preferred. 
The above mentioned articles appear to agree that methods which fully rely on a 
normal distribution of the incremental cost-effectiveness ratio should be avoided in 
determining confidence intervals of R. Different methods of calculating nonparametric 
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bootstrap intervals and the Fieller method fulfil this criterion. In this article we report our 
experiences comparing Fieller intervals and three methods for calculating bootstrap intervals: 
the percentile method and two Bias Corrected and Accelerated (BCA) methods. 
METHODS 
Trial data and simulation 
The data used for comparing he methods in estimating confidence intervals was gathered in 
the framework of the Dutch PSOT study. The PSOT study was designed as a two-group 
randomised multicentre clinical trial concerning orthodontic treatment of children bom with 
unilateral cleft lip and palate. One group of patients received presurgical orthopaedic 
treatment (PSOT, N=10), and the other group did not (non-PSOT, N=10). All other 
interventions were the same. Costs reported in this article are solely direct medical costs 
related to the PSOT intervention during the children's first year of life. A professional 
judgement of the overall speech and language performance (10 point scale) at the age of 2.5 
year was used as a measure for treatment effectiveness. More detailed information about the 
PSOT study is reported elsewhere (Severens et al., 1998). 
From the trial data, for each group mean and variance of cost and effectiveness, and 
the correlation between them were computed. These statistics were used to simulate a 
subsequent 10,000 trials by repeatedly drawing 2 times 10 cases from normal distributions 
with these statistics as parameters. Results were rounded to the same number of decimal 
places as in the original trial. For each simulation, R] was calculated; when the difference in 
effect equalled zero, R* was made missing (unknown). The mean ICER R was calculated, 
and this value was used as estimate for the true population ICER, R (Figure 6.1). 
Confidence intervals of the ICER 
Fieller theorem method 
The Fieller theorem method is a parametric method for calculating a confidence interval of a 
ratio of means. The assumption on which this method is based is bivariate normality of 
numerator and denominator, here the difference between the means of the cost and the means 
of effect (Laska et al, 1997a). Let ΔΕ and AC denote the mean difference in effect and 
cost respectively, S\E and S¿ c their estimated variances and r the estimated (Pearson) 
correlation coefficient between them. Let ƒ„,_„ denote the upper percentage point of the F-
distribution, with 1 and ν degrees of freedom, ν being the number of degrees of freedom 
upon which the estimated variance of Δ E - Δ С is based ( 18 in our case). 
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trialdata 10,000 simulations 
10PSOT 
10non-PSOT 
10,000 ICERs Φ mean ICER = "true" ICER 
Figure 6.1 Overview of the relation between the trial data and the simulation data. The statistics 
of the original trial data were used to simulate a subsequent 10,000 trials. For each of the simulations 
the incremental cost-effectiveness ratio (ICER) was calculated. The mean ICER was used as estimate 
for the true population ICER. 
Compute (Laska et al., 1997a): 
_ (MAC- / „ . у ^ ^ - Ц М А С - fr.^rs^Y -(ΔΕ
2 - / „ ^ 4 ) ( Δ ( ? - f,¿¿¡¿f2 
¿ ι = : 
Δ* 2 "/,, 
and 
= (MAC- Д . у ^ ^ + КМАС- ƒ„ , V W i i f f -(ΔΕ
2 -/ ν , ,_4)(Α^ ~ W l c ) ] " ' 
Now, if there is a statistically significant difference in effect, then (and only then) the 
denominators of ¿, and L, are positive. The Fieller ( I - α ) interval is then the interval 
( L , , L J ) . If there is no significant difference in effect, the denominators are negative and 
Fieller's interval consists of the union of the intervals (-»,¿2) and (Ц,+°°). For further 
details see Laska et al. (1997a). (Note that in that paper there is a misprint on page 235: the 
second plus-sign in the numerator of the formula for the upper confidence limit estimator 
should be a minus-sign, as in the lower confidence limit). On the basis of each R's of the 
10,000 simulations, a 90% Fieller confidence interval was calculated. 
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Bootstrapping 
The principle of bootstrapping is that a random sample of size η with replacement from the 
data is taken a large number of times (Efron et al., 1993). Considering the fact that each R is 
estimated based on two replicated samples (treatment group and no treatment group) each 
simulation sample is used as a basis for the bootstrap replication which leads to, respectively, 
C' and E' for treatment, and C'„ and E'a for control. As a result from each bootstrap series 
the bootstrap ratio R"h can be calculated: 
-, C'-C' 
Rb=Zl, _°. 
For each trial simulation we performed 25,000 bootstrap replicates to avoid problems when 
using a too small number of replicates. On the basis of the bootstraps replicates, confidence 
intervals for R can be calculated. 
Bootstrap confidence intervals 
We used three methods to calculate a bootstrap confidence interval. First we used the 
percentile method, which is based on the principle of sorting the R'b. When 25,000 replicates 
have been made and the 90% confidence interval has to be determined, the percentile method 
uses the 1,250th and 23,750th ranked Rb as the confidence interval limits. 
Another method for calculating confidence intervals based on bootstrap replicates is 
the so called bias corrected and accelerated (BCA) percentile method. The basic principle of 
the BCA method is a modification of the percentile method making a correction for bias and 
the skewness of the estimator of the sampling distribution (Briggs et al, 1997b). For an 
extensive description of this method we suggest Efron & Thibshirani (1993). and Efron 
(1987). The BCA method uses an acceleration constant which is used to adjust for the 
skewness of the sampling distribution of Rb. This acceleration constant is calculated using a 
jack-knife estimate. Since the jack-knife method is not straightforward described in case of 
comparison of two groups, we used two options: BCA-1 and BCA-2. For BCA-1 an estimator 
is used that leaves out only one measurement at a time, irrespective of the origin (treatment or 
no treatment). BCA-2 uses an estimator based on simultaneously leaving out one 
measurement from each of the two samples, treatment and no treatment. 
Because in our study we simulated 10,000 trials, 25,000 bootstrap replicates were 
performed 10,000 times. Thus, for each of the three methods of calculating 90% confidence 
intervals based on the bootstrap replicates (percentile method, BCA-1, and BCA-2), 10,000 
confidence intervals were determined (Figure 6.2). 
Effect of E, - E0 = 0 on the confidence intervals 
Our original trial data showed a significant difference in effectiveness between the two groups 
of 1.34 on the scale of 1 to 10. To investigate the impact of the relative importance of the 
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magnitude of the difference in effectiveness between the groups, we simulated four other 
situations: the difference in effectiveness was assumed to be 0.5 and 1.0 less, and 1.0 and 5.0 
more than in the original trial which, respectively, reflects the situations where El-E0= 0 
and where E{ - E0 > 0. Hence, in total five groups were used to compare the results of Fieller 
intervals and three bootstrap intervals; in all groups the same simulation data were used, 
except for subtraction from- or addition of the given constants to the (mean) difference in 
effect. 
Adequacy of the confidence intervals 
The adequacy of the different methods to calculate confidence intervals for R was 
investigated by comparing the confidence intervals contaimng R , the mean of the 10,000 
Л,. The percentage of confidence intervals containing this estimate of the true R was 
determined for each of the four methods. Approximately 90% of the intervals should contain 





















does 90% of the confidence intervals contain the 'true' ICER? 
Figure 6 2 Overview of the simulation data, methods for calculating confidence intervals (Fieller 
theorem, Bootstrap percentile method, Bootstrap Bias Corrected and Accelerated 1 (BCA-1), and 
Bootstrap Bias Corrected and Accelerated 2 (BCA-2)) and calculation of the adequacy of these 
methods Based on the 10,000 simulated trials, for each simulation 90% confidence intervals were 
computed using the four methods The adequacy of these methods was investigated by calculating the 
percentage of confidence intervals containing the estimate of the true ICER. 
118 
Statistical analysis of cost effectneness ratios 
RESULTS 
Trial data 
The tnal concerned 20 patients (10 PSOT treated, 10 no PSOT treatment) For the treatment 
group the mean medical cost was Dfl 2,544 (Dutch guilders), standard deviation Dfl 646 and 
the mean effectiveness score (for speech and language development) and standard deviation 
were, respectively, 3 52 and 1 75 For this group, correlation between costs and effectiveness 
was 0 35 Mean costs and standard deviation for the no treatment group turned out to be Dfl 
881 and Dfl 151 Mean effectiveness and standard deviation were respectively 2 18 and 0 62 
Correlation between costs and effectiveness for no-treatment was -0 06 
Combining the results of both groups, with the t-test the cost difference between the 
groups was significant Both the difference between the means of the costs (Dfl 1,663) and 
the means of effectiveness (1 34) were significant The correlation between difference in cost 
and difference in effects was + 0 30 The incremental cost-effectiveness ratio based on the 
tnal data for the speech development score is Dfl 1,241 / point score improvement 
Simulations 
Table 6 1 Results of the simulations for five levels of difference in effectiveness 
Level of difference in effectiveness N R, (mean ICER) 
baseline difference minus 1 0 g 935 
baseline difference minus 0 5 9,982 
baseline difference (1 34) 9,997 
baseline difference plus 10 10,000 
baseline difference plus 5 0 10,000 
Table 6 1 summarises the result of the simulations for the chosen levels of difference in 
effectiveness Note that from the baseline difference of 1 34 in speech and language score the 
values 0 5 and 1 0 are subtracted to obtain the situation where £, - E0 ~ 0 The baseline 
simulation and the baseline difference in effectiveness increased by 1 0 and 5 0, respectively, 
reflecting the situation that E¡ - £0 > 0 From this table it can be seen that the number of 
simulated trials on which Rs is based is not always equal to 10,000 This is due to the fact 
that whenever a simulated tnal leads to E'sl-E's0=0, R's can not be calculated for this 
simulation and therefore is neglected when calculating Rs Whenever the difference in 
effectiveness is significant, the probability that one of the simulations leads to £*, - E"s0 = 0 








Confidence intervals for R 
The results of determining the adequacy of the four different methods to compute confidence 
intervals for R are shown in Table 6 2 The percentages of the confidence intervals that 
contain R , are mentioned for the four different methods, separately for the different levels of 
difference in effectiveness As can be seen from this table, in case £, - E0 = 0 (baseline 
difference minus 1 0), both bootstrap based BCA-1 and BCA-2 calculations lead to 
confidence intervals that contain R in less than 70% of the cases In contrast, the bootstrap 
percentile method contains 96% of the time R , indicating (much) too wide intervals This is 
not surprising in view of the fact that the denominator of R*b often is practically zero The 
Fieller method seems to have intermediate results, however, the results do not appear to be 
stable when comparing the situation regarding a baseline difference minus 0,5 (reflecting 
£, - E0 » 0 to a lesser extent) and the baseline effectiveness difference (reflecting 
£, - E0 * 0 ) In the situation when El-E0> 0 (baseline difference plus 1 0 and 5 0 
respectively), the target percentage of 90% coverage of R by the 10,000 confidence intervals 
is best obtained by the Fieller method All bootstrap based calculating methods give somewhat 
too narrow intervals, thus less than 90% contain R 
s 
Table 6 2 Percentage of the 10,000 90% confidence intervals that contain the mean incremental 
cost-effectiveness ratio R for four methods of calculating the confidence intervals 
level of difference in effectiveness 
baseline difference minus 1 0 
baseline difference minus 0 5 
baseline difference (1 34) 
baseline difference plus 1 0 



























We did not investigate the impact of varying the correlation between cost and effectiveness on 
our study findings Polsky et al (1997) state that the bootstrap percentile method seems to 
perform slightly better than the Fieller theorem method when correlation of cost and 
effectiveness was positive In case of a negative correlation this seems to be the other way 
around However, in this study based on bootstrap replicates only the percentile method was 
used for calculating confidence intervals Other parametric approaches were highly influenced 
by correlation between cost and effectiveness For comparison in our study, the correlation 
between difference in cost and difference in effects was + 0 30 
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Recently, an alternative approach was suggested which gives a solution to the difficulty in 
calculating confidence intervals for ratios (Tambour et al, 1998b). In this approach the 
effectiveness units as used in a study are multiplied by the price per effectiveness unit, thus 
resulting in expression of both costs and effectiveness in monetary terms. Tambour et al. 
(1998b) describe that in this way the net benefits of the medical intervention which are 
compared can be determined and that standard statistical techniques can be used to calculate 
confidence intervals for the net benefits. However, we think that this approach in general is 
difficult to apply. First, the method makes it necessary to determine a price per effectiveness 
unit and this seems to be rather arbitrary. Although sensitivity analyse might be used to 
explore the impact of varying the unit price on the studies' conclusions (Briggs et al, 1994) it 
can be argued that specific measures of effectiveness are difficult to express in monetary 
terms. Second, the example which is used by the authors expresses the effectiveness in 
QALYs which seems to be possible to translate into monetary terms quite easily. However, 
the question arises hoe to translate effectiveness other measures, because QALYs are only one 
of many alternatives to express effectiveness (Severens & van der Wilt, 1999). 
In conclusion, to answer the question which method should be used to determine a 
confidence interval for an incremental cost-effectiveness ratio, - either the Fieller theorem 
method or one of the three bootstrap based calculations used in our analyses - a distinction 
must be made between the situation where £, - E0 = 0 and where Ei - E0 > 0. Actually, in 
case a trial does not show a significant difference in effectiveness it does not make sense to 
calculate confidence intervals for R, making the discussion about which confidence interval 
method to use academic (Chaudhary & Steams, 1996). In such cases it would be better to 
concentrate solely on cost differences. If in such situations nevertheless confidence limits are 
determined, as already noted by Briggs et al (1997b), one should be very wary when trying to 
interpret bootstrap results. The same can be said of Fieller's limits, because such intervals 
consist of two parts: from minus infinity to a negative value and from a positive value to plus 
infinity. Such intervals are in practice of no use. 
In the situation where £, - E0 Φ 0, the different methods for calculating confidence 
intervals for R can be used but do not seem to give very different results. When using the 
bootstrap method it seems advisable to show the bootstrap results on the cost-effectiveness 
plane (Briggs et al, 1997b). This clearly shows in which quadrant of the plane the 
'population' ratio can be expected, which is important to decide about inferiority or 
dominance of one medical alternative to another. Calculating the confidence interval of this 
ratio is an additional step which should be applied only when the difference in mean 
effectiveness is large enough. However, bootstrap replication has the disadvantage that a 
rather powerful computer is necessary, while the Fieller theorem method, which is based on a 
single formula, can be applied without simulation techniques. And besides this, Fieller limits 
seem to approximate the target coverage of 90% better. It could be argued, that Fieller's limits 
appear to be the best in this study, because we sampled from normal distributions. We believe 
however, that in many practical situations both cost and effect differences can be very well 
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approximated with a normal distribution. Furthermore, even in situations where deviations 
from normality are non-negligible, if sample sizes are large enough (say, > 50) the central 
limit theorem guarantees a satisfactory approximation. 
Recommendations 
Based on our comparison of Fieller intervals and three methods for calculating bootstrap 
intervals - the percentile method and two Bias Corrected Accelerated (BCA) methods - the 
following recommendation can be given. First, a possible difference in effectiveness between 
groups compared should be tested with the t-test. When there is no significant difference in 
effectiveness it is absolutely not useful to calculate the incremental cost-effectiveness ratio. In 
such a case one should concentrate on estimating cost differences instead. Whenever there is a 
strictly significant difference in effectiveness between groups, calculating a confidence 
interval for the ICER is useful. Fieller's theorem leads to satisfactory results, and the 
necessary calculations are relatively easily done compared to bootstrap simulations. We 






In this thesis several methodological issues related to the economic evaluation of health care 
technologies were discussed: the choice of the competing alternative; the relevant costs and 
consequences; the accurate measurement of costs and consequences; credible valuing of costs 
and consequences; and the issue of uncertainty of the results of an economic evaluation. These 
and the other issues that are mentioned by Drummond et al. (1997) aim to assist users of 
economic evaluations in assessing the validity of the results they encounter. For each separate 
issue a specific aspect was studied. Besides the Drummond checklist, guidelines for economic 
evaluations exist in several countries. The purpose of these guidelines is to provide guidance 
on the appropriate concepts to consider or use when conducting such economic evaluations 
(Jacobs et al., 1995). The aspects we studied are discussed below within the framework of 
guidelines for (pharmaco-) economic evaluation, including the guidelines from Canada 
(Canadian Coordinating Office for Health Technology Assessment, 1997), Ontario (Jacobs et 
al., 1995), Australia (Access and Financing Division, 1998), United Kingdom (Towse, 1997), 
and The Netherlands (National Health Insurance Board, 1999). 
The choice of the competing alternative: the sequence of diagnostic tests and modelling 
therapeutic alternatives 
As is stated by Drummond et al. (1997), clear identification of the primary objective of the 
alternatives being compared is essential for the readers of the results of an economic 
evaluation to judge the applicability to their own settings. In this case it can be determined if 
any important alternatives were omitted. 
All national guidelines are more specific and indicate that the competing alternative to 
which an often experimental technology is compared should be an alternative strategy that is 
used to treat the same condition. The Canada and Ontario guidelines state that the most 
commonly used and least expensive health care alternative should act as the comparator. The 
Australian guidelines indicate that the comparator that is most likely to be replaced has to be 
used in the analysis. The UK guidelines state only to justify the choice of the comparator. The 
Dutch guidelines indicate to use the standard option that is defined as the option of first choice 
in day to day practice of which the effectiveness has been proven. 
First, we studied the choice of the competing alternative regarding diagnostic 
technologies. A literature review regarding the economic evaluation of diagnostic 
technologies showed that 90% of the studies compared test vs. another test and test vs. no-test 
(Severens & van der Wilt, 1999). However, specifically for the evaluation of a new diagnostic 
facility the question rises whether the technology aims to replace a diagnostic alternative or 
whether the technology is an add-on for existing diagnostic technologies. In the first situation, 
a straightforward test vs. test comparison is relevant. The latter situation is more complicated: 
specification of the appropriate diagnostic pathways and thus, the aspect of test sequence is 
relevant and should be studied (Wagner, 1983). Although in practise it is impossible to 
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empirically compare all possible test sequences separately, as was shown modelling can be 
helpful to investigate all theoretically possible test combinations and sequences. 
Second, we studied the choice of the competing alternative regarding a therapeutic 
alternative of which no trial results were available. In this case, as was shown, modelling 
allows comparison against the alternative desired. The main difference between empirical 
studies and modelling studies is that empirical studies gather information, whereas the 
modelling studies synthesise information (often empirical data) without the aim of gathering 
new empirical data (Brennan & Akehurst, 1999). 
All national guidelines concentrate on (pharmaco-) treatment and are sufficiently 
detailed regarding the choice of the competing alternative. However, no guideline makes 
specific remarks about the economic evaluation of diagnostic technologies. This sequence-
aspect is distinctive for diagnostic technologies. Thus, regarding the evaluation of diagnostic 
technologies separate guidelines or perhaps addenda to existing guidelines should be 
considered. Such guidelines should concentrate on the fact that evaluation of a diagnostic 
technology should be designed in such a way that it reflects the future role of the technology: 
should it replace an existing diagnostic technology or be an add on to the current diagnostic 
practise. And if the latter is to be the fact, which sequence of the different diagnostic 
technologies is to be considered? 
The choice of the comparator is highly relevant for the findings of an economic 
evaluation. A strict definition of a rule for defining the comparator, both in evaluating 
diagnostic and therapeutic technologies, does not seem to be useful, because the relevance is 
determined by the interest of the initiator of the study. Gold et al. (1996) state that ideally, all 
possible alternatives have to be identified (including a do-nothing alternative) and all of them 
should be studied. Normally this is practically impossible; thus, the technology under 
consideration has to be compared to existing practice. However, a practical problem may arise 
concerning how to define existing practice in the situation of a mixture of different 
approaches. As a possible solution they suggest to incorporate the main alternatives as 
separate options in the study or use the mixture as such as the competing alternative. In the 
situation that an evaluation is to be performed early in the life cycle of a medical technology, 
it is difficult to define the most relevant competing alternative. In this case both researcher and 
decision-maker should decide in consultation about the comparison made to target the study to 
the relevant policy question (Elsinga & Rutten, 1997). In our opinion, justification of the 
choice of the competing alternative should be made explicitly in the sense that one should 
determine if the criterion of choice is related to comparison with the most effective, cheapest, 
most frequently used, or any other possible alternative criterion. 
The relevant costs and consequences: the time horizon and the perspective of a study 
A full identification of the important and relevant costs and consequences of the alternatives 
should be provided. This will make a judgement possible of what specific costs and 
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consequences are appropriate to include in the analysis (Drummond et al, 1997). Related to 
this idea one should be aware that effects of health care technologies may influence resource 
use in the future and therefore the appropriate time horizon should be chosen. Besides this, the 
users of economic evaluations should ask the question whether the analysis covered all 
relevant perspectives. 
Summarising the national guidelines, there are several aspects that influence the 
relevance of costs and consequences. All guidelines that have been studied emphasise that the 
relevance of costs and consequences to be analysed in an economic evaluation depends on the 
disease and type of patients studied. Costs and consequences that arc not related to the specific 
disease should, in general, not be studied at all. Besides this, the differential approach of 
economic evaluations, aiming to find differences between the (often experimental) technology 
and its comparator, also highly influences the choice of the costs and consequences which are 
to be studied. Regarding the time horizon, Canada and Ontario recommend long range final 
end-points and, if necessary, utilisation of modelling techniques to estimate long-term costs 
and benefits. The Australian guidelines simply state that the time horizon should be 
appropriate to the disease and the UK guidelines indicate that the treatment path should be 
fully described. Thus, although formulated differently, the guidelines seem to agree about the 
issue of the time horizon. Regarding the study's perspective, the different guidelines have 
dissimilar opinions. The Canada, Ontario, UK and The Netherlands guidelines recommend a 
societal (or social) perspective and thus indicate to include medical, patient and caregiver, and 
productivity costs. The Australian guidelines expect the researcher to only include direct costs 
(medical and patient and caregiver costs), thus indicating the health care perspective. Only in 
the situation that productivity costs materially affect the results should these costs be included. 
To study the impact of choosing the time horizon of an economic evaluation we 
studied different diagnostic strategies for invasive aspergillosis. Obviously, several time 
horizons can be used to determine the short and longer-term impact of the diagnostic 
technologies. The main objective of a diagnostic strategy is to indicate a patient for treatment; 
thus the end of the diagnostic phase can be the time frame for evaluating diagnostic 
alternatives. However, it was shown that extending the time horizon and thus including the 
therapeutic phase could have a significant impact on the study conclusions. 
Studying the impact of a study's perspective on the relevant costs and consequences, 
we showed the difficulty in comparing results of economic evaluations in case different 
perspectives were used. And, as described before, not only the types of costs but also the way 
costs are calculated depend upon the perspective chosen. 
Regarding the time horizon, it seems rather impossible to formulate the guidelines 
explicitly and to define the time horizon that has to be used in the economic evaluation of 
health technologies. However, in our opinion, the guidelines should be more directive: the 
researcher should be able to justify the choice of the time horizon. In principle a long-term 
time horizon should be chosen. If not, a short time horizon should be well motivated by 
indicating the robustness of the study results in case a shorter or longer time horizon was the 
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basis for the analyses. This can be done in accordance with the principles of sensitivity 
analyses. In addition, it seems useful to formulate specific diagnostic technology guidelines. In 
case a diagnostic technology is subject to an economic evaluation, limiting the time horizon to 
the diagnostic phase instead of including the therapeutic phase should be justified in the sense 
that a specific diagnostic outcome automatically leads to a defined therapeutic outcome. Thus, 
in both situations of evaluating diagnostic and therapeutic technologies, the impact of the time 
horizon chosen should be explored by estimating longer-term costs and consequences on the 
basis of the intermediate endpoints used. Again, modelling can be helpful to combine short-
term costs and consequences (e.g. intermediate outcome as measured in a prospective study) 
and longer term costs and consequences (final outcome). 
Given the difficulty in comparing results from cost analyses that are performed using 
different perspectives, the question remains which perspective is appropriate. Economic 
evaluations are often conducted with a specific policymaking motive. The institution or 
individual that is responsible for the eventual policy choice will determine the perspective of 
primary interest (Gold et ai, 1996). Therefore, using this decision-maker approach, 
perspectives like the third party payer perspective, health care perspective, provider 
perspective, and patients' perspective seem to be logical. However, it is more and more 
recognised that if the main objective of performing economic evaluations is to identify use of 
social resources for health care, than the most relevant perspective is the societal perspective. 
The analysis needs to consider both those who gain and those who pay the health care 
technology (Johannesson & Meltzer, 1998). The limited health care perspective, which is 
often incorrectly referred to as a societal perspective, is especially subject to criticism. As 
Johannesson (1995b) states, using the health care perspective is inconsistent with a societal 
approach because all costs and benefits irrespective of to whom they accrue should be 
determined and no theoretical foundation can be given for ignoring costs outside the health 
care sector. 
Related to reimbursement decisions, in our opinion the use of the societal perspective 
is preferred. Using a different perspective can be motivated in the situations where it can be 
argued that costs outside the health care sector are relatively small or are expected to 
strengthen the result related to a limited perspective (Johannesson & Meltzer, 1998). In 
addition, a limited perspective can also be sufficient when costs outside the health care sector 
are expected not to be different between the health care technologies compared. Besides being 
directive in the choice of the perspective, the guidelines should be expanded, indicating to 
report the different types of costs, which are related to the distinguished perspectives, 
separately. This will enable the decision-maker to judge about the relevance of the different 
cost types and outcome components separately. 
127 
Chapter 7 
The accurate measurement of cost and consequences: productivity costs 
Drummond et al. (1997) state that once the important and relevant costs and consequences 
have been identified, they must be measured in appropriate units. In general, randomised trials 
are considered to be the best method for gathering information about costs and consequences 
and trials are therefore used frequently as a vehicle for economic evaluation (Drummond & 
Davies, 1991). 
The guidelines have different opinions about accurate measurement of cost and 
consequences. The Ontario guidelines prefer using data based on meta-analyses of randomised 
trials. Information from randomised trials are recommended by the Australian guidelines 
supplemented with additional information if desired. Considering this aspect, the guidelines of 
Canada, The UK, and The Netherlands are not prescriptive. 
When performing prospective trials, accurate measurement of quantities for cost 
calculations seems to be possible. Accurate retrospective measurement can still be relevant in 
prospective trials because questionnaires that measure quantities retrospectively are often used 
in such trials. Regarding the issue of accurate measurement of costs and consequences we 
studied the possibility of measuring absence from work retrospectively as a basis for 
calculating productivity costs. The measurement of productivity costs was highlighted because 
there is considerable debate going on about this topic. As was shown, the recall period used 
when measuring absence from work should be appropriately short. 
The existing guidelines give no guidance on the matter of accurate, retrospective 
measurement of costs and consequences because they implicitly assume that all empirical data 
in economic evaluations are measured prospectively. This is often not the case. For instance, 
in one of our trials we used a diary to measure medical consumption prospectively (Laheij et 
al., 1998). After the follow-up of 12 months, we asked the respondent if they filled in the 
diary on a daily, weekly or monthly basis. It turned out that nearly all respondents registered 
their medical consumption retrospectively, either on a weekly or monthly basis. Adjustment of 
most guidelines on this point should be considered: in case quantities as a basis for cost 
analyses are measured retrospectively a maximum recall period should be advised. For 
measuring absence from work retrospectively, a recall period of two months seems to be 
advisable. General recall recommendations can hardly be made regarding all types of relevant 
quantities. For instance, compared to frequent recurring visits to the general physician by a 
dyspeptic complaint patient, a longer recall period can probably be used whenever measuring 
respondents' number of open-heart surgeries. Thus, for other retrospectively measured 
quantities such as medical consumption, further research is necessary. 
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The credible valuing of costs and consequences: productivity costs and willingness to 
pay 
A clear description of the sources and methods of valuation of costs and consequences is 
obliged. The objective of valuing costs is to obtain an estimate of the worth of resources. 
Regarding the credible valuing of consequences, one should ask whether the appropriate type 
of economic evaluation was chosen (Drummond et al., 1997) 
The guidelines make the issue of credible valuing of costs and consequences 
operational in a different manner. The Australian guidelines require the use of a standard 
resource and cost list. Because of the limited perspective that is indicated, productivity costs 
and the way to handle compensating mechanisms is not described. The Netherlands guidelines 
indicate that a standard resource and cost list will be published mid 1999 and that these 
standards have to be used. The friction cost method will be recommended to calculate 
productivity costs. This method uses a 0.8 index to indicate the relation between absence from 
work and the productivity costs. The UK guidelines indicate that full costing (thus costs 
including overheads and depreciation of equipment and facilities) should be performed with 
no remarks on compensating mechanisms. The remaining guidelines are not directive in the 
way costs should be measured. 
Related to the issue of credible valuing of costs and consequences we studied two 
aspects. First, we studied the credible valuing of costs, using the aspect of productivity costs, 
because considerable debate is going on about this topic. It was shown that the method that is 
used to calculate productivity costs - taking self-reported compensating mechanisms into 
account - influences the estimates of this type of costs. Second, regarding the credible valuing 
of consequences, we studied the appropriateness of the willingness-to-pay method for valuing 
the consequences of non-decisional diagnostic information. The validity of using this method 
could not be proven using Dutch respondents. 
Although the studies perspectives might have been the same, Drummond et al. (1992) 
found that, comparing cross-national differences in cost-effectiveness of health care 
technologies, prices for resources were the aspects of the analysis that differed most between 
countries. Aspects that may influence the results and possible comparison of cost analyses are 
related to the time, place and patient population of analysis. Four types of biases can be 
distinguished in this respect; scale bias, methods bias, case mix bias, and site selection bias 
(Jacobs & Baladi, 1996). Scale bias is related to the idea that average cost of a health care 
program are independent of the magnitude of the program, thus assuming that the marginal 
costs are equal to the average costs. Methods bias can occur when allocation of fixed costs is 
not performed at all or not performed properly, thus underestimating the real costs involved. 
In case a volume parameter can be related to different intensities of resource use, and no 
correction has been made for case mix (for instance case mix weighted days in hospital) case 
mix bias might be the fact. Site selection bias might occur when costs are measured at a single 
site. The question is whether this site is the most or least efficient, or somewhere in between. 
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Adjustment for cost biases is possible; however, the most efficient way to investigate the 
influence of possible biases in cost estimates is to perform extensive sensitivity analyses 
(Jacobs &Baladi, 1996). 
For calculating productivity costs, two competing methods can be found in the 
literature: the human capital approach and the friction cost approach. The first method denies 
any relationship between absence from work and compensating mechanisms. The friction cost 
method incorporates an index of 0.8 (chosen from a range between 0.6 to 0.9) for adjusting 
absence figures to actual productivity costs (Koopmanschap et al., 1995). Our study shows 
that this index might not be sufficient. In fact, these differences in the calculations indicate 
methods bias. However, the way the latter should be prevented is not clear because the 
methods to be used to calculate productivity costs are still developing. This can be illustrated 
by the results from additional analyses regarding this topic. Using data from respondents 
working at a company, we found, as expected, that the reported compensating mechanisms are 
clearly related to the duration of absence. 
Even in the situation where the study's perspective has clearly been defined and bias in 
the cost analysis has been prevented as much as possible, there will always be differences in 
the cost of diagnostic or therapeutic interventions between countries and even hospitals. 
Methods used to calculate costs should be clearly reported in a disaggregated, standardised 
way to make clear interpretation of the results possible (Drummond et al., 1992) and in this 
manner guidelines could be more directive. This will make it easier to compare the results of 
cost analyses and provide more information on which principles and information cost 
estimates are based. 
Uncertainty: statistical analysis of ratios 
Two aspects of uncertainty can be distinguished in economic evaluations. First, the 
uncertainty can be related to deterministic variables, which can be explored by sensitivity 
analyses. Second, statistical uncertainty is related to stochastic variables that can include both 
cost and consequences. Besides this, the incremental cost-effectiveness ratio is subject to 
some degree of uncertainty. As Drummond et al. (1997) state: AU economic evaluations do 
have some degree of uncertainty, imprecision, or methodological controversy. In principle, 
sensitivity analysis, statistical inference, or a combination of the two methods should allow for 
uncertainty in the costs and consequences. 
All guidelines recommend the use of sensitivity analysis to investigate the robustness 
of the study findings regarding the variables. Different methods of sensitivity analyses are 
described in the literature, such as one- or more way sensitivity analysis and threshold analysis 
(Briggs et al., 1994; Briggs & Sculpher, 1995). None of the national guidelines prescribe how 
to deal with stochastic uncertainty. 
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The methods to determine uncertainty related to the incremental cost-effectiveness 
ratios are still being developed (Briggs, 1999). Therefore, we studied the statistical analysis of 
this ratio and recommended the Fieller method. 
It seems irrelevant to adjust the guidelines in a way that they prescribe the methods to 
be used to investigate stochastic uncertainty of the incremental ratio for the time being. 
However, after comparing several methods to explore uncertainty in the incremental costs-
effectiveness ratio, we found that at least the difference in effectiveness should be established 
before any method to explore uncertainty of the incremental ratio is performed. Thus, the 
guidelines should be adjusted to emphasise that first of all, the difference in effectiveness has 
to be explored before any uncertainty analyses on the incremental ratio are performed. In case 
investigators did use some method to explore uncertainty related to the incremental cost-
effectiveness ratios, the methods used and the related results should be described clearly. 
CONCLUSION 
The guidelines for (pharmaco-) economic evaluation that exist in different countries are quite 
generally phrased. Two years' experience with the Canada guidelines led to the conclusion 
that except for the perspective of the analysis, guidelines were, in many respects, adhered to 
and did not restrict investigators to specific methodologies or specific techniques (Baladi et 
al.y 1998). The question arises whether such guidelines should be strictly directive on all 
aspects. It seems hardly possible to gain consensus on all elements for the economic 
evaluation, because the methodological choices that have to be made are dependent on the 
specific purpose of the study. Besides this, as is shown in this thesis, the measurements of 
many elements that are the basis for the cost-effectiveness outcome are still in the 
developmental stage. However, as was described above, several recommendations for 
adjustments of some of the guidelines have been made. It seems logical that if the results of 
economic evaluations have to be comparable, more restrictive guidelines are necessary. It can 
be concluded that, for the time being, the results of different economic evaluations of health 
care technologies are not validly comparable, unless, after detailed exploration, the methods 
used are considered to be similar (Mason et al., 1993). To facilitate this, it seems to be more 
logical to ensure that researchers report their methods in a transparent and standardised way, 
although more discussion and debate about the appropriate standards for reporting results of 
economic evaluations is still necessary (Mason & Drammond, 1995). However, in case these 
standards are defined, it will be possible for the users, i.e. the decision-makers to understand 
the principles of the underlying methods used and to validly make judgements about the costs 
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This thesis concentrates on some methodological issues in the economic evaluation in health 
care. The objective of the economic evaluations of health care technologies in general is to 
provide information about efficiency of competing alternatives. The methodology of 
economic evaluation is still evolving. However, the methodological principles of the 
economic evaluations that are currently executed are of influence on the study results. The 
following issues are discussed: the choice of the competing alternative, the relevant costs and 
consequences, the accurate measurement of costs and consequences, credible valuing of costs 
and consequences, and the uncertainty of the results of an economic evaluation. 
The issue of the choice of the competing alternative is discussed using two topics 
(Chapters 2.1 and 2.2). First, the competing alternative when evaluating diagnostic 
technologies is discussed, concentrating on the problem of deciding about the optimal 
sequence of diagnostic tests. Test sequences can be structured in decision trees, but 
unmanageable bushy decision trees result when the sequence of two or more tests is 
investigated. Most modelling techniques include tests on the basis of gain in certainty. The 
aim of studying this issue was to explore a model for optimising the sequence of diagnostic 
tests based on efficiency criteria. The probability modifying plot shows when, in a specific test 
sequence, further testing is redundant and which costs are involved. In this way different 
sequences can be compared. The sequence of diagnostic tests was optimised on the basis of 
efficiency, which was either defined as the test sequence with the least number of tests or the 
least total cost for testing. Further research on the model is needed to handle current 
limitations. The model is illustrated with two applications using data on the diagnosis of 
Helicobacter Pylori and Bladder Outlet Obstruction (Benign Prostatic Hyperplasia)(Chapter 
2.1). 
Second, the competing alternative when evaluating health care technologies is 
discussed, concentrating on the problem of modelling therapeutic alternatives. A decision 
analytic model was developed to compare the effectiveness and costs of two strategies for the 
empirical treatment of invasive fungal infection (IFI) in patients with haematological 
malignancies. Empirical treatment with amphotericin В desoxycholate (DC-Amb), followed 
by liposomal amphotericin В (L-Amb) in case of treatment failure or nephrotoxicity (strategy 
DC/L-Amb) was compared to first line treatment with L-Amb (strategy L·Amb). Estimates for 
the probability variables for successful treatment, treatment failure and the occurrence of side 
effects were derived from published reports. Effectiveness was expressed as survival to 
hospital discharge. Drug costs and the costs associated with the treatment of side effects were 
determined according to the perspective of the health-care system. The incremental cost 
effectiveness ratio was calculated to reflect the financial effort needed to gain more 
effectiveness. Extensive sensitivity analyses were performed using both probability and cost 
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variables to analyse the impact of the variables on the study findings. The L-Amb strategy 
increased the probability of survival from 77% using DC/L-Amb to 85%. The expected cost 
of L-Amb was USD 27,810 per patient compared to USD 12,776 per patient for the DC/L-
Amb strategy. The incremental cost per life saved was nearly USD 183,000. The sensitivity 
analysis revealed that if the cost of L-Amb per day is less than USD 122, L-Amb is more 
effective expressed in lives saved at a lower cost compared to the DC/L-Amb strategy. The L-
Amb strategy results in a higher survival to hospital discharge. The expected costs are higher 
compared to DC/L-Amb strategy. Decreasing the costs of L-Amb has a positive impact on the 
incremental cost-effectiveness ratio. It was shown that modelling is a method that makes 
comparison of relevant alternatives, which have not been described in the literature, possible 
(Chapter 2.2). 
The issue of the relevant costs and consequences in an economic evaluation of a health 
care technology is discussed using two separate topics (Chapters 3.1 and 3.2). First, a decision 
analytic model for the diagnosis of invasive aspergillosis studied the importance of defining a 
time horizon of analysis. A diagnostic approach was devised, based on screening plasma for 
an Aspergillus antigen with use of a sandwich enzyme-linked immunosorbent assay (ELISA), 
thoracic computed tomographic scanning (CT), and radionuclide imaging (IgG) for managing 
patients at risk for invasive aspergillosis. The conventional strategy relied only on the 
presence of clinical symptoms: persistent fever, and chest roentgenographic findings. Use of 
the alternative strategy reduced the number of patients who would receive antifungal 
treatment empirically, but this strategy was more expensive. A 13% prevalence of infection 
resulted in equal costs for both strategies. As much as 43.3% of the patients treated 
empirically could be given liposomal amphotericin В (L-AmB) before the conventional 
strategy became the most expensive. The costs of the alternative strategy were less than those 
of the conventional strategy when >5.3% of all patients, irrespective of strategy, were treated 
with L-AmB. The model shows the relevance of defining the time horizon when evaluating 
diagnostic technologies. Limiting the time horizon to the diagnostic process itself gave 
different results compared to a longer time horizon, thus incorporating the treatment process 
(Chapter 3.1). 
Second, the importance of defining the study's perspective is studied (Chapter 3.2). 
The definition of the perspective influences the relevancy of the different costs that have to be 
analysed. Besides this, the choice of the perspective determines the way cost prices should be 
calculated. A cost analysis was performed alongside a clinical study of cochlear implants in 
children in The Netherlands. Between 1993 until 1996 106 deaf children were screened as 
candidates for a cochlear implant. Of these, 20 children were implanted. For the selection and 
implantation, data from the University Hospital Nijmegen were used. Data of rehabilitation 
and after care were obtained from the Institute for the Deaf in Sint Michielsgestel. Real costs 
of medical care were calculated, using a societal perspective and a time horizon of five years. 
Volumes of utilization of human resources and materials were prospectively registered during 
the follow up of one year. For the subsequent period volumes were modeled on the basis of 
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planned after care activities. Basis for the calculations were 1994 prices. The economic 
consequences of cochlear implants on educational needs were not taken into account because 
of the limited period of follow up. Total medical costs of an implanted child were Dfl. 
117,617. The breakdown of the costs are as follows: costs of selection phase were Dfl. 14,256, 
costs of implantation, including the hardware, Dfl. 56,014, costs of rehabilitation Dfl. 24,706 
and the costs of after care Dfl. 22,641. The cochlear implants hardware was a large part of the 
total costs (Dfl. 46,397). Non medical costs were Dfl. 3,383. Sensitivity analysis of the rate of 
implanted children as part of the number of screened children did not show a large impact on 
the total costs. Compared to the results from cost analyses of other studies, the costs of the 
paediatric cochlear implants program in The Netherlands are relatively high. Most difference 
can be explained by methodological differences. For most studies the study's perspective is 
not defined (Chapter 3.2). 
The issue of accurate measurement of costs and consequences is illustrated by the 
concept of productivity costs (Chapter 4). The purpose of this study was to discuss precision 
and accuracy of a retrospective self-administered questionnaire on sick leave. Employees of a 
company were asked to indicate the number of days absent from work due to illness during 
the past 2 weeks, 4 weeks, 2 months, 6 months, and the past 12 months. The percentage of 
respondents with an absolute difference of a maximum of respectively 0, 1,2, 3, 4, 5, 6, 7, 8, 
and 9 or more days between reported, and company-registered absence due to illness, the so 
called level of precision, was determined. A systematic difference was tested with a sign rank 
test. Of the reported data, 95% matched the registered data perfectly when the recall period 
was limited to 2 and 4 weeks. This percentage decreased to 87%, 57%, and 51% for 2 months, 
6 months, and 12 months, respectively. No systematic positive or negative difference was 
found between registered and reported sick leave. This was confirmed by the fact that no 
increasing proportional errors could be found. The results suggest that the recall period for 
retrospective measurement of sick leave is limited according to the precision level, which 
seems to be appropriate for the subject and the purpose of the study. We recommend using a 
recall period of no more than two months. 
Credible valuing of costs and consequences of health care technologies is studied 
regarding two aspects (Chapter 5.1 and 5.2). First, using an example in the field of 
gastrointestinal disease, credible valuing of productivity costs is discussed. Productivity costs 
are normally calculated by multiplying days absent valued by gross earnings. This, however, 
might lead to an overestimation because compensating mechanisms are not accounted for. A 
conservative approach is proposed for calculating productivity costs, taking absence-
compensating mechanisms into account. Patients who visited their general practitioner for the 
first time with dyspeptic complaints and patients who were known to have persistent 
dyspeptic complaints were enrolled in two studies. In total, 136 patients completed a 
questionnaire about their employment situation, absence from work and absence 
compensating mechanisms. Sixty-six of the respondents had a paid job, of which 25 (38%) 
reported absence from work during the previous 4 weeks (average 3.0 days, 1.9 days related to 
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dyspeptic complaints). More than 50% of the employed respondents answered that colleagues 
could compensate for absence, and only in 8% of the cases was absence compensated for by 
overtime. Using our conservative approach, only one-quarter of the productivity costs 
remained, compared to the current approach of valuing each day absent as a loss of 
productivity. Using both the current and the conservative approaches, analogous to the 
principles of sensitivity analysis, to avoid overestimation of productivity costs seems 
advisable (Chapter 5.1). 
Second, several alternatives can be used to value the consequences of a health care 
technology. In this study focus is on the construct validity of the willingness to pay (WTP) 
method to value non-decisional diagnostic information. Six hypotheses were tested regarding 
the relationship between WTP and, respectively, the subjective importance of testing, the 
burden of testing, the perceived reliability of the test, the subjective belief of being infected, 
the perceived severity of the disease, and the perceived possibility of treatment. The 
hypotheses were tested among individuals at increased risk of histoplasmosis using a 
questionnaire. Univariate and multivariate relationships were examined by chi-squared test 
and logistic regression, respectively. Eighty-four Dutch speleologists participated in the study, 
76 of whom gave WTP information. A significant relation was found between WTP and 
subjective importance of testing. No significant relationship was found between WTP and the 
other hypotheses. The multivariate analysis showed no further significant relationships. Our 
results indicate that WTP measurement is not a valid method to assess the value that the 
respondents place on non-decisional diagnostic information. This may primary be related to 
the fact that being Dutch citizens the respondents were not familiar with paying health care 
facilities out of pocket. This would mean that WTP is not a valid method of choice when 
assessing the monetary value that subjects place on health care interventions in countries with 
comprehensive coverage schemes (Chapter 5.2). 
The issue of uncertainty of the results of an economic evaluation is described in the 
final study (Chapter 6). Several methods have been explored to estimate the confidence 
interval of the incremental cost-effectiveness ratio (ICER). In this study Fieller intervals and 
three methods for calculating bootstrap intervals are compared. Based on trial data, 10,000 
trials were simulated, resulting in 10,000 ICERs and 10,000 confidence intervals for each 
method. The mean of the ICERs was used as estimate for the true population ICER. The 
adequacy of the methods to compute confidence intervals was determined by comparing the 
percentage of confidence intervals containing this estimate. The impact of 'no significant 
difference of effectiveness' was investigated by varying the difference in effectiveness. Both 
Fieller and bootstrap methods lead to unsatisfactory results when the difference in 
effectiveness is approximately zero. In the situation where this difference is significant, the 
four methods for calculating confidence intervals for ICER do not give very different results, 
but Fieller's interval performs best. Since Fieller's confidence limits are relatively easy to 
compute compared to bootstrap simulations, we recommend using this method. 
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The methodological issues in the economic evaluation in health care that were dealt 
with are discussed within the framework of guidelines for (pharmaco-) economic evaluation 
that exist in Canada, Ontario, Australia, United Kingdom, and The Netherlands (Chapter 7). It 
is concluded that the guidelines are quite generally phrased. It seems hardly possible to gain 
consensus on all methodological aspects of economic evaluations, because, as was shown in 
this thesis, the methods of this type of research are still being developed. However, 
appropriate standards for reporting study results should ensure researchers to report their 
methods in a transparent and standardised way. This will enable decision-makers to validly 





Dit proefschrift behandelt een aantal methodologische aspecten van economische evaluaties in 
de gezondheidzorg. Het doel van economische evaluaties van medische technologieën 
(producten, apparaten of processen) die toegepast (gaan) worden in de gezondheidszorg is 
hoofdzakelijk het genereren van informatie over de efficiëntie van mogelijke alternatieven. De 
methoden die bij dergelijk onderzoek toegepast worden zijn in ontwikkeling. Echter, de 
methodologische principes die momenteel gehanteerd worden zijn medebepalend voor de 
uitkomsten van economische evaluaties. De volgende aspecten worden behandeld: de keuze 
van het vergelijkingsalternatief, de relevantie van kosten en effecten, accuraatheid van het 
meten van kosten en effecten, betrouwbaarheid van de waardering van kosten en effecten en 
de onzekerheid van de resultaten van een economische evaluatie. 
Het aspect de keuze van het vergelijkingsaltematief wordt aan de hand van twee 
onderwerpen besproken (Hoofdstukken 2.1 en 2.2). Allereerst staat de keuze centraal van het 
vergelijkingsaltematief bij een economische evaluatie van diagnostische technologieën 
waarbij de nadruk ligt op de optimale sequentie van diagnostische tests. Testsequenties 
kunnen worden bestudeerd met behulp van besliskundige modellen, echter, weinig 
inzichtelijke beslisbomen ontstaan bij het onderzoeken van de sequentie van twee of meer 
testen. Andere modellen includeren testen in de volgorde van afnemende winst in zekerheid 
omtrent de ziektetoestand van patiënten. Hoofdstuk 2.1 beschrijft een evaluatiemethode om de 
optimale sequentie, gericht op efficiëntie, te bepalen van diagnostische tests. Deze methode 
laat in grafieken zien in welke situatie een volgende diagnostische test in relatie tot een 
behandelingsbeslissing overbodig is, en op grond waarvan de daarmee gepaarde kosten 
kunnen worden bepaald. Op deze manier kunnen alle mogelijke sequenties van tests worden 
geanalyseerd, waarna de optimale volgorde kan worden bepaald. De methode wordt 
geïllustreerd aan de hand van databestanden betreffende de diagnose van Helicobacter Pylori 
en Benigne Prostaat Hyperplasie. 
Vervolgens staat de keuze van het vergelijkingsalternatief bij een economische 
evaluatie van therapeutische technologieën centraal, waarbij de nadruk ligt op modellering 
van therapeutische alternatieven. Een besliskundig model wordt beschreven waarin de 
effectiviteit en kosten van twee empirische strategieën worden vergeleken voor de 
behandeling van patiënten verdacht van invasieve fungale infectie (IFI) bij hematologische 
maligniteiten. Empirische behandeling met amphotericine В desoxycholaat (DC-Amb) 
eventueel gevolgd door behandeling met het liposomale amphotericine В (L-Amb) wordt 
vergeleken met directe behandeling met L-Amb. In de literatuur is geen prospectieve studie 
beschreven waarin de sequentiële strategie wordt bestudeerd. Rapportage betreffende de 
kansen op succesvolle behandeling, falen van de behandeling, en vóórkomen van 
bijwerkingen van louter DC-Amb en L-Amb zijn wel in de literatuur voorhanden. In het 
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model wordt overleving tot ontslag uit het ziekenhuis als effectmaat gehanteerd. Kosten van 
medicatie en ziekenhuisverblijf zijn berekend op basis van een bedrijfseconomische 
perspectief. Uitgebreide sensitiviteitsanalyses laten de invloed van aannames in het model 
zien. Directe behandeling met L-Amb verhoogt de overlevingskans van 77% naar 85%, 
waarbij de kosten respectievelijk US dollar (USD) 27,810 en 12,776 zijn. De increméntele 
kosten per gewonnen leven komen uit op USD 183,000. De kosten van liposomale 
amphotericine В hebben een grote invloed op de uitkomsten. Dit hoofdstuk illustreert de 
mogelijkheid om vergelijking van beleidsrelevante alternatieven die niet in de literatuur 
beschreven worden met behulp van een modelleringstudie expliciet te analyseren (Hoofdstuk 
2.2). 
Het aspect van de relevantie van kosten en effecten in een economische evaluatie 
wordt behandeld aan de hand van twee studies (Hoofdstukken 3.1 en 3.2). Een besliskundig 
model beschrijft het belang van het vaststellen van de tijdshorizon van analyse bij de 
vergelijking van twee diagnostische strategieën voor het diagnostiseren van invasieve 
aspergillose. Eén strategie is gebaseerd op regelmatige controle van plasma op de 
aanwezigheid van aspergillus antigen (ELISA test), eventueel bevestigend door CT-scan of 
IgG-scan. De conventionele benadering is gebaseerd op het vóórkomen van klinische 
verschijnselen (persisterende koorts) en een röntgenfoto van de longen, echter deze strategie 
leidt tot overbehandeling: 24% van de risicopatiënten wordt behandeld terwijl slechts 4% 
daadwerkelijk een invasieve infectie heeft. De alternatieve benadering gebaseerd op de ELISA 
tests reduceerde het aantal patiënten dat in aanmerking zou komen voor anti-fungus 
behandeling, maar deze strategie is wat betreft de kosten van diagnostiek minder gunstig. 
Echter, door in het model het kostbare liposomale amphotericine В op te nemen, blijkt de 
ELISA strategie te prefereren. Dus door de tijdshorizon van analyse te verbreden van alleen 
het diagnostisch traject naar het therapeutische trajet en zodoende ook de kosten van dit 
therapeutische traject in de analyse te betrekken worden de resultaten van de vergelijking 
beïnvloed. Dit illustreert het belang van een juiste bepaling van de tijdshorizon van een 
economische evaluatie (hoofdstuk 3.1). 
Ten tweede wordt het aspect van de relevantie van kosten en effecten in een 
economische evaluatie bestudeerd aan de hand van het perspectief van een economische 
evaluatie (Hoofdstuk 3.2). De keuze van het perspectief is medebepalend voor de uitkomsten 
van een economische evaluatie omdat hierdoor de keuze van de kostensoorten en de manier 
waarop kostprijzen worden berekend wordt beïnvloed. Een kostenanalyse die onderdeel was 
van een klinische studie betreffende cochleaire implantaten bij kinderen wordt beschreven. 
Tussen 1993 en 1996 doorliepen 106 dove kinderen een selectieprocedure voor mogelijke 
behandeling met een cochleair implantaat. Uiteindelijk werden hiervan 20 kinderen 
geïmplanteerd. Voor de kosten van selectie en feitelijke implantatie werden gegevens uit het 
AZN St. Radboud gebruikt. Gegevens over de kosten van rehabilitatie en nazorg waren 
beschikbaar gesteld door het Instituut voor Doven te Sint Michielsgestel. Zogenaamde 
werkelijke kosten gebaseerd op een tijdshorizon van 5 jaar werden berekend. Volumes van de 
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inzet van menskracht en middelen waren prospectief geregistreerd gedurende selectie, 
implantatie en rehabilitatie in het eerste jaar na implantatie en kosten van nazorg werden op 
basis van geplande zorg bepaald. De totale medische kosten kwamen uit op Dfl. 117.617 per 
geïmplanteerd kind (selectie Dfl. 14.256, implantatie 56.014, rehabilitatie Dfl. 24.706 en 
nazorg Dfl. 22.641). Deze resultaten werden vergeleken met de resultaten van een aantal 
buitenlandse studies waaruit bleek dat de Nederlandse berekeningen hoog uit kwamen. Echter, 
het is onmogelijk deze resultaten zonder meer te vergelijken omdat onduidelijk is vanuit welk 
perspectief de buitenlandse studies zijn uitgevoerd en dus welke kostensoorten en methoden 
van kostenberekeningen zijn gehanteerd. 
Het aspect accuraatheid van het meten van kosten en effecten wordt geïllustreerd aan 
de hand van het concept van de productiviteitskosten (Hoofdstuk 4). Productiviteitskosten zijn 
kosten gerelateerd aan arbeidsverzuim als gevolg van de gezondheidstoestand van personen. 
Het doel van de studie is de precisie en accuraatheid van het retrospectief meten van 
arbeidsverzuim met behulp van een vragenlijst te onderzoeken. In de literatuur worden 
herinneringsperioden tot 12 maanden gevonden. In deze studie werd medewerkers van een 
commercieel bedrijf gevraagd aan te geven hoeveel dagen zij zich hadden ziek gemeld in 
verband met hun gezondheidstoestand gedurende de laatste 2 weken, 4 weken, 2 maanden, 6 
maanden en 12 maanden. Deze gegevens werden vergeleken met de gegevens uit de 
bedrijfsregistratie die als gouden standaard werd gehanteerd. Het percentage respondenten met 
een absoluut verschil tussen zelfrapportage en registratie van 0, 1,2, 3, 4, 5, 6, 7, 8 en 9 of 
meer dagen werd berekend. Een systematisch verschil werd onderzocht met een 
rangtekentoets. Bij het hanteren van een herinneringsperiode van 2 en 4 weken rapporteerden 
95% van de respondenten het juiste aantal dagen. Dit percentage neemt af tot 87%, 57% en 
51% voor de langere herinneringsperioden. Statistische analyses konden geen systematische 
afwijking aantonen. De resultaten suggereren dat de precisie van retrospectieve meting van 
arbeidsverzuim afneemt met het langer worden van de herinneringsperiode op basis waarvan 
een herinneringsperiode van maximaal 2 maanden aan te bevelen is. 
Betrouwbaarheid van de waardering van kosten en effecten werd bestudeerd aan de 
hand van betrouwbare waardering van productiviteitskosten en de construct validiteit van de 
effectiviteitmaat 'willingness-to-pay' (WTP). Productiviteitskosten als gevolg van arbeids-
verzuim gerelateerd aan de gezondheidstoestand van een persoon worden normaliter berekend 
door de afwezigheiddagen te vermenigvuldigen met de gemiddelde salarislast voor de 
werkgever. Echter, deze waardering van arbeidsverzuim zou kunnen leiden tot een 
overschatting omdat bij deze calculatie geen rekening wordt gehouden met mogelijke 
compensatiemechanismen om verzuim op te vangen. In deze studie wordt een conservatieve 
methode voorgesteld die rekening houdt met compensatiemechanismen bij kortdurend 
arbeidsverzuim waarbij gebruik wordt gemaakt van gegevens uit een klinische studie 
betreffende patiënten met maagklachten. In de eerste studie betrof het patiënten die voor het 
eerst bij de huisarts kwamen met maagklachten en in een tweede studie betrof het patiënten 
die met aanhoudende maagklachten weer hun huisarts bezochten. In totaal vulden 136 
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patiënten een vragenlijst in betreffende arbeidsverzuim en compensatiemechanismen bij 
verzuim. Van degenen met betaald werk in deze groep (66 patiënten) rapporteerden 25 
patiënten te hebben verzuimd in de laatste 4 weken. Meer dan 50% van de werkenden 
rapporteerden dat collegae in staat waren hun afwezigheid te compenseren zonder daarvoor te 
hoeven overwerken. Rekening houdend met de gerapporteerde compensatiemechanismen 
resteerde ongeveer 25% van de productiviteitskosten in vergelijking met de conventionele 
methode. Aangeraden wordt om in economische evaluatie met behulp van een 
sensitiviteitsanalyse het verschil tussen de conventionele en de meer conservatieve benadering 
te analyseren (Hoofdstuk 5.1). 
De construct validiteit van WTP als uitkomstmaat van een economische evaluatie 
werd bestudeerd in het kader van de niet-beslissing informatie van een diagnostische test 
(Hoofdstuk 5.2). Diagnostische tests genereren informatie en in het geval daar geen 
behandelingsbeslissing op gebaseerd wordt, wordt dit ook wel de niet-beslissing informatie 
van een test genoemd. De vraag werd onderzocht hoe dergelijke informatie betrouwbaar 
gewaardeerd kan worden. Zes hypothesen werden uit de literatuur afgeleid waarmee de relatie 
werd beschreven tussen WTP en het subjectieve belang van een test, de belasting van een test, 
de veronderstelde betrouwbaarheid van een test, de veronderstelde aanwezigheid van 
aandoening, de veronderstelde emst van de aandoening, en de veronderstelde mogelijkheid 
voor behandeling. Deze hypothesen werden getoetst in een studie bij een risicopopulatie voor 
een histoplasmose-infectie. Een groep van 84 Nederlandse speleologen nam deel aan de studie 
waarvan 76 de WTP vraag beantwoorden. Er werd een significante relatie gevonden tussen de 
WTP antwoorden en de antwoorden betreffende het subjectieve belang van een test. Geen 
enkele andere relatie kon worden aangetoond tussen de WTP-antwoorden en de antwoorden 
betreffende de hypothesen. Deze resultaten leiden tot de veronderstelling dal de construct 
validiteit van WTP als uitkomstmaat voor niet-beslissing informatie van een diagnostische 
test onvoldoende is. Een mogelijke verklaring hiervoor is dat de meeste Nederlanders niet 
gewend zijn om rechtstreeks voor voorzieningen in de gezondheidszorg te betalen. 
Het aspect onzekerheid van de resultaten van een economische evaluatie wordt 
besproken in Hoofdstuk 6. Verschillende methoden werden vergeleken waarmee een 
betrouwbaarheidsinterval van een increméntele kosten-effectiviteitsratio kan worden 
berekend. In dit hoofdstuk werden Ficller intervallen en drie methoden voor de berekening 
van betrouwbaarheidsintervallen op basis van bootstrap simulaties vastgesteld waarbij 
gegevens uit een prospectieve studie werden gebruikt. Deze studie werd nog eens 10.000 keer 
gesimuleerd en hierbij werden 10.000 ratio's bepaald. Het gemiddelde hiervan werd als 
werkelijke populatie waarde beschouwd. Voor iedere simulatie met de bijbehorende ratio 
werden betrouwbaarheidsintervallen vastgesteld uitgaande van de vier verschillende 
methoden. De nauwkeurigheid van iedere methode werd weergegeven door het percentage 
van de intervallen dat de 'werkelijke' populatie ratio bevatte. Zowel de Fieller methode als de 
drie bootstrap gebaseerde methoden leidden tot onbevredigende resultaten in het geval het 
effectverschil tussen alternatieven dicht bij nul ligt. Bij een significant verschil in effectiviteit 
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leiden zowel Fieller als de bootstrap methoden tot acceptabele resultaten, alhoewel Fieller hel 
meest nauwkeurig is. Aangezien deze methode in vergelijking met de bootstrap methoden 
relatief eenvoudig is krijgt deze de voorkeur. 
Het proefschrift wordt afgesloten met een beschouwing van de behandelde 
methodologische aspecten van economische evaluaties in het kader van richtlijnen voor het 
uitvoeren van deze studies (Hoofdstuk 7). De conclusie wordt getrokken dat de richtlijnen 
voor (pharmaco-) economische evaluaties zoals die bestaan in Canada, Ontario, Australië, 
Verenigd Koninkrijk en Nederland vrij algemeen verwoord zijn. Een van de redenen hiervoor 
is dat de methodologie van economische evaluaties zich nog ontwikkelt. In dit proefschrift 
worden met betrekking tot enkele aspecten van economische evaluaties concrete suggesties 
gedaan. Met het doel een betere vergelijking van de resultaten van dergelijk onderzoek 
mogelijk te maken is het zinvol de onderzoeksmethoden van economische evaluaties in de 
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proefschrift heb je me ervan kunnen overtuigen om verschillende onderdelen te herschikken 
om zo de puntjes op de i te zetten. Beste Gert-Jan van der Wilt, jouw rol is doorslaggevend 
geweest. Op die ene dag in februari dat we er eens de tijd voor namen, bedacht jij uit materiaal 
dat grotendeels voorhanden was een structuur en een theoretisch kader voor het werk. Jouw 
idee dat dit dan voor de jaarwisseling zou moeten resulteren in het manuscript leek mij zeer 
ambitieus, maar je uitdaging kwam op het juiste moment. Ongeacht je hoge werklast bleef je 
daarna tijd maken om voor mij als klankbord te dienen; een bewijs van een hoge 
gestandaardiseerde sukkel-dichtheid op onze werkkamer? Dank voor jullie onmisbare hulp bij 
de totstandkoming van dit proefschrift. 
Gegevens en verwerking van gegevens zijn essentieel geweest voor bijna alle 
onderdelen van mijn onderzoek. De wil dan ook de mensen bedanken van wie en met wie ik 
allerlei gegevens en informatie heb kunnen gebruiken voor het uitwerken van mijn ideeën. 
Beste André Verbeek, jij gaf me de dataset op basis waarvan het model over de testsequenties 
werd ontwikkeld. Je constructieve suggesties hebben een belangrijke bijdrage geleverd aan dit 
onderdeel. Beste Gabe Sonke, op jouw dataset heb ik het testsequentie-model fraai kunnen 
toepassen. Beste Robert Laheij, niet alleen de diagnostiek dataset, maar vooral ook de 
arbeidsverzuimgegevens die jij tijdens je dyspepsie-projecten verzamelde bleken waardevol. 
Beste Paul Verweij, Jacques Meis en Peter Donnelly, het modelleringswerk op het terrein van 
infecties steunt op jullie gegevens en medisch-inhoudelijke kennis en ervaring. Beste Emmy 
Konst, de cijfers uit het PSOT-project waren een prima basis voor het proberen van nieuwe 
statistische methoden. 
En natuurlijk zijn datasets niks zonder goed datamanagement: beste Wim en Liesbeth 
Lemmens, Albert Reintjes, Jan Mulder en Leo van Rossum, dank voor jullie bereidheid om 
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raad en daad te stellen bij dataverwerking en om steeds weer additionele analyses te doen. En 
beste Theo de Boo, zonder jouw statistische adviezen was ik gegarandeerd vaker in allerlei 
valkuilen gelopen. Daarnaast zijn om alles draaiende te houden in dit soort werk kom-sputters 
onontbeerlijk. Beste Rob Reuzel, zeker in de afrondingsfase van dit proefschrift was jouw 
onmisbare hulp geruststellend, vooral tijdens mijn ruzie met software en printers (zie omslag). 
Beste Hans Groenewoud en Pieter Zanstra, voor mij als adactylognost (Harry Severens, De 
Volkskrant d.d. 17 mei 1997) is technische ondersteuning essentieel, ook op zondagmorgen! 
Hand- en spandiensten werden verleend door student-assistenten, zowel voor het proefschrift 
zelf als voor andere ontlastende werkzaamheden: Jolanda Habraken, Leandra de Winter, 
Kirsten Gertsen en Joep Duijnstee, bedankt voor jullie enthousiaste hulp. Beth White, jou wil 
ik bedanken voor het corrigeren van mijn Engels, zelfs nadat je terug was gegaan naar de 
States bleef je bereid via email voor me te werken. 
Ook de andere collegae van de afdeling MTA, Paul Krabbe, Margriet Hartman, 
Patricia Lottman, Mieke Nieuwenhuizen en Gina Wielink wil ik bedanken voor de goede 
samenwerking en bereidheid klussen voor elkaar op te knappen. Zeker in een 
multidisciplinaire groep als de onze zijn ruggespraak, referaten en seminars een prima bron 
voor reflectie en inspiratie. Collegae en ex-collegae van de andere afdelingen van MIES -
Medische Informatiekunde, Epidemiologie en Statistiek: ik vind het belangrijk dat er naast 
werken (weer) tijd is voor gezellige dingen: koffie met vlaai, de kroeg in tijdens de LVVDM-
VGB, het bos in om wat hard te lopen, en op de racefiets genieten van de omgeving van 
Nijmegen. 
Verder bedank ik mijn vrienden die me stimuleerden om ook wat anders te doen dan 
achter mijn bureau te zitten: Les Cochons en vrienden-speleologen, bedankt dat jullie me 
regelmatig eens ouderwets onder de grond vergezelden; de Hardlopers In Training oftewel 
НГТ-ters, dank voor jullie gezelschap bij de snelle kilometers en lange duurlopen als afleiding 
van al het denk- en schrijfwerk: mijn gezeur en geklaag zal nu wel voorbij zijn. 
En Anita, jij 
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behorende bij het proefschrift 
Some Methodological Issues 
in Economie Evaluation in Health Care 
1. Het rangschikken van medische technologieën naar kosten-effectiviteit is onverantwoord 
(dit proefschrift). 
2. Aanvragers van diagnostische tests vragen zich onvoldoende af of die aankoop zijn geld 
waard is (dit proefschrift). 
3. Modellering is een oplossing voor de wrijving tussen de informatiebehoefte van 
beleidsmakers en die van onderzoekers (ditproefschrift). 
4. De huidige methoden voor de berekening van productiviteitskosten leiden tot een 
overschatting van deze kosten (dit proefschrift). 
5. De rol van statistische methoden in economische evaluaties is om schijnzekerheid te 
vermijden (dit proefschrift). 
6. Kosten-effectiviteitsratio's dwingen opdrachtgevers en gebruikers van economische 
evaluaties tot het vaststellen van referentiekaders (dit proefschrift). 
7. Speleologen zijn niet rationeel (dit proefschrift). 
8. De indeling van kostensoorten naar direct en indirect, en medisch en niet-medisch is 
onnodig verwarrend. 
9. De term 'kosten-baten analyse' wordt doorgaans foutief gehanteerd. 
10. Evaluaties van medische technologieën dienen niet alleen de relatieve doelmatigheid, 
maar ook de financiële consequenties te bepalen 
11. Het nieuwe voorgestelde medicijnbeleid (commissie-De Vries) zal niet leiden tot een 
toename van de concurrentie tussen zorgverzekeraars. 
12. De functie van het publiek bij het promotieritueel is het bijdragen aan de stress en het 
gevoel van succes van de promovendus (Bram Buunk, De Volkskrant d.d. 20 maart 1999). 
13. What good's a disease that won't hurt you? (Lou Reed, The Thesis). 
14. Hardlopers zijn doorlopers. 
J.L. Scverens 
Nijmegen, 2 december 1999 



